


10/785,120



G1 C,N

G2 O,N

G3 X,Cy,C,O,S,N

Structure attributes must be viewed using STN Express query preparation.
L4 QUE ABB=ON PLU=ON L3

(FILE 'HOME' ENTERED AT 15:02:16 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:02:41 ON 01 MAR 2006
ACT A10785120/A

L1 STR
L2 3101 SEA FILE=REGISTRY SSS FUL L1

FILE 'STNGUIDE' ENTERED AT 15:03:13 ON 01 MAR 2006

L3 FILE 'REGISTRY' ENTERED AT 15:05:08 ON 01 MAR 2006
L4 STRUCTURE UPLOADED
L5 QUE L3
L6 46 S L4 SAM SUB=L2
1087 S L4 FUL SUB=L2

L7 FILE 'CAPLUS' ENTERED AT 15:06:47 ON 01 MAR 2006
128 S L6

L8 FILE 'REGISTRY' ENTERED AT 15:06:58 ON 01 MAR 2006
L9 45 S L6
1151 S L6 FUL

L10 FILE 'CAPLUS' ENTERED AT 15:08:55 ON 01 MAR 2006
129 S L9

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE
ENTRY
661.95


SINCE FILE
ENTRY
-96.75

TOTAL
SESSION
871.78


TOTAL
SESSION
-96.75

10/785,120

L10 ANSWER 1 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1117988 CAPLUS
 DN 144:22900
 TI Synthetic Utilization of Polynitroaromatic Compounds. 3. Preparation of Substituted Dibenz[b,f][1,4]oxazepine-11(10H)-ones from 2,4,6-Trinitrobenzoic Acid via Nucleophilic Displacement of Nitro Groups
 AU Samet, Alexander V.; Marshalkin, Victor N.; Kislyi, Konstantine A.; Chernysheva, Natalya B.; Strelenko, Yuri A.; Semenov, Victor V.
 CS N. D. Zelinsky Institute of Organic Chemistry, RAS, Moscow, 119991, Russia
 SO Journal of Organic Chemistry (2005), 70(23), 9371-9376
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 GI




AB 1,3-Dinitrodibenz[b,f][1,4]oxazepin-11(10H)-one, prepared by intramol. displacement of nitro group in N-(2-hydroxyphenyl)-2,4,6-trinitrobenzamide, reacts with O- and S-nucleophiles to yield the products of mono- or bis-substitution of the nitro groups. The nitro group in position 3 is displaced first. This observation is in contrast with earlier results for the nitro-substituted benzoannulated five-membered heterocycles. This difference in reactivity is likely due to the increased steric hindrance for peri-nitro group displacement in the case of the benzoannulated seven-membered heterocycle. N-Alkylation of the nitro-substituted dibenz[b,f][1,4]oxazepin-11(10H)-ones yields analogs of a known antidepressant drug Sintamil, e. g. I. The structure of the products is confirmed by NOE expts. and alternative synthesis.
 IT **870552-97-9 870552-99-1**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via nucleophilic displacement of nitro groups and subsequent N-alkylation)
 RN 870552-97-9 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(1-methylethoxy)-1-nitro- (9CI)
 (CA INDEX NAME)



RN 870552-99-1 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(cyclohexyloxy)-1-nitro- (9CI)
(CA INDEX NAME)




IT 309735-46-4P 447455-70-1P 728000-38-2P
728003-32-5P 728884-28-4P 870552-93-5P
870553-04-1P 870553-24-5P 870553-26-7P
870553-27-8P 870553-29-0P 870553-31-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via
nucleophilic displacement of nitro groups and subsequent N-alkylation)


RN 309735-46-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-dinitro- (9CI) (CA INDEX NAME)



RN 447455-70-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis[(4-methylphenyl)thio]- (9CI)
(CA INDEX NAME)



RN 728000-38-2 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis(butylthio)- (9CI) (CA INDEX
NAME)

10/785,120




RN 728003-32-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(butylthio)-1-nitro- (9CI) (CA INDEX NAME)



RN 728884-28-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-bis(3-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 870552-93-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy-1-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 870553-04-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-phenoxy- (9CI) (CA INDEX NAME)




RN 870553-24-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-diphenoxy- (9CI) (CA INDEX NAME)



RN 870553-26-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(butylthio)-1-phenoxy- (9CI) (CA INDEX NAME)



RN 870553-27-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-(butylthio)-3-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 870553-29-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy-1-[(phenylmethyl)thio]-
(9CI) (CA INDEX NAME)



RN 870553-31-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-[(4-methylphenyl)thio]-3-phenoxy-
(9CI) (CA INDEX NAME)




IT 681845-18-1P 681850-38-4P 870552-94-6P
870552-96-8P 870553-01-8P 870553-03-0P
870553-05-2P 870553-07-4P 870553-09-6P
870553-11-0P 870553-13-2P 870553-15-4P
870553-19-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted dibenzoxazepinones from trinitrobenzoic acid via
nucleophilic displacement of nitro groups and subsequent N-alkylation)


RN 681845-18-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-(phenylthio)- (9CI) (CA
INDEX NAME)




RN 681850-38-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-[(phenylmethyl)thio]-
(9CI) (CA INDEX NAME)




RN 870552-94-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-ethoxy-1-nitro- (9CI) (CA INDEX
NAME)



RN 870552-96-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-propoxy- (9CI) (CA INDEX
NAME)



RN 870553-01-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-hydroxyethoxy)-1-nitro- (9CI)
(CA INDEX NAME)

10/785,120




RN 870553-03-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-nitro-3-(phenylmethoxy)- (9CI)
(CA INDEX NAME)




RN 870553-05-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(3-methylphenoxy)-1-nitro- (9CI)
(CA INDEX NAME)




RN 870553-07-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-methylphenoxy)-1-nitro- (9CI)
(CA INDEX NAME)




RN 870553-09-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-methoxyphenoxy)-1-nitro- (9CI)
(CA INDEX NAME)




RN 870553-11-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-methoxyphenoxy)-1-nitro- (9CI)
(CA INDEX NAME)




RN 870553-13-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(2-bromophenoxy)-1-nitro- (9CI)
(CA INDEX NAME)



RN 870553-15-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-(4-bromophenoxy)-1-nitro- (9CI)
(CA INDEX NAME)



RN 870553-19-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(4-methylphenyl)thio]-1-nitro- (9CI)
(CA INDEX NAME)

10/785,120



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1051145 CAPLUS
 DN 144:6772
 TI Intramolecular Carbonylation Reactions with Recyclable Palladium-Complexed Dendrimers on Silica: Synthesis of Oxygen, Nitrogen, or Sulfur-Containing Medium Ring Fused Heterocycles
 AU Lu, Shui-Ming; Alper, Howard
 CS Centre for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, Ottawa, ON, K1N 6N5, Can.
 SO Journal of the American Chemical Society (2005), 127(42), 14776-14784
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 144:6772
 GI




AB Palladium-complexed dendrimers supported on silica were evaluated as catalysts for intramol. carbonylation reactions. The results showed that dendritic catalysts display high activity, affording oxygen, nitrogen, or sulfur-containing seven- or eight-membered ring fused heterocycles, e.g. I (X = O, S, MeN; Y = nothing, CH₂; R₁ = H, Me, MeO, MeCO, CN, F₃C, etc.; R₂ = H, Me, MeO₂C, Cl, F, etc.), from aminophenyl ethers, thioethers or amines, e.g. II (R₃ = Br, iodo), in excellent yields. Moreover, these catalysts have competitive advantages in that they can be easily recovered by simple filtration in air and reused for up to eight cycles with only a slight loss of activity.

IT 869790-73-8P 869790-74-9P 869790-75-0P
 869790-76-1P 869790-77-2P 869790-78-3P
 869790-79-4P 869790-80-7P 869790-81-8P
 869790-83-0P 869790-84-1P 869790-85-2P
 869790-86-3P 869790-87-4P 869791-14-0P
 869791-15-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of oxygen, nitrogen, or sulfur-containing medium ring fused heterocycles via intramol. carbonylation reactions of aminophenyl ethers, thioethers or amines using recyclable Pd-complexed dendrimers on silica)

RN 869790-73-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl-8-(trifluoromethyl)- (9CI)
 (CA INDEX NAME)



10/785,120


RN 869790-74-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 10,11-dihydro-2-methyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 869790-75-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-methyl- (9CI) (CA INDEX
NAME)




RN 869790-76-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-8-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 869790-77-2 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carbonitrile, 2-chloro-10,11-dihydro-11-oxo-
(9CI) (CA INDEX NAME)



RN 869790-78-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-chloro- (9CI) (CA INDEX
NAME)

10/785,120




RN 869790-79-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 869790-80-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 10,11-dihydro-11-oxo-8-(trifluoromethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 869790-81-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carboxylic acid, 8-cyano-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 869790-83-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-difluoro- (9CI) (CA INDEX NAME)



10/785,120


RN 869790-84-1 CAPLUS

CN Dibenz[b, f][1,4]oxazepine-8-carbonitrile, 2-fluoro-10,11-dihydro-11-oxo-
(9CI) (CA INDEX NAME)




RN 869790-85-2 CAPLUS

CN Dibenz[b, f][1,4]oxazepine-8-carbonitrile, 3-fluoro-10,11-dihydro-11-oxo-
(9CI) (CA INDEX NAME)




RN 869790-86-3 CAPLUS

CN Dibenz[b, f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-fluoro- (9CI) (CA INDEX
NAME)



RN 869790-87-4 CAPLUS


CN Dibenz[b, f][1,4]oxazepin-11(10H)-one, 8-acetyl-3-fluoro- (9CI) (CA INDEX
NAME)



RN 869791-14-0 CAPLUS


CN Dibenz[b, f][1,4]oxazepin-11(10H)-one, 8,8'-sulfonylbis[2-methyl- (9CI)
(CA INDEX NAME)]

10/785,120



RN 869791-15-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8,8'-sulfonylbis[2-chloro- (9CI)
(CA INDEX NAME)




RE.CNT 112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 3 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:633268 CAPLUS
DN 143:133408
TI Preparation of tricyclic compounds with NOS activity
IN Rakhit, Suman; Ramnauth, Jailall; Bratovanov, Svetoslav; Maddaford, Shawn
PA Neuraxon Inc., Can.
SO U.S., 17 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 6919328 | B1 | 20050719 | US 2002-265624 | 20021008 |
| PRAI | US 2001-327317P | P | 20011009 | | |
| OS | MARPAT 143:133408 | | | | |
| GI | | | | | |



AB The title compds. I [R1 = CO(alkenyl), CONHR2, CONHCOR2, CSNH2, etc.; R2 = (un)substituted (hetero)aryl; X = O, NH, N(alkyl), S] and their pharmaceutically acceptable salts, useful as neuroprotectants, in particular, for treating stroke, were prepared E.g., a 3-step synthesis of II, starting from Me 2-chloro-4-nitrobenzoate and 1,2-diaminobenzene, was given. The compound II showed IC50 of 400 μ M and of 500 μ M against nNOS and iNOS, resp. The pharmaceutical composition comprising the compound I is disclosed.

IT **859158-37-5P 859158-38-6P 859158-44-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of dibenzo[b,e][1,4]diazepin-11-one and dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating stroke)


RN 859158-37-5 CAPLUS
CN Benzamide, N-[[[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 859158-38-6 CAPLUS
CN Thiourea, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)- (9CI)


10/785,120

(CA INDEX NAME)



RN 859158-44-4 CAPLUS

CN Benzamide, N-[[[10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



IT 359644-13-6P 859158-36-4P 859158-39-7P

859158-40-0P 859158-41-1P 859158-42-2P

859158-43-3P 859158-45-5P 859158-46-6P


859158-47-7P 859158-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzo[b,e][1,4]diazepin-11-one and dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating stroke)


RN 359644-13-6 CAPLUS

CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 859158-36-4 CAPLUS


CN Acetamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)- (9CI) (CA INDEX NAME)



10/785,120


RN 859158-39-7 CAPLUS

CN Carbamimidiothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 859158-40-0 CAPLUS


CN Ethanimidamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 859158-41-1 CAPLUS

CN Carbamimidiothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)



RN 859158-42-2 CAPLUS


CN Carbamimidiothioic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



10/785,120


RN 859158-43-3 CAPLUS

CN Ethanimidamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
(9CI) (CA INDEX NAME)




RN 859158-45-5 CAPLUS

CN Thiourea, (10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 859158-46-6 CAPLUS


CN 2-Thiophenecarboximidamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 859158-47-7 CAPLUS

CN 2-Thiophenecarboximidamide, N-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

10/785,120

RN 859158-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(2-thiazolylamino)-
(9CI) (CA INDEX NAME)




IT 16398-16-6P 23474-66-0P 54255-81-1P
213208-07-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of dibenzo[b,e][1,4]diazepin-11-one and
dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating
stroke)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



RN 54255-81-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA
INDEX NAME)



RN 213208-07-2 CAPLUS

10/785,120

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5,10-dihydro- (9CI) (CA
INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:612094 CAPLUS

DN 143:133403

TI Amino-substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists, their preparation and use in the treatment of neuropsychiatric disorders

IN Ek, Fredrik; Olsson, Roger; Ohlsson, Joergen

PA Acadia Pharmaceuticals Inc., USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2005063254 | A2 | 20050714 | WO 2004-US43224 | 20041221 |
| | WO 2005063254 | A3 | 20050915 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2005192268 | A1 | 20050901 | US 2004-19555 | 20041221 |
| PRAI | US 2003-531927P | P | 20031222 | | |
| | US 2004-548090P | P | 20040224 | | |
| | US 2004-548604P | P | 20040227 | | |
| OS | MARPAT 143:133403 | | | | |
| GI | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of novel amino-substituted dibenzazepines I, benzazepines II and related clozapine analogs, which are agonists of muscarinic receptors. In compds. I and II, W is N, CH, O, or S; Y is N, O, or CH; R1, R6, and R7 are independently absent or selected from H, halo, amino, (un)substituted C1-20 alkyl, (un)substituted C3-8 cycloalkyl, (un)substituted aryl, etc., or R1R6 is -CH2CH2-; each R2, R3, R4, and R5 is independently selected from H, halo, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, cyano, etc., or R2 and R3, or R3 and R4, or R4 and R5 taken together, along with the ring carbons to which they are attached, form a 5- or 6-membered cycloalkyl, heterocyclyl or heteroaryl ring, or a 6-membered aryl ring; Z is (un)substituted NH, O, S, or CH2; and R8 and R9 are independently selected from H, halo, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, cyano, etc., or R8 and R9 taken together, along with the ring carbons to which they are attached, form a 5- or 6-membered cycloalkyl, heterocyclyl or heteroaryl ring, or a 6-membered aryl ring; including pharmaceutically acceptable salts, esters, amides or prodrugs of these, provided that compound I is not clozapine or N-desmethylozapine. The invention also relates to the preparation of I, preparation of a combinatorial library of compds. I, pharmaceutical compns. containing compound I with a physiol. acceptable carrier, diluent, or excipient, optionally including a neuropsychiatric agent as well as to the use of the

compns. for treating neuropsychiatric disorders. Substitution of 4-chloro-2-fluoronitrobenzene with 2-amino-5-chlorobenzoic acid followed by reduction of the nitro group, ring-closing coupling, and condensation with piperazine gave dibenzodiazepine III. The compds. of the invention express efficacy (eff) at muscarinic M1 receptors in the range of -11 to 92 and potency (expressed as pEC50) of 5.5 to 7.2; the compds. had eff at M2 receptors of -14 to 187 and pEC50 of 5.4 to 6.6.


IT **858670-39-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of amino-substituted diarylcycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders)

RN 858670-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-bromo-8-chloro-5,10-dihydro- (9CI)
(CA INDEX NAME)




IT **67104-22-7**

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of amino-substituted diarylcycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:76302 CAPLUS
 DN 142:170068
 TI Small molecule toll-like receptor (TLR) antagonists
 IN Lipford, Grayson B.; Forsbach, Alexandra; Zepp, Charles M.
 PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.
 SO PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2005007672 | A2 | 20050127 | WO 2004-US19714 | 20040618 |
| | WO 2005007672 | A3 | 20050915 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2005119273 | A1 | 20050602 | US 2004-872196 | 20040618 |
| PRAI | US 2003-480588P | P | 20030620 | | |
| | US 2004-556007P | P | 20040323 | | |

OS MARPAT 142:170068

AB The invention provides methods and compns. useful for modulating signaling through Toll-like receptors (TLR). The methods involve contacting a TLR-expressing cell with a small mol. having a core structure including at least two rings. Certain of the compds. are 4-primary amino quinolines. Many of the compds. and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft vs. host disease, infection, sepsis, cancer, and immunodeficiency.


IT 16398-16-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mol. toll-like receptor antagonists such as 4-primary amino quinolines to inhibit immunostimulatory signaling in response to antigens such as nucleic acids for treatment of autoimmune disorders)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 6 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1082026 CAPLUS

DN 142:38288

TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer

IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sullivan, Gerard M.; Wang, Le; Xia, Ping

PA USA

SO U.S. Pat. Appl. Publ., 137 pp.



CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2004254159 | A1 | 20041216 | US 2004-785120 | 20040225 |
| | CA 2515790 | AA | 20040910 | CA 2004-2515790 | 20040226 |
| | WO 2004076424 | A1 | 20040910 | WO 2004-US5728 | 20040226 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1606268 | A1 | 20051221 | EP 2004-715097 | 20040226 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRAI | US 2003-450476P | P | 20030227 | | |
| | US 2003-375412 | A | 20030227 | | |
| | US 2004-785120 | A | 20040225 | | |
| | WO 2004-US5728 | W | 20040226 | | |
| OS | MARPAT 142:38288 | | | | |
| GI | | | | | |



AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH,


NO₂; R₂-R₅ = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclylalkoxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R₆ and R₇ = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR₁₃; R₁₃ = aryl, cycloalkyl, heterocyclyl; X = O, NR₁₄, CO, S, SO₂, (CH₂)_n, CONR₁₄, NR₁₄CO, SO₂NR₁₄, NR₁₄SO₂, O(CH₂)_m, (CH₂)_mO, CH=CH, C.tplbond.C; R₁₄ = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR₁₅, O; R₁₅ = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K₂CO₃ in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC₅₀ values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate, kinase inhibitor; preparation of

dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755035-60-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



IT **755026-94-9P 755026-98-3P 755027-01-1P**, 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**, 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P**, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**, 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**, 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P**, **755028-00-3P 755028-37-6P**, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-44-5P**, **755028-45-6P**, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755028-47-8P**
755028-48-9P, 3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P**
755028-68-3P, 7-Amino-3-chloro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755028-80-9P**,
 3-Chloro-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755028-82-1P**,
 3-Chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755028-96-7P**
755028-97-8P 755029-00-6P, 3-Chloro-8-(2-hydroxyethyl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-02-8P**
755029-06-2P, 3-Chloro-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-12-0P**,
 8-Acetyl-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-21-1P, 3-Chloro-8-[2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-32-4P**,
 7-Bromo-3-chloro-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755029-33-5P 755029-35-7P 755029-37-9P**,
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755029-50-6P**
755029-52-8P, 3-Chloro-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-71-1P**,
 3-Chloro-8-(3-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755029-73-3P 755029-76-6P 755029-81-3P**
755029-98-2P 755030-00-3P, 3-Chloro-7-(2-hydroxy-2-
 methylpropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-03-6P, 3-Chloro-7-(2-hydroxyethyl)-8-methoxy-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755030-05-8P**,
 3-Chloro-8-methoxy-7-(2-oxopropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-13-8P**
755030-14-9P, 3-Chloro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-22-9P**,
 7-Bromo-3-chloro-8-(trifluoromethoxy)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-24-1P**
755030-25-2P 755030-26-3P, 3-Chloro-7-(3-hydroxypropyl)-
 8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-29-6P, 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-
 (trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-41-2P, 7-Bromo-3-chloro-8-methyl-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-43-4P**
755030-45-6P 755030-47-8P, 3-Chloro-7-(3-hydroxy-3-
 methylbutyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-51-4P, 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P**,
 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P**,
 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P**,
 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-87-6P**
755030-88-7P 755030-90-1P 755030-96-7P
755031-23-3P 755031-29-9P 755031-30-2P
755031-40-4P 755031-41-5P, 3-Chloro-7-(3-hydroxypropyl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-44-8P**,
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-46-0P**,
 3-Chloro-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-48-2P**,
 3-Chloro-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-50-6P**,
 3-Chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-11H-


dibenzo[b,e][1,4]diazepin-11-one **755031-59-5P**,
 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-63-1P**
755031-64-2P, 3-Chloro-8-[2-[[4-(morpholin-4-
 yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-72-2P, 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-74-4P**,
 3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-75-5P**,
 8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-76-6P**,
 3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-16-7P**
755032-64-5P 755032-66-7P 755032-68-9P,
 3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755032-70-3P**
755033-33-1P, 3-Chloro-8-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-42-2P**,
 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755033-45-5P**, (S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-
 yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-47-7P**
 , 3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755033-51-3P**, 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-62-6P**,
 3-Chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-72-8P**
755033-85-3P, 3-Chloro-8-(2-oxopropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-95-5P**
755034-06-1P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-10-7P**,
 3-Chloro-7-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-27-6P**,
 3-Chloro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-28-7P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]
]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-36-7P**
 , 3-Chloro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-37-8P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]
]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-66-3P**
 , 3-Chloro-7-hydroxy-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755034-67-4P 755034-68-5P 755034-75-4P**
 , 3-Chloro-7-ethoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-77-6P, 3-Chloro-7-hydroxy-5-[[2-
 (trimethylsilyl)ethoxy]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755034-78-7P 755034-90-3P**, 3-Chloro-7-
 (methoxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-92-5P, 7-(Bromomethyl)-3-chloro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-94-7P**,
 3-Chloro-7-[[[2-(dimethylamino)ethyl](methyl)amino]methyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-96-9P**,
 3-Chloro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-99-2P**,
 3-Chloro-8-hydroxy-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755035-00-8P 755035-02-0P**, 3-Chloro-7-methoxy-8-
 vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-03-1P, 3-Chloro-8-ethyl-7-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-05-3P**
755035-06-4P, 3-Chloro-8-methoxy-7-vinyl-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-10-0P**,
 8-Bromo-3-chloro-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-

one **755035-11-1P** **755035-12-2P** **755035-13-3P**,
 3-Chloro-8-(3-hydroxypropyl)-7-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-15-5P**,
 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755035-18-8P**,
 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-24-6P**,
 Methyl 3-chloro-7-methoxy-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-8-carboxylate **755035-41-7P**
755035-81-5P, 3-Chloro-8-[(4-methylpiperazin-1-yl)methyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-83-7P**,
 8-[(4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-
 dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-90-6P, 3-Chloro-8-(hydroxymethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-97-3P**,
 3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase
 inhibitors for treatment of cancer)


RN 755026-94-9 CAPLUS

CN Methanesulfonamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-
 dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755026-98-3 CAPLUS


CN Acetamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-
 yl)- (9CI) (CA INDEX NAME)



RN 755027-01-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-
 dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-07-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-13-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-35-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-
10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755028-00-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-
5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/785,120




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-44-5 CAPLUS

CN Butanamide, 4-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755028-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-47-8 CAPLUS

CN Pentanamide, 5-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-68-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-80-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-82-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755028-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)


RN 755028-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

RN 755029-00-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-02-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-06-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-12-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-21-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-32-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-33-5 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-35-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-37-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-50-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 755029-71-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 755029-73-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-76-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-81-3 CAPLUS

CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755029-98-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-00-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-03-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755030-05-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755030-13-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-14-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-22-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-24-1 CAPLUS

CN 2-Propenoic acid, 3-[3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-5H-dibenzo[b,e][1,4]diazepin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-25-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-26-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-29-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-41-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-43-4 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methyl-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 755030-45-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755030-47-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-55-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/785,120




RN 755030-57-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-87-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-88-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-90-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755031-29-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-30-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-40-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 755031-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755031-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-48-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 755031-50-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-59-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-63-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-74-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-75-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755032-64-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-66-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-33-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755033-42-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-51-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755033-62-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(2-ethyl-2-hydroxybutyl)- 5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-85-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-95-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)



RN 755034-06-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755034-10-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-27-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-28-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-36-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-37-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-66-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-67-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]butoxy]-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-75-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethoxy-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-77-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-5-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-78-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[1,1-dimethylethyl]dimethylsilyl]oxy]butoxy]-5,10-dihydro-5-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-90-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(methoxymethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-92-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(bromomethyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-94-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-96-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-99-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-00-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 755035-02-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethenyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-03-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-05-3 CAPLUS


CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-06-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethenyl-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755035-10-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-11-1 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 755035-12-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 755035-13-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-18-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-24-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755035-90-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




IT 755026-34-7P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-36-9P, 8-Bromo-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-38-1P, 3-Chloro-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-40-5P, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile 755026-45-0P 755026-53-0P, 3-Bromo-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-56-3P, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-57-4P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid 755026-72-3P 755026-73-4P 755026-74-5P 755027-09-9P 755027-12-4P 755027-23-7P 755027-24-8P 755027-25-9P 755027-41-9P 755027-43-1P 755027-44-2P 755027-96-4P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate 755028-36-5P 755028-41-2P, 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-51-4P 755028-57-0P 755028-65-0P, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-69-4P 755029-08-4P 755029-13-1P 755029-56-2P 755029-58-4P 755029-69-7P, 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-70-0P, 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755030-02-5P, 7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P 755032-40-7P 755032-41-8P 755032-44-1P 755032-47-4P 755032-56-5P 755032-58-7P 755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic)

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-34-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-36-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro- (9CI)
(CA INDEX NAME)




RN 755026-38-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-nitro- (9CI)
(CA INDEX NAME)



RN 755026-40-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 3-chloro-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-45-0 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-53-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-bromo-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755026-57-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-72-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755026-73-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 755027-09-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-12-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-25-9 CAPLUS


CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755027-41-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-43-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3


CMF C20 H16 N4 O4




CM 2

10/785,120


CRN 76-05-1
CMF C2 H F3 O2




RN 755028-36-5 CAPLUS
CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755028-41-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755029-08-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-13-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-69-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755029-70-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-02-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-40-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-41-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-56-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-58-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 755026-42-7P, 3-Chloro-8-(trifluoromethyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755026-48-3P,

8-Amino-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755026-50-7P, 3-Chloro-8-hydroxy-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755026-54-1P,

3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one 755026-55-2P 755026-58-5P, 3-(4-Hydroxy-3-

methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-59-6P**
755026-60-9P, N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-61-0P 755026-62-1P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-63-2P**
755026-64-3P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-65-4P 755026-66-5P**,
 N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-67-6P**,
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-68-7P**,
 N-[2-(Acetylamino)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-69-8P**
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-70-1P**,
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-71-2P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-piperidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-75-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-76-7P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-77-8P 755026-78-9P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-79-0P**
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-80-3P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-81-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-82-5P**
755026-83-6P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-84-7P 755026-85-8P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-86-9P**
755026-87-0P 755026-88-1P 755026-89-2P
755026-90-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile **755026-91-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-92-7P**,
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one hydrochloride **755026-93-8P**
755026-95-0P 755026-97-2P 755026-99-4P
755027-00-0P, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-02-2P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-04-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-06-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-08-8P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-10-2P**
755027-11-3P 755027-14-6P, 3-(3-Methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-15-7P**,
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-17-9P**, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755027-19-1P**
755027-20-4P, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-22-6P**
755027-26-0P 755027-27-1P 755027-28-2P
755027-29-3P 755027-32-8P, 3-(2-Methoxypyridin-4-yl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-34-0P**,
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755027-39-5P**
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
755027-40-8P 755027-45-3P 755027-46-4P
755027-47-5P, 8-[2-(3-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-
 methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755027-48-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-
 diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755027-50-0P 755027-51-1P**, 8-[2-(4-Hydroxy-1-
 piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-52-2P**
755027-53-3P 755027-54-4P 755027-55-5P
755027-56-6P 755027-57-7P 755027-58-8P
755027-59-9P 755027-60-2P 755027-61-3P
755027-62-4P 755027-63-5P 755027-66-8P
755027-67-9P 755027-68-0P 755027-69-1P
755027-71-5P 755027-72-6P 755027-73-7P
755027-74-8P 755027-75-9P 755027-76-0P
755027-77-1P 755027-78-2P, 8-[2-(4-Ethyl-1-piperazinyl)-
 2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-79-3P**,
 8-[2-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-oxoethyl]-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755027-80-6P 755027-81-7P, 3-(3-Methoxy-4-nitrophenyl)-8-
 [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-82-8P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-[4-(pyridin-2-yl)-1-
 piperazinyl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755027-83-9P 755027-84-0P 755027-85-1P
755027-86-2P 755027-87-3P 755027-88-4P
755027-89-5P 755027-90-8P 755027-91-9P
755027-92-0P 755027-93-1P 755027-94-2P,
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755027-95-3P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-97-5P**
755027-98-6P 755027-99-7P 755028-01-4P
755028-02-5P 755028-03-6P 755028-04-7P
755028-05-8P 755028-06-9P 755028-07-0P
755028-08-1P 755028-09-2P 755028-10-5P
755028-11-6P 755028-12-7P 755028-13-8P
755028-14-9P 755028-15-0P 755028-16-1P
755028-19-4P 755028-21-8P 755028-22-9P
755028-24-1P 755028-25-2P 755028-26-3P
755028-27-4P 755028-28-5P 755028-29-6P
755028-30-9P 755028-31-0P 755028-32-1P
755028-33-2P 755028-34-3P 755028-35-4P
755028-38-7P 755028-39-8P 755028-40-1P
755028-42-3P 755028-43-4P, 3-(3-Methoxy-4-nitrophenyl)-8-
 (2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-46-7P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-49-0P**,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755028-52-5P**

755028-53-6P, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-54-7P 755028-55-8P 755028-56-9P
755028-58-1P, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-59-2P 755028-60-5P 755028-61-6P
755028-62-7P 755028-63-8P 755028-64-9P
755028-70-7P 755028-71-8P 755028-72-9P
755028-73-0P 755028-74-1P 755028-75-2P
755028-76-3P 755028-77-4P 755028-78-5P
755028-79-6P, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-81-0P, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-83-2P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-84-3P, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-86-5P
755028-87-6P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-88-7P, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-89-8P, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-90-1P, 3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-91-2P, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-92-3P, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-93-4P, 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-94-5P
755028-95-6P 755028-98-9P 755028-99-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-01-7P
755029-03-9P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-04-0P, 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-05-1P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-07-3P
755029-09-5P 755029-10-8P, 3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-11-9P, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-14-2P, 3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-15-3P
755029-16-4P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-17-5P 755029-18-6P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-19-7P
755029-20-0P, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-22-2P, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-23-3P, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-39-1P, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755029-41-5P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-43-7P, 3-Chloro-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-44-8P**,
 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-46-0P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-54-0P**,
 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-60-8P**
755029-61-9P 755029-63-1P, 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**
755029-67-5P, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-68-6P 755029-72-2P 755029-74-4P
755029-78-8P, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-80-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-83-5P 755029-85-7P, 7-(2-Hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P**,
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P**,
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P**,
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-31-0P, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-48-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-53-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-60-5P 755030-62-7P 755030-63-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755026-42-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755026-48-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-chloro-5,10-dihydro- (9CI)
(CA INDEX NAME)




RN 755026-50-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy- (9CI) (CA INDEX NAME)




RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755026-55-2 CAPLUS


CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 755026-58-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-59-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-58-5


CMF C28 H30 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-60-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-61-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-60-9


CMF C26 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-62-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-63-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1

CMF C28 H30 N4 O5


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5




CM 2

10/785,120


CRN 76-05-1
CMF C2 H F3 O2




RN 755026-66-5 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-67-6 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-68-7 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-69-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)


10/785,120



RN 755026-70-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-75-6 CAPLUS


CN 3-Piperidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-76-7 CAPLUS

10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-77-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-76-7


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-78-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-79-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-80-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-82-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-84-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-83-6

CMF C27 H22 N4 O4


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-85-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-86-9 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-87-0 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-88-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-89-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 755026-90-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-91-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)

10/785,120



RN 755026-92-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-95-0 CAPLUS


CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-97-2 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-02-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-04-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-10-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-11-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-17-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-19-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-20-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-22-6 CAPLUS

CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-32-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-34-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-40-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755027-48-6 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 755027-50-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-51-1 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-52-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-53-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-55-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-57-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-58-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/785,120



RN 755027-59-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 755027-60-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-61-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


10/785,120



RN 755027-62-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-63-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-66-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-68-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-69-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755027-71-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-74-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-75-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-76-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)



RN 755027-78-2 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 755027-79-3 CAPLUS


10/785,120

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-81-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755027-82-8 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-83-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-86-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-90-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidiny)propyl]- (9CI) (CA INDEX NAME)



RN 755027-91-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-94-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755027-95-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-97-5 CAPLUS

CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755027-98-6 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755027-99-7 CAPLUS


CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-01-4 CAPLUS

CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-02-5 CAPLUS

CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-03-6 CAPLUS


CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 755028-04-7 CAPLUS


CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-07-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 755028-08-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-11-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-12-7 CAPLUS


CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS

CN Benzenebutamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-16-1 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[(4-methylphenyl)sulfonyl]amino]- (9CI)
(CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-22-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-24-1 CAPLUS

CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-25-2 CAPLUS

CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 755028-26-3 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 755028-27-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -methoxy-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-30-9 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -methoxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-33-2 CAPLUS


CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS

10/785,120


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS

CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-39-8 CAPLUS


CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-43-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755028-46-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemesanesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-54-7 CAPLUS

CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-58-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-59-2 CAPLUS


CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-62-7 CAPLUS


CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755028-63-8 CAPLUS


CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-64-9 CAPLUS

CN Benzanide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-73-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-74-1 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-75-2 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-76-3 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)



RN 755028-79-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-81-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 755028-90-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 755028-91-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-94-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 755028-95-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-98-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)

RN 755029-03-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 755029-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-09-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-10-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-11-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-18-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755029-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755029-44-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755029-46-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-63-1 CAPLUS

CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-66-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-67-5 CAPLUS

CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-74-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-28-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-31-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-60-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-62-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755030-63-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT **755030-65-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-66-1P, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-67-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-69-4P 755030-71-8P 755030-73-0P
755030-75-2P 755030-77-4P 755030-80-9P
755030-91-2P 755030-97-8P 755030-99-0P
755031-01-7P 755031-03-9P 755031-05-1P
755031-07-3P 755031-10-8P 755031-12-0P
755031-15-3P 755031-16-4P 755031-17-5P
755031-19-7P 755031-20-0P 755031-24-4P
755031-31-3P 755031-33-5P 755031-35-7P
755031-36-8P, 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-43-7P**,
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-45-9P**,
 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-47-1P**,
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-49-3P**,
 8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-51-7P**,
 7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-52-8P**,
 8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-53-9P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-54-0P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-55-1P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-57-3P**,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-58-4P**,

3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-60-8P**,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-61-9P**
755031-62-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-65-3P 755031-67-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(5-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-68-6P**
755031-69-7P, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-70-0P 755031-71-1P, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-73-3P**,
 8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-77-7P 755031-78-8P, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**
755031-87-9P 755031-89-1P 755031-91-5P, 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**
755031-94-8P 755031-95-9P 755031-96-0P
755031-97-1P 755031-98-2P 755031-99-3P
755032-00-9P 755032-01-0P 755032-02-1P
755032-03-2P 755032-04-3P 755032-05-4P
755032-06-5P 755032-07-6P 755032-08-7P
755032-09-8P 755032-10-1P 755032-11-2P
755032-12-3P 755032-13-4P 755032-14-5P
755032-15-6P 755032-17-8P 755032-18-9P,
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-19-0P 755032-20-3P, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**
755032-22-5P 755032-23-6P 755032-24-7P
755032-25-8P 755032-26-9P 755032-27-0P
755032-28-1P 755032-29-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P 755032-31-6P 755032-32-7P**
755032-33-8P 755032-34-9P 755032-35-0P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**
755032-38-3P, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-39-4P, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-42-9P 755032-43-0P 755032-45-2P,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate
755032-48-5P 755032-49-6P, (S)-8-[2-[(2-Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**
755032-51-0P 755032-52-1P 755032-53-2P,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-

5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-(2-(hydroxymethyl)pyrrolidin-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-55-4P 755032-57-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**
755032-65-6P 755032-67-8P, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**
755032-71-4P 755032-75-8P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**
755032-79-2P, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-80-5P, 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-81-6P 755032-82-7P 755032-83-8P
755032-84-9P, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-85-0P 755032-86-1P 755032-87-2P,
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-88-3P 755032-89-4P 755032-90-7P
755032-91-8P 755032-92-9P, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**
755032-96-3P 755032-97-4P 755032-99-6P
755033-01-3P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-03-5P 755033-04-6P 755033-05-7P
755033-06-8P 755033-07-9P 755033-08-0P
755033-09-1P 755033-10-4P, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-14-8P 755033-15-9P 755033-16-0P
755033-17-1P 755033-18-2P 755033-19-3P
755033-20-6P 755033-21-7P 755033-22-8P
755033-23-9P 755033-24-0P 755033-25-1P
755033-26-2P 755033-27-3P 755033-28-4P
755033-29-5P, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,


8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-54-6P**
755033-59-1P, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-65-9P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-68-2P 755033-75-1P 755033-79-5P,
 8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-81-9P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-83-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-87-5P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-89-7P**,
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-92-2P**
755033-93-3P 755033-96-6P, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-00-5P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-02-7P**, Methyl
 11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-08-3P**, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-11-8P, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-12-9P 755034-14-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-18-5P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-20-9P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-29-8P, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-38-9P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-39-0P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-40-3P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-41-4P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-42-5P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-43-6P 755034-44-7P 755034-45-8P,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755034-46-9P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-48-1P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-49-2P**, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-50-5P**, (R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-51-6P**
755034-52-7P, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-53-8P**, 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-54-9P**, 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-55-0P**, 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-56-1P **755034-57-2P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-58-3P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate **755034-59-4P**, 7-[2-(Dimethylamino)ethoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-61-8P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-63-0P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-64-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-65-2P**, 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-69-6P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755030-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-66-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-67-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-71-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



10/785,120


RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-


10/785,120

10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-
(9CI) (CA INDEX NAME)




RN 755030-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-
10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-
(9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA
INDEX NAME)




RN 755031-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)- α,α -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA
INDEX NAME)




RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755031-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755031-10-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755031-12-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-16-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-31-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-33-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-36-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-43-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-45-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 755031-55-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 755031-57-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-61-9 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755031-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-73-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-77-7 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-87-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-89-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-

10/785,120


methyl-4-pyridinyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-
11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 755031-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

RN 755031-96-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)


RN 755031-97-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/785,120


RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 755032-01-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 755032-02-1 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-05-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-06-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-07-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-08-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-09-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-13-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-14-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755032-15-6 CAPLUS .

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS

CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755032-19-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro-
α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX
NAME)




RN 755032-20-3 CAPLUS

CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-
dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX
NAME)




RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-
dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]-
(9CI) (CA INDEX NAME)




RN 755032-22-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-
dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA
INDEX NAME)




RN 755032-23-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-25-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755032-26-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




acetamide, N-(4-fluorophenyl)-10,11-
 yl)- α,α -dimethyl-11-oxo- (9CI)



-one, 5,10-dihydro-3-(3-methoxy-4-
 oxy)ethyl]- (9CI) (CA INDEX NAME)




-one, 5,10-dihydro-3-(3-methoxy-4-



acetamide, N-(2-ethoxyethyl)-10,11-dihydro-
 dimethyl-11-oxo- (9CI) (CA


10/785,120

nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-33-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-34-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-36-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-37-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

10/785,120

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-49-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755032-50-9 CAPLUS

CN Carbamic acid, [1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-51-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-52-1 CAPLUS


CN Carbamic acid, [1-[[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-55-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-57-6 CAPLUS


10/785,120

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-61-2 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-62-3 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-67-8 CAPLUS

CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-69-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-78-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-79-2 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-80-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755032-84-9 CAPLUS


CN Azetidinium, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-85-0 CAPLUS


10/785,120

CN 3-Piperidinecarboxamide, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755032-88-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755033-05-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-06-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-


10/785,120

yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-09-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-10-4 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755033-13-7 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755033-14-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/785,120

RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-27-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-28-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-35-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-39-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidiny)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-


10/785,120

(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755033-68-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 755033-75-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755033-83-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-87-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755033-93-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-96-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755034-08-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-11-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-12-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755034-18-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-39-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidiny)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-40-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-48-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755034-51-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-50-5

CMF C26 H26 N4 O6


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-52-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-53-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-54-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-55-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

COc1cc(C2=CC=C3C(=C2)N(C(=O)N3Cc4ccc(OC)c(Oc5ccccc5)cc4)c5ccc(OC)c5)cc(OC)c1

CN 1-Propanesulfonic acid, 3-[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy-(9CI) (CA INDEX NAME)




CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 755034-57-2
CMF C24 H24 N4 O6




10/785,120

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



IT **755034-70-9P 755034-71-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-72-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-73-2P**, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-76-5P**, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-80-1P**, 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-82-3P**, 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-83-4P**, 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-84-5P**, 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-91-4P**, 7-[(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-93-6P**, 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-95-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755034-97-0P**, 8-Ethyl-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-04-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-07-5P**,
 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-14-4P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-16-6P, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-17-7P, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-19-9P**,
 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-20-2P**
755035-22-4P, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-25-7P, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-26-8P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-27-9P** **755035-28-0P** **755035-30-4P**
755035-31-5P **755035-33-7P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-34-8P**,
 (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-35-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-36-0P**
755035-37-1P **755035-38-2P** **755035-39-3P**, (R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-42-8P** **755035-44-0P** **755035-45-1P**,
 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P**
755035-47-3P **755035-48-4P** **755035-49-5P** **755035-50-8P**, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-51-9P, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-52-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-53-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-54-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-56-4P, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-57-5P, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**,
 8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**,
 7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-63-3P, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-


nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-64-4P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-65-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-67-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-68-8P 755035-69-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**, 8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-73-5P 755035-74-6P, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-75-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-82-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-84-8P 755035-86-0P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-91-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-99-5P**, (R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl)methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-00-1P, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-01-2P, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-02-3P 755036-04-5P, 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-84-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-91-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 755034-97-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-04-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-isoquinolinylloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755035-22-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755035-25-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-26-8 CAPLUS

CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-27-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-N,N,α,α-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-28-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-2-


10/785,120

thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-37-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-42-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



10/785,120


RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-51-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-52-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-53-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-57-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-61-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-63-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755035-65-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755035-67-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-70-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)



RN 755035-71-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755035-73-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-74-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 755035-84-8 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755035-86-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)

10/785,120



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755036-00-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755036-01-2 CAPLUS


10/785,120

CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755036-02-3 CAPLUS

CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)



RN 755036-04-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755031-66-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 7 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:967765 CAPLUS

DN 142:129218

TI Identification of a novel non-carbohydrate molecule that binds to the ribosomal A-site RNA

AU Maddaford, Shawn P.; Motamed, Mina; Turner, Kevin B.; Choi, Min Soo K.; Ramnauth, Jailall; Rakhit, Suman; Hudgins, Robert R.; Fabris, Daniele; Johnson, Philip E.

CS MCR Research Inc., Toronto, ON, M3J 1P3, Can.

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(24), 5987-5990
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 142:129218

AB We report the identification of a novel compound that binds to the Escherichia coli 16S ribosomal A-site. Binding by the compound was observed using NMR and mass spectrometry techniques. We show that the compound binds in the same position in the A-site RNA as occupied by the aminoglycoside class of antibiotics.


IT **16398-16-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel non-carbohydrate mol. MCR13 that binds to the ribosomal A-site RNA)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 8 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:740305 CAPLUS

DN 141:260782

TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer

IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sowin, Tom; Sullivan, Gerard M.; Wang, Le; Xia, Ping Xia

PA Abbott Laboratories, USA

SO PCT Int. Appl., 382 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004076424 | A1 | 20040910 | WO 2004-US5728 | 20040226 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004254159 | A1 | 20041216 | US 2004-785120 | 20040225 |
| | CA 2515790 | AA | 20040910 | CA 2004-2515790 | 20040226 |
| | EP 1606268 | A1 | 20051221 | EP 2004-715097 | 20040226 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRAI | US 2003-375412 | A | 20030227 | | |
| | US 2004-785120 | A | 20040225 | | |
| | US 2003-450476P | P | 20030227 | | |
| | WO 2004-US5728 | W | 20040226 | | |
| OS | MARPAT 141:260782 | | | | |
| GI | | | | | |



AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH,

NO₂; R₂-R₅ = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclyloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R₆ and R₇ = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR₁₃; R₁₃ = aryl, cycloalkyl, heterocyclyl; X = O, NR₁₄, CO, S, SO₂, (CH₂)_n, CONR₁₄, NR₁₄CO, SO₂NR₁₄, NR₁₄SO₂, O(CH₂)_m, (CH₂)_mO, CH=CH, C.tplbond.C; R₁₄ = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR₁₅, O; R₁₅ = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K₂CO₃ in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC₅₀ values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

- IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate, kinase inhibitor; preparation of
 dibenzo[b,e][1,4]diazepin-11-
 ones as kinase inhibitors for treatment of cancer)
 RN 755035-60-0 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



- IT **755026-94-9P 755026-98-3P 755027-01-1P**,
 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**,
 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P**
755027-16-8P, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**,
 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**,
 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P**
755028-00-3P 755028-37-6P, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-44-5P**
755028-45-6P, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755028-47-8P**
755028-48-9P, 3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P**
755028-68-3P, 7-Amino-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-80-9P**,
 3-Chloro-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-82-1P**,
 3-Chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-96-7P**
755028-97-8P **755029-00-6P**, 3-Chloro-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-02-8P**
755029-06-2P, 3-Chloro-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-12-0P**,
 8-Acetyl-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-21-1P**, 3-Chloro-8-(2-(pyridin-2-yloxy)ethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-32-4P**,
 7-Bromo-3-chloro-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-33-5P** **755029-35-7P** **755029-37-9P**,
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-50-6P**
755029-52-8P, 3-Chloro-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-71-1P**,
 3-Chloro-8-(3-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-73-3P** **755029-76-6P** **755029-81-3P**
755029-98-2P **755030-00-3P**, 3-Chloro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-03-6P**,
 3-Chloro-7-(2-hydroxyethyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-05-8P**,
 3-Chloro-8-methoxy-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-13-8P**
755030-14-9P, 3-Chloro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-22-9P**,
 7-Bromo-3-chloro-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-24-1P**
755030-25-2P **755030-26-3P**, 3-Chloro-7-(3-hydroxypropyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-29-6P**,
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-41-2P**,
 7-Bromo-3-chloro-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-43-4P**
755030-45-6P **755030-47-8P**, 3-Chloro-7-(3-hydroxy-3-methylbutyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-51-4P**,
 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P**,
 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P**,
 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P**,
 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-87-6P**
755030-88-7P **755030-90-1P** **755030-96-7P**
755031-23-3P **755031-29-9P** **755031-30-2P**
755031-40-4P **755031-41-5P**, 3-Chloro-7-(3-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-44-8P**,
 3-Chloro-7-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-46-0P**,
 3-Chloro-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-48-2P**,
 3-Chloro-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-50-6P**,
 3-Chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755031-59-5P**,
 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-63-1P**
755031-64-2P, 3-Chloro-8-[2-[[4-(morpholin-4-
 yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-72-2P, 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-74-4P**,
 3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-75-5P**,
 8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755031-76-6P**,
 3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-16-7P**
755032-64-5P 755032-66-7P 755032-68-9P,
 3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755032-70-3P**
755033-33-1P, 3-Chloro-8-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-42-2P**,
 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755033-45-5P**, (S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-
 yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-47-7P**
 , 3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755033-51-3P**, 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-62-6P**,
 3-Chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-72-8P**
755033-85-3P, 3-Chloro-8-(2-oxopropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755033-95-5P**
755034-06-1P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-10-7P**,
 3-Chloro-7-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-27-6P**,
 3-Chloro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-28-7P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]
]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-36-7P**
 , 3-Chloro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-37-8P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]
]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-66-3P**
 , 3-Chloro-7-hydroxy-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755034-67-4P 755034-68-5P 755034-75-4P**
 , 3-Chloro-7-ethoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-77-6P, 3-Chloro-7-hydroxy-5-[[2-
 (trimethylsilyl)ethoxy]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755034-78-7P 755034-90-3P**, 3-Chloro-7-
 (methoxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-92-5P, 7-(Bromomethyl)-3-chloro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-94-7P**,
 3-Chloro-7-[[[2-(dimethylamino)ethyl](methyl)amino]methyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-96-9P**,
 3-Chloro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-99-2P**,
 3-Chloro-8-hydroxy-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755035-00-8P 755035-02-0P**, 3-Chloro-7-methoxy-8-
 vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-03-1P, 3-Chloro-8-ethyl-7-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-05-3P**
755035-06-4P, 3-Chloro-8-methoxy-7-vinyl-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-10-0P**,
 8-Bromo-3-chloro-7-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-


one **755035-11-1P** **755035-12-2P** **755035-13-3P**,
 3-Chloro-8-(3-hydroxypropyl)-7-methoxy-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-15-5P**,
 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755035-18-8P**,
 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-24-6P**,
 Methyl 3-chloro-7-methoxy-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-8-carboxylate **755035-41-7P**
755035-81-5P, 3-Chloro-8-[(4-methylpiperazin-1-yl)methyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-83-7P**,
 8-[(4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-
 dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-90-6P, 3-Chloro-8-(hydroxymethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-97-3P**,
 3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase
 inhibitors for treatment of cancer)


RN 755026-94-9 CAPLUS

CN Methanesulfonamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-
 dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755026-98-3 CAPLUS


CN Acetamide, N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-
 yl)- (9CI) (CA INDEX NAME)



RN 755027-01-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-
 dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-07-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-13-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-35-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755028-00-3 CAPLUS

CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/785,120




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-44-5 CAPLUS

CN Butanamide, 4-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



RN 755028-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-47-8 CAPLUS

CN Pentanamide, 5-chloro-N-(3-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-68-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755028-80-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-82-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755028-97-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-00-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-02-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-06-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 755029-12-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755029-21-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-32-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-33-5 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-35-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-37-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-50-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 755029-71-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 755029-73-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-76-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-81-3 CAPLUS

CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755029-98-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-00-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-03-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755030-05-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755030-13-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-8-methoxy-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-14-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-22-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-24-1 CAPLUS

CN 2-Propenoic acid, 3-[3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-5H-dibenzo[b,e][1,4]diazepin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-25-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-8-(trifluoromethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-26-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-29-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-41-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-bromo-3-chloro-5,10-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-43-4 CAPLUS

CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-8-methyl-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl)-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 755030-45-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-8-methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120



RN 755030-47-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-55-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/785,120




RN 755030-57-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-87-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-88-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-90-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755031-29-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-chloro-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755031-30-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-40-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 755031-44-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 755031-46-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-48-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 755031-50-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-59-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-63-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-74-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755031-75-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755032-64-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-66-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-33-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755033-42-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-51-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-62-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-85-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-95-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)



RN 755034-06-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755034-10-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-27-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-methoxy-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)



RN 755034-28-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)



RN 755034-36-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-37-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-66-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-67-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-75-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethoxy-5,10-dihydro-
(9CI) (CA INDEX NAME)




RN 755034-77-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-hydroxy-5-
[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-78-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[4-[[[(1,1-
dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-5-[[2-
(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 755034-90-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-
(methoxymethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-92-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(bromomethyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755034-94-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755034-96-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 755034-99-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy-7-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-00-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl ester (9CI) (CA INDEX NAME)




RN 755035-02-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethenyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-03-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-ethyl-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-05-3 CAPLUS


CN Methanesulfonic acid, trifluoro-, 3-chloro-10,11-dihydro-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-06-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-7-ethenyl-5,10-dihydro-8-methoxy- (9CI) (CA INDEX NAME)




RN 755035-10-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 755035-11-1 CAPLUS


CN 2-Propenoic acid, 3-(3-chloro-10,11-dihydro-7-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 755035-12-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-13-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[(2-methyl-3-pyridinyl)oxy]propyl- (9CI) (CA INDEX NAME)



RN 755035-18-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-24-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-7-methoxy-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755035-90-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



IT 755026-34-7P, Methyl 3-chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-36-9P, 8-Bromo-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-38-1P, 3-Chloro-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-40-5P, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile 755026-45-0P 755026-53-0P, 3-Bromo-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-56-3P, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-57-4P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid 755026-72-3P 755026-73-4P 755026-74-5P 755027-09-9P 755027-12-4P 755027-23-7P 755027-24-8P 755027-25-9P 755027-41-9P 755027-43-1P 755027-44-2P 755027-96-4P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate 755028-36-5P 755028-41-2P, 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-51-4P 755028-57-0P 755028-65-0P, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-69-4P 755029-08-4P 755029-13-1P 755029-56-2P 755029-58-4P 755029-69-7P, 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-70-0P, 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755030-02-5P, 7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P 755032-40-7P 755032-41-8P 755032-44-1P 755032-47-4P 755032-56-5P 755032-58-7P 755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic


10/785,120

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-34-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-36-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-bromo-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-38-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-nitro- (9CI) (CA INDEX NAME)



RN 755026-40-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 3-chloro-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-45-0 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-chloro-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-53-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-bromo-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755026-57-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-72-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755026-73-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 755027-09-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-12-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-25-9 CAPLUS


CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755027-41-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-43-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3


CMF C20 H16 N4 O4




CM 2

10/785,120


CRN 76-05-1
CMF C2 H F3 O2




RN 755028-36-5 CAPLUS
CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755028-41-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS
CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755029-08-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-13-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-69-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755029-70-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-02-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-40-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-41-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-56-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-58-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT **755026-42-7P**, 3-Chloro-8-(trifluoromethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-48-3P**,

8-Amino-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755026-50-7P, 3-Chloro-8-hydroxy-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one **755026-54-1P**,

3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755026-55-2P** **755026-58-5P**, 3-(4-Hydroxy-3-

methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-59-6P**
755026-60-9P, N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-61-0P 755026-62-1P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-63-2P**
755026-64-3P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-65-4P 755026-66-5P**,
 N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-67-6P**,
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-68-7P**,
 N-[2-(Acetylaminomethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-69-8P**
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-70-1P**,
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[(2-(hydroxymethyl)-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-71-2P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(2-(hydroxymethyl)-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-75-6P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-76-7P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-77-8P 755026-78-9P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-79-0P**
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-80-3P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-81-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-82-5P**
755026-83-6P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-84-7P 755026-85-8P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-86-9P**
755026-87-0P 755026-88-1P 755026-89-2P
755026-90-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile **755026-91-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-92-7P**,
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one hydrochloride **755026-93-8P**
755026-95-0P 755026-97-2P 755026-99-4P
755027-00-0P, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-02-2P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-04-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-06-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-08-8P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-10-2P**
755027-11-3P 755027-14-6P, 3-(3-Methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-15-7P**,
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-17-9P**, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-

dibenzo[b,e][1,4]diazepin-11-one 755027-19-1P
 755027-20-4P, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755027-22-6P
 755027-26-0P 755027-27-1P 755027-28-2P
 755027-29-3P 755027-32-8P, 3-(2-Methoxypyridin-4-yl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-34-0P,
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755027-39-5P
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
 755027-40-8P 755027-45-3P 755027-46-4P
 755027-47-5P, 8-[2-(3-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-
 methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-48-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-
 diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one 755027-50-0P 755027-51-1P, 8-[2-(4-Hydroxy-1-
 piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755027-52-2P
 755027-53-3P 755027-54-4P 755027-55-5P
 755027-56-6P 755027-57-7P 755027-58-8P
 755027-59-9P 755027-60-2P 755027-61-3P
 755027-62-4P 755027-63-5P 755027-66-8P
 755027-67-9P 755027-68-0P 755027-69-1P
 755027-71-5P 755027-72-6P 755027-73-7P
 755027-74-8P 755027-75-9P 755027-76-0P
 755027-77-1P 755027-78-2P, 8-[2-(4-Ethyl-1-piperazinyl)-
 2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755027-79-3P,
 8-[2-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-oxoethyl]-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-80-6P 755027-81-7P, 3-(3-Methoxy-4-nitrophenyl)-8-
 [2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755027-82-8P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-[4-(pyridin-2-yl)-1-
 piperazinyl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-83-9P 755027-84-0P 755027-85-1P
 755027-86-2P 755027-87-3P 755027-88-4P
 755027-89-5P 755027-90-8P 755027-91-9P
 755027-92-0P 755027-93-1P 755027-94-2P,
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-95-3P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755027-97-5P
 755027-98-6P 755027-99-7P 755028-01-4P
 755028-02-5P 755028-03-6P 755028-04-7P
 755028-05-8P 755028-06-9P 755028-07-0P
 755028-08-1P 755028-09-2P 755028-10-5P
 755028-11-6P 755028-12-7P 755028-13-8P
 755028-14-9P 755028-15-0P 755028-16-1P
 755028-19-4P 755028-21-8P 755028-22-9P
 755028-24-1P 755028-25-2P 755028-26-3P
 755028-27-4P 755028-28-5P 755028-29-6P
 755028-30-9P 755028-31-0P 755028-32-1P
 755028-33-2P 755028-34-3P 755028-35-4P
 755028-38-7P 755028-39-8P 755028-40-1P
 755028-42-3P 755028-43-4P, 3-(3-Methoxy-4-nitrophenyl)-8-
 (2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-46-7P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-49-0P,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one 755028-52-5P

755028-53-6P, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-54-7P** **755028-55-8P** **755028-56-9P**
755028-58-1P, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-59-2P **755028-60-5P** **755028-61-6P**
755028-62-7P **755028-63-8P** **755028-64-9P**
755028-70-7P **755028-71-8P** **755028-72-9P**
755028-73-0P **755028-74-1P** **755028-75-2P**
755028-76-3P **755028-77-4P** **755028-78-5P**
755028-79-6P, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-81-0P, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-83-2P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-84-3P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-86-5P**
755028-87-6P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-88-7P, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-89-8P**, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-90-1P, 3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-91-2P, 3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-92-3P, 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-93-4P**, 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-94-5P**
755028-95-6P **755028-98-9P** **755028-99-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-01-7P**
755029-03-9P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-04-0P**, 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-05-1P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-07-3P**
755029-09-5P **755029-10-8P**, 3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-11-9P, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-14-2P**, 3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-15-3P**
755029-16-4P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-17-5P **755029-18-6P**, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-19-7P**
755029-20-0P, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-22-2P**, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-23-3P, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-39-1P, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755029-41-5P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-43-7P, 3-Chloro-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-44-8P**,
 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-46-0P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-54-0P**,
 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-60-8P**
755029-61-9P 755029-63-1P, 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**
755029-67-5P, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-68-6P 755029-72-2P 755029-74-4P
755029-78-8P, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-80-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-83-5P 755029-85-7P, 7-(2-Hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P**,
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P**,
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P**,
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-31-0P, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-48-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-53-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-60-5P 755030-62-7P 755030-63-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755026-42-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755026-48-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-chloro-5,10-dihydro- (9CI)
(CA INDEX NAME)




RN 755026-50-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-hydroxy- (9CI) (CA INDEX NAME)




RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755026-55-2 CAPLUS


CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 755026-58-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-59-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-58-5


CMF C28 H30 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-60-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-61-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-60-9


CMF C26 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-62-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-63-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1

CMF C28 H30 N4 O5


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5




CM 2

10/785,120


CRN 76-05-1
CMF C2 H F3 O2




RN 755026-66-5 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-67-6 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-68-7 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-69-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)


10/785,120



RN 755026-70-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-75-6 CAPLUS


CN 3-Piperidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-76-7 CAPLUS

10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-77-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-76-7


CMF C27 H22 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 755026-78-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-79-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-80-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-82-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/785,120

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-84-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-83-6

CMF C27 H22 N4 O4


10/785,120



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-85-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-86-9 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-87-0 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-88-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-89-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 755026-90-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-91-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)

10/785,120



RN 755026-92-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-95-0 CAPLUS


CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755026-97-2 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-02-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 755027-04-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-10-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-11-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-17-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-19-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)


10/785,120




RN 755027-20-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755027-22-6 CAPLUS
CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS
CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS
CN Benzanide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-32-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-34-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-40-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-11-oxo-N-[3-(1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755027-48-6 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 755027-50-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-51-1 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-52-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-53-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


10/785,120




RN 755027-55-5 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-56-6 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-57-7 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-58-8 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/785,120



RN 755027-59-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755027-60-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-61-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-68-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-69-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755027-71-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-74-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-75-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-76-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)



RN 755027-78-2 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)



RN 755027-79-3 CAPLUS


10/785,120

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-81-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755027-82-8 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-83-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755027-86-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-90-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-91-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-94-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755027-95-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-97-5 CAPLUS

CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755027-98-6 CAPLUS


CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755027-99-7 CAPLUS


CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-01-4 CAPLUS

CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-02-5 CAPLUS

CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-03-6 CAPLUS

CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-04-7 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-07-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 755028-08-1 CAPLUS


CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-11-6 CAPLUS


CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-12-7 CAPLUS


CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS

CN Benzenebutanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-16-1 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[(4-methylphenyl)sulfonyl]amino]- (9CI)
(CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-22-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755028-24-1 CAPLUS

CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-25-2 CAPLUS

CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 755028-26-3 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 755028-27-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -methoxy-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-30-9 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -methoxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-33-2 CAPLUS


CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS

10/785,120


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS

CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-39-8 CAPLUS


CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-43-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755028-46-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemethanesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-53-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755028-54-7 CAPLUS


CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-58-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-59-2 CAPLUS


CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-62-7 CAPLUS


CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 755028-63-8 CAPLUS


CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-64-9 CAPLUS

CN Benzamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-73-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-74-1 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-75-2 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-76-3 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)



RN 755028-79-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755028-81-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 755028-90-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)



RN 755028-91-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-94-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 755028-95-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-98-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)

RN 755029-03-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 755029-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-09-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-10-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-11-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-18-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 755029-19-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755029-44-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755029-46-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-61-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-63-1 CAPLUS


CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-66-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-67-5 CAPLUS

CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-74-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-78-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-28-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-31-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-60-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-62-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755030-63-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT **755030-65-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-66-1P, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-67-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-69-4P **755030-71-8P** **755030-73-0P**
755030-75-2P **755030-77-4P** **755030-80-9P**
755030-91-2P **755030-97-8P** **755030-99-0P**
755031-01-7P **755031-03-9P** **755031-05-1P**
755031-07-3P **755031-10-8P** **755031-12-0P**
755031-15-3P **755031-16-4P** **755031-17-5P**
755031-19-7P **755031-20-0P** **755031-24-4P**
755031-31-3P **755031-33-5P** **755031-35-7P**
755031-36-8P, 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-43-7P**,
7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-45-9P**,
8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-47-1P**,
8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-49-3P**,
8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-51-7P**,
7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-52-8P**,
8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-53-9P**,
3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-54-0P**,
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-55-1P**,
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-57-3P**,
3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-58-4P**,

3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-60-8P**,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-61-9P**
755031-62-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-65-3P 755031-67-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[5-methylpyridin-2-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-68-6P**
755031-69-7P, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-70-0P 755031-71-1P, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-73-3P**,
 8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-77-7P 755031-78-8P, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**
755031-87-9P 755031-89-1P 755031-91-5P, 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**
755031-94-8P 755031-95-9P 755031-96-0P
755031-97-1P 755031-98-2P 755031-99-3P
755032-00-9P 755032-01-0P 755032-02-1P
755032-03-2P 755032-04-3P 755032-05-4P
755032-06-5P 755032-07-6P 755032-08-7P
755032-09-8P 755032-10-1P 755032-11-2P
755032-12-3P 755032-13-4P 755032-14-5P
755032-15-6P 755032-17-8P 755032-18-9P,
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-19-0P 755032-20-3P, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**
755032-22-5P 755032-23-6P 755032-24-7P
755032-25-8P 755032-26-9P 755032-27-0P
755032-28-1P 755032-29-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P 755032-31-6P 755032-32-7P**
755032-33-8P 755032-34-9P 755032-35-0P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**
755032-38-3P, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-39-4P, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-42-9P 755032-43-0P 755032-45-2P,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate
755032-48-5P 755032-49-6P, (S)-8-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**
755032-51-0P 755032-52-1P 755032-53-2P,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-

5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-55-4P 755032-57-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**
755032-65-6P 755032-67-8P, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**
755032-71-4P 755032-75-8P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**
755032-79-2P, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-80-5P**,
 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-81-6P 755032-82-7P 755032-83-8P**
755032-84-9P, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-85-0P 755032-86-1P 755032-87-2P**,
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-88-3P 755032-89-4P 755032-90-7P**
755032-91-8P 755032-92-9P, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**
755032-96-3P 755032-97-4P 755032-99-6P
755033-01-3P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-03-5P 755033-04-6P 755033-05-7P**
755033-06-8P 755033-07-9P 755033-08-0P
755033-09-1P 755033-10-4P, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-14-8P 755033-15-9P 755033-16-0P**
755033-17-1P 755033-18-2P 755033-19-3P
755033-20-6P 755033-21-7P 755033-22-8P
755033-23-9P 755033-24-0P 755033-25-1P
755033-26-2P 755033-27-3P 755033-28-4P
755033-29-5P, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,

8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-54-6P**
755033-59-1P, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-65-9P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-68-2P 755033-75-1P 755033-79-5P,
 8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-81-9P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-83-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-87-5P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-89-7P**,
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-92-2P**
755033-93-3P 755033-96-6P, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-00-5P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-02-7P**, Methyl
 11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-08-3P**, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-11-8P, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-12-9P 755034-14-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-18-5P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-20-9P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-29-8P, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-38-9P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-39-0P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-40-3P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-41-4P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-42-5P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-43-6P 755034-44-7P 755034-45-8P,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755034-46-9P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-48-1P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-49-2P, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-50-5P, (R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-51-6P, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-52-7P, 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-53-8P, 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-54-9P, 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-55-0P, 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-56-1P **755034-57-2P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-58-3P, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-59-4P, 7-[2-(Dimethylamino)ethoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-61-8P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-63-0P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-64-1P, 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-65-2P, 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-69-6P, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755030-65-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-66-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755030-67-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-71-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



10/785,120


RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-


10/785,120

10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-
(9CI) (CA INDEX NAME)




RN 755030-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-
10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-
(9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA
INDEX NAME)




RN 755031-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)- α,α -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA
INDEX NAME)




RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755031-07-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755031-10-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755031-12-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-16-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-31-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-33-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-36-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-45-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)-cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 755031-55-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 755031-57-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755031-61-9 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755031-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-73-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755031-77-7 CAPLUS


10/785,120

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-87-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-89-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-

10/785,120


methyl-4-pyridinyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-
11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 755031-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-
dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-
trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA
INDEX NAME)




RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)

RN 755031-96-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)


RN 755031-97-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)

10/785,120


RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-02-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-05-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-06-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-07-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-08-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-09-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-13-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755032-14-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755032-15-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS


CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755032-19-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro-
α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX
NAME)

RN 755032-20-3 CAPLUS

CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-
dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX
NAME)


RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-
dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]-
(9CI) (CA INDEX NAME)

RN 755032-22-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-
dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA
INDEX NAME)

10/785,120




RN 755032-23-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-25-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755032-26-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-27-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2-ethoxyethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-29-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-quinolinylloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-30-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-33-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-34-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-36-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-37-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

10/785,120

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




10/785,120


RN 755032-49-6 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10/785,120



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-55-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-57-6 CAPLUS


10/785,120

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-61-2 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-62-3 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-67-8 CAPLUS

CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-69-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-78-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-79-2 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-80-5 CAPLUS


CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-81-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755032-84-9 CAPLUS


CN Azetidine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-85-0 CAPLUS


10/785,120

CN 3-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755032-88-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)




10/785,120

RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755033-05-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-06-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-


10/785,120

yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-09-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-10-4 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755033-13-7 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755033-14-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/785,120

RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

10/785,120


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755033-27-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 755033-28-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-35-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-39-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidiny)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-


10/785,120

(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-68-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-75-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755033-83-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 755033-87-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755033-93-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-96-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-08-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755034-12-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755034-18-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)



10/785,120


RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(5-methyl-3-isoxazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-48-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)


10/785,120



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755034-51-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-50-5

CMF C26 H26 N4 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/785,120




RN 755034-52-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-53-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-54-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-55-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-56-1 CAPLUS

CN 1-Propanesulfonic acid, 3-[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 755034-57-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-58-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-57-2

CMF C24 H24 N4 O6




10/785,120

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)



RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



IT **755034-70-9P 755034-71-0P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-72-1P**, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-73-2P**, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-76-5P**, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-80-1P**, 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-82-3P**, 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-83-4P**, 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-84-5P**, 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-91-4P**, 7-(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-93-6P**, 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-95-8P**, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-

11-one **755034-97-0P**, 8-Ethyl-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-04-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-07-5P**,
 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-14-4P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-16-6P, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-17-7P, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-19-9P**,
 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-20-2P**
755035-22-4P, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-25-7P, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-26-8P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-27-9P** **755035-28-0P** **755035-30-4P**
755035-31-5P **755035-33-7P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-34-8P**,
 (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-35-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-36-0P**
755035-37-1P **755035-38-2P** **755035-39-3P**, (R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-42-8P** **755035-44-0P** **755035-45-1P**,
 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P**
755035-47-3P **755035-48-4P** **755035-49-5P**, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-51-9P, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-52-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-53-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-54-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-56-4P, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-57-5P, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**,
 8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**,
 7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-63-3P, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-


nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-64-4P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-65-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-67-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-68-8P 755035-69-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**,
 8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-73-5P 755035-74-6P, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-75-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-82-6P, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-84-8P 755035-86-0P, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-91-7P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-99-5P**,
 (R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-00-1P, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-01-2P, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-02-3P 755036-04-5P, 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-84-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-91-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-97-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-04-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-
isoquinolinyl)oxypropyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA
INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-
4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX
NAME)




RN 755035-22-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-
(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-25-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-
11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-26-8 CAPLUS

CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-27-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-N,N,α,α-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-28-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-2-


10/785,120

thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/785,120


RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-37-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)


10/785,120



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-42-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-


10/785,120

nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-51-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-52-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-53-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755035-56-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-57-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinylloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-61-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-63-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinylloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyl)oxy]ethyl- (9CI) (CA INDEX NAME)




RN 755035-65-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-67-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)



RN 755035-70-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)



RN 755035-71-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-73-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755035-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 755035-84-8 CAPLUS


CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 755035-86-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)

10/785,120



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755036-00-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755036-01-2 CAPLUS

10/785,120


CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755036-02-3 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 755036-04-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755031-66-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:634064 CAPLUS

DN 141:167757

TI Farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents

IN Bachmann, Brian O.; Mcalpine, James B.; Zazopoulos, Emmanuel; Farnet, Chris M.; Pirae, Mahmood

PA Ecopia Biosciences Inc., Can.

SO PCT Int. Appl., 269 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004065591 | A1 | 20040805 | WO 2004-CA69 | 20040121 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| | CA 2466340 | AA | 20040809 | CA 2004-2466340 | 20040121 |
| | EP 1585814 | A1 | 20051019 | EP 2004-703733 | 20040121 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRAI | US 2003-441126P | P | 20030121 | | |
| | US 2003-492997P | P | 20030807 | | |
| | US 2003-518286P | P | 20031110 | | |
| | WO 2004-CA69 | W | 20040121 | | |

OS MARPAT 141:167757

AB This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivs., and to methods for obtaining such compds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivs. as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxxygenase, and to pharmaceutical compns. comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

IT 733011-09-1DP, derivs.


RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(farnesyl dibenzodiazepinones, their production with microorganisms, and their use as antitumor, antibacterial, and antiinflammatory agents)

RN 733011-09-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,6,8-trihydroxy- (9CI)
(CA INDEX NAME)

10/785,120



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:546376 CAPLUS

DN 141:84051

TI Preparation of dibenzo(hetero)azepine derivatives as insecticides, acaricides and nematocides

IN Steiner, Gerd; Schmidt, Thomas; Kordes, Markus; Von Deyn, Wolfgang; Goetz, Norbert; Hofmann, Michael; De Kramer, Jacobus Jan; Heffernan, Gavin; Culbertson, Deborah L.; Treacy, Michael F.; Oloumi-Sadeghi, Hassan; Ebuenga, Cecille; Tedeschi, Livio; Bucci, Toni; Parra, Rapado Liliana; Rack, Michael; Baumann, Ernst; Puhl, Michael

PA BASF Aktiengesellschaft, Germany

SO PCT Int. Appl., 91 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004056182 | A1 | 20040708 | WO 2003-EP14443 | 20031218 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1578198 | A1 | 20050928 | EP 2003-782439 | 20031218 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | BR 2003017528 | A | 20051122 | BR 2003-17528 | 20031218 |
| PRAI | US 2002-434801P | P | 20021220 | | |
| | WO 2003-EP14443 | W | 20031218 | | |
| OS | MARPAT 141:84051 | | | | |
| GI | | | | | |



I

AB The dibenzo(hetero)azepine derivs. I [X = S, O, SO or SO₂, NH, CH₂, etc.; R₁, R₂ = halo, OH, SH, NH₂, CN, NO₂, alkyl, alkoxy, alkylamino, dialkylamino, alkylthio, alkenyl, alkenyloxy, alkenylamino, alkenylthio, alkynyl, alkynyloxy, alkynlamino, alkynylthio, alkylsulfonyl, alkylsulfoxyl, alkenylsulfonyl, alkynylsulfoxyl, formyl, alkylcarbonyl, hydroxycarbonyl, alkoxy carbonyl, carbonyloxy, alkylcarbonyloxy, phenyloxy, alkylcarbonylamino, etc.; R₃, R₄ = H, (halo)alkyl, alkylamino, alkoxy, cycloalkyl, etc.; m, n = 0, 1-4] are prepared as insecticides, acaricides and nematocides.

IT 167997-02-6P 714221-44-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate in preparation of dibenzothiazepine derivative as insecticide,

10/785,120

acaricide and nematocide)


RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 714221-44-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-methyl- (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:202759 CAPLUS
DN 142:176726
TI Product class 5: seven-membered hetarenes with two or more heteroatoms
AU Herr, R. J.
CS Medicinal Chemistry Dept., Albany Molecular Research, Inc., Albany, NY,
12212-5098, USA
SO Science of Synthesis (2004), 17, 929-977
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
AB A review. Methods for preparing diazepines are reviewed including
cyclization, ring transformation, and substituent modification.
IT **183583-25-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(review prepn of diazepines via cyclization, ring transformation, and
substituent modification)
RN 183583-25-7 CAPLUS
CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-
dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)




IT **162930-70-3P 167996-99-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(review prepn of diazepines via cyclization, ring transformation, and
substituent modification)
RN 162930-70-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA
INDEX NAME)



RN 167996-99-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA
INDEX NAME)


10/785,120



RE.CNT 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120


L10 ANSWER 12 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:795028 CAPLUS
DN 140:5028
TI Solid-phase synthesis of dibenzoxazepinones
AU Hone, Neal D.; Salter, James I.; Reader, John C.
CS Millennium Pharmaceuticals Ltd, Cambridge, CB1 6ET, UK
SO Tetrahedron Letters (2003), 44(44), 8169-8172
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:5028
GI



AB Two solid-phase routes to the pharmaceutically relevant dibenzoxazepinones, e.g., I, are described. In one, a key cyclization step involves intramol. phenolate displacement of an activated aryl fluoride. In the second, the tricyclic nucleus is prepared in solution prior to derivatization on a resin.

IT **627546-00-3DP**, amide derivs.
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid-phase preparation of combinatorial dibenzoxazepinone libraries via ester hydrolysis of dibenzoxazepinonecarboxylates followed by coupling to oxime resin, N-deprotection, alkylation with alkyl halides followed by resin cleavage with amines)

RN 627546-00-3 CAPLUS
CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2-nitro-11-oxo- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 13 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:555345 CAPLUS

DN 139:350712

TI Synthesis of substituted dibenzoxazepines and dibenzthiazepine using of 4-bromo-5-nitrophthalonitrile

AU Abramov, Igor' G.; Smirnov, Alexey V.; Kalandadze, Levan S.; Sakharov, Vladimir N.; Plakhtinskii, Vladimir V.

CS Yaroslavl State Technical University, Yaroslavl, 150023, Russia

SO Heterocycles (2003), 60(7), 1611-1614

CODEN: HTCYAM; ISSN: 0385-5414

PB Japan Institute of Heterocyclic Chemistry

DT Journal

LA English

OS CASREACT 139:350712

AB Proposed a method of synthesis of new cyano containing compds. of oxazepine and thiazepine series based on activated aromatic nucleophilic substitution reaction of bromine atom and nitro group in 4-bromo-5-nitrophthalonitrile (I) by various bifunctional O-, N-, S-nucleophiles. For example, reaction of I with 2-(5-phenyl-4H-1,2,4-triazol-3-yl)phenol in DMF at 90° for 2 h gave 79% 3-phenylbenzo[b]-1,2,4-triazolo[4,3-d][1,4]benzoxazepine-6,7-dicarbonitrile.


IT 619261-38-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of substituted dibenzoxazepines and dibenzthiazepine using 4-bromo-5-nitrophthalonitrile)

RN 619261-38-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-7,8-dicarbonitrile, 2-bromo-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 14 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:551518 CAPLUS

DN 139:101151

TI Preparation of dibenzodiazepine derivates and use as inhibitors of
poly(ADP-ribose) polymerase

IN Lubisch, Wilfried; Grandel, Roland; Braje, Wilfried; Subkowski, Thomas;
Mueller, Reinhold; Wernet, Wolfgang; Drescher, Karla

PA Abbott G.m.b.H. & Co. K.-G., Germany

SO PCT Int. Appl., 40 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003057699 | A1 | 20030717 | WO 2003-EP192 | 20030110 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003139394 | A1 | 20030724 | US 2002-41556 | 20020110 |
| | CA 2472107 | AA | 20030717 | CA 2003-2472107 | 20030110 |
| | AU 2003235806 | A1 | 20030724 | AU 2003-235806 | 20030110 |
| | EP 1463731 | A1 | 20041006 | EP 2003-729243 | 20030110 |
| | EP 1463731 | B1 | 20050928 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005516031 | T2 | 20050602 | JP 2003-558014 | 20030110 |
| | AT 305472 | E | 20051015 | AT 2003-729243 | 20030110 |
| PRAI | US 2002-41556 | A | 20020110 | | |
| | WO 2003-EP192 | W | 20030110 | | |
| OS | CASREACT 139:101151; MARPAT 139:101151 | | | | |
| GI | | | | | |




I



III



IV



V

AB The invention relates to compds. I [A = (un)saturated or partially unsatd. C6-ring, unsatd. or partially unsatd. ring containing 3 - 5 C, 1 - 3 N, 1 O and/or 1 S; B = (un)saturated or partially unsatd. mono- bi- or tricyclic ring containing 3 - 15 C or 3 - 14 C, 0 - 5 N, 0 - 2 O and/or 0 - 2 S, etc.; R1 = H, Cl, Br, F, I, (un)branched C1-6-alkyl, OH, NO2, CF3, CN, NR11R12, NHCOR13, O-(C1-6-alkyl) R11, R12 = H, C1-4-alkyl; R13 = H, C1-4-alkyl, (C1-4-alkyl)phenyl, Ph ; X1 = S, O, NH] and their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their preparation and use. Their preparation comprises: condensing aldehyde,

BCHO

(II) with benzodiazepine III; III is prepared by reaction nitrobenzoic esters IV [R2 = (un)branched, (un)saturated C1-6-alkyl, Z = leaving group] with diamines V in a polar solvent and in the presence of a base, and with subsequent hydrogenation. Thus, I (B = Ph) was prepared from IV (R1 = H, R2 = Me, Z = Cl) via cyclization with 1,2-C6H4(NH2)2 in DMF containing K2CO3, hydrogenation over Pd/C in DMF and cyclocondensation with PhCHO in MeOH containing AcOH. Inhibition of the enzyme, poly(ADP-ribose) polymerase (PARP) by I was tested (no data).

IT **561054-28-2P**, 4-Amino-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one dihydrochloride


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and condensation of, with aldehydes; preparation of dibenzodiazepine

derivates and use as inhibitors of poly(ADP-ribose) polymerase)


RN 561054-28-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **162930-70-3P**, 4-Nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrogenation of; preparation of dibenzodiazepine derivatives and
 use as inhibitors of poly(ADP-ribose) polymerase)
 RN 162930-70-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:391737 CAPLUS

DN 136:386147

TI Preparation of [3-(naphthyridinylethoxy)dibenzoxazepin-10-yl]acetic acid
av integrin receptor antagonists

IN Patane, Michael A.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002040505 | A2 | 20020523 | WO 2001-US45499 | 20011019 |
| | WO 2002040505 | A3 | 20020808 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2425117 | AA | 20020523 | CA 2001-2425117 | 20011019 |
| | AU 2002039435 | A5 | 20020527 | AU 2002-39435 | 20011019 |
| | EP 1331937 | A2 | 20030806 | EP 2001-987196 | 20011019 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004513953 | T2 | 20040513 | JP 2002-543513 | 20011019 |
| | US 2004019035 | A1 | 20040129 | US 2003-415032 | 20030423 |
| | US 6943156 | B2 | 20050913 | | |
| PRAI | US 2000-242829P | P | 20001024 | | |
| | US 2000-242929P | P | 20001024 | | |
| | WO 2001-US45499 | W | 20011019 | | |

GI



AB The dibenzoxazepine (I) was prepared as an $\alpha v \beta 3$ or $\alpha v \beta 5$ integrin receptor antagonist. Thus, 2-fluoronitrobenzene was coupled with Me 4-methoxysalicylate, the nitro group reduced using Pd/C, the amine cyclized with NaH, and the ketone reduced with LiAlH_4 to give 3-methoxy-10,11-dihydrodibenzo[1,4]oxazepine. N-alkylation with $\text{BrCH}_2\text{CO}_2\text{Et}$ and NaH, conversion to the alc., coupling with 2-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)ethanol in the presence of PPh_3 and di-Et azodicarboxylate, and saponification afforded I. The latter is useful for inhibiting bone resorption, treating and/or preventing

10/785,120

osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer and metastatic tumor growth (no data). Examples also include detailed syntheses of two radioligands for SPAV3 and SPAV5 assays.


IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of dibenzoxazepine α integrin receptor antagonists from salicylates, nitrobenzenes, bromoacetates, and naphthyridineethanol for treatment of osteoporosis, cancer, and other diseases)


RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



10/785,120


L10 ANSWER 16 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:461681 CAPLUS
DN 135:257221
TI Synthesis of nitro-substituted benzoannelated seven-membered heterocycles
from trinitrotoluene
AU Chernysheva, Natalya B.; Samet, Alexander V.; Marshalkin, Viktor N.;
Polukeev, Valery A.; Semenov, Victor V.
CS N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences,
Moscow, 119992, Russia
SO Mendeleev Communications (2001), (3), 109-110
CODEN: MENCEX; ISSN: 0959-9436
PB Russian Academy of Sciences
DT Journal
LA English
OS CASREACT 135:257221
AB 1,3-Dinitrodibenz[b,f]oxepin, 1,3-dinitrobenzo[f]naphth[2,1-
b][1,4]oxazepine and 1,3-dinitrodibenz[b,f][1,4]oxazepin-11(10H)-one were
prepared starting from TNT (2-methyl-1,3,5-trinitrobenzene) and
2-hydroxybenzaldehyde, 1-nitroso-2-naphthalenol and N-(2-hydroxyphenyl)-
2,4,6-trinitrobenzamide.
IT **309735-46-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of nitro-substituted benzoannelated seven-membered heterocycles
from trinitrotoluene)
RN 309735-46-4 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,3-dinitro- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:592558 CAPLUS
 DN 133:193180
 TI Preparation of dibenzooxazepinones and related compounds as
 $\alpha\text{v}\beta 3$, $\alpha\text{v}\beta 5$, and/or $\alpha\text{v}\beta 6$ integrin receptor
 antagonists.
 IN Patane, Michael A.; Newton, Randall C.
 PA Merck and Co., Inc., USA
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000048603 | A1 | 20000824 | WO 2000-US3796 | 20000214 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2362334 | AA | 20000824 | CA 2000-2362334 | 20000214 |
| | EP 1169042 | A1 | 20020109 | EP 2000-911811 | 20000214 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AU 750584 | B2 | 20020725 | AU 2000-33643 | 20000214 |
| | JP 2002537260 | T2 | 20021105 | JP 2000-599395 | 20000214 |
| PRAI | US 1999-120564P | P | 19990217 | | |
| | WO 2000-US3796 | W | 20000214 | | |
| OS | MARPAT 133:193180 | | | | |
| GI | | | | | |



AB Title compds. [I; U, V = N, CR6; ≤ 1 U = N, ≤ 1 V = N; W CO, SO₂, CR₁R₂; X = O, S, SO, SO₂, NR₄, CR₁R₂; Y = (substituted) (CH₂)₀₋₄, (CH₂)₀₋₄O(CH₂)₁₋₄, (CH₂)₀₋₄NR₄(CH₂)₁₋₄, (CH₂)₀₋₄SO(CH₂)₁₋₄, (CH₂)₀₋₄SO₂(CH₂)₁₋₄, etc.; Z = (substituted) 5-6 membered monocyclic aromatic or nonarom. ring system having 1-4 N, O, S atoms, 9-14 membered polycyclic ring system, wherein ≥ 1 of the rings is aromatic; R₁, R₂ = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, cycloalkylalkyl, cycloheteroalkylalkyl, aryl, aralkyl, aminoalkyl, acylaminoalkyl, alkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, carboxyalkyl, alkoxy carbonylalkyl, CF₃; R₄ = H, alkyl, alkenyl, alkynyl, aralkyl, alkoxyalkyl, cycloalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl,

alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, alkylcarbonyl, arylcarbonyl, etc.; R5 = H, alkyl, aryl, aralkyl, alkylcarbonyloxyalkyl, alkylaminocarbonylmethylene, etc.; R6 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, amino, etc.], were prepared. A solution of 2-fluoronitrobenzene, Me 4-methoxysalicylate, and K₂CO₃ in DMF was warmed to 50°C overnight to give Me 4-methoxy-2-(2-nitrophenoxy)-benzoate. The latter in MeOH was added to a suspension of 10% Pd/C in EtOH and treated with H₂ at room temperature and pressure for 3 h to give Me

2-(2-aminophenoxy)-4-

methoxybenzoate. This was stirred with NaH in THF to give 3-methoxy-10H-dibenzo[1,4]oxazepin-11-one, which was converted in several steps to [11-oxo-3-[3-(pyridin-2-ylamino)-1-propoxy]-11H-dibenzo[1,4]oxazepin-10-yl]acetic acid. Tested I at 1 μM gave ≥50% inhibition of attachment of αvβ5-expressing cells to vitronectin-coated plates.


IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzooxazepinones and related compds. as αvβ3, αvβ5, and/or αvβ6 integrin receptor antagonists)

RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:221253 CAPLUS

DN 133:38104

TI In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones

AU Cohen, V. I.; Jin, B.; McRee, R. C.; Boulay, S. F.; Cohen, E. I.; Sood, V. K.; Zeeberg, B. R.; Reba, R. C.

CS N.W., 2300 Eye St., Walter G. Ross Hall, Section of Radiopharmaceutical Chemistry, George Washington University Medical Center, Washington, DC, USA

SO Brain Research (2000), 861(2), 305-315

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB Alzheimer's disease (AD) involves selective loss of muscarinic m2, but not m1, subtype receptors in cortical and hippocampal regions of the human brain. Emission tomog. study of the loss of m2 receptors in AD has been limited by the absence of available m2-selective radioligands, which can penetrate the blood-brain barrier. We now report on the in vitro and in vivo m2 muscarinic subtype selectivity of a series of dibenzodiazepinones and pyridobenzodiazepinones determined by competition studies against (R)-3-quinuclidinyl (S)-4-iodobenzilate ((R,S)-[125I]IQNB or [3H]QNB. Of the compds. examined, three of the 5-[[4-[(4-dialkylamino)butyl]-1-piperidinyl]acetyl]-10,11-dihydro-5-H-dibenzo[b,e][1,4]diazepin-11-ones (including DIBA) and three of the 11-[[4-[4-(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido [2,3-b][1,4]benzodiazepin-6-ones (including PBID) exhibited both high binding affinity for the m2 subtype (≤ 5 nM) and high m2/m1 selectivity (≥ 10). In vivo rat brain dissection studies of the competition of PBID or DIBD against (R,S)[125I]IQNB or [3H]QNB exhibited a dose-dependent preferential decrease in the binding of the radiotracer in brain regions that are enriched in the m2 muscarinic subtype. In vivo rat brain autoradiog. studies of the competition of PBID, BIBN 99, or DIBD against (R,S)[125I]IQNB exhibited an insignificant effect of BIBN 99 and confirmed the effect of PBID and DIBD in decreasing the binding of (R,S)[125I]IQNB in brain regions that are enriched in the m2 muscarinic subtype. We conclude that PBID and DIBD are potentially useful parent compds. from which in vivo m2 selective derivs. may be prepared for potential use in positron emission tomog. (PET) study of the loss of m2 receptors in AD.

IT 213208-22-1 213208-23-2 213208-24-3

213208-25-4 213208-33-4 213208-35-6


213208-41-4 213208-42-5

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(In vitro and in vivo m2 muscarinic subtype selectivity of dibenzodiazepinones and pyridobenzodiazepinones for potential use in tomog. brain imaging)


RN 213208-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-23-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-24-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)


10/785,120



(i-Bu)₂N-(CH₂)₄

RN 213208-25-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



EtNH-(CH₂)₃


RN 213208-33-4 CAPLUS

CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-35-6 CAPLUS

CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 213208-41-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RN 213208-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:331933 CAPLUS

DN 131:124930

TI New (Sulfonyloxy)piperazinyldibenzazepines as Potential Atypical Antipsychotics: Chemistry and Pharmacological Evaluation

AU Liao, Yi; Venhuis, Bastiaan J.; Rodenhuis, Nienke; Timmerman, Wia; Wikstroem, Hkan; Meier, Eddie; Bartoszyk, Gerd D.; Boettcher, Henning; Seyfried, Christoph A.; Sundell, Staffan

CS Department of Medicinal Chemistry, University of Groningen, Groningen, 9713 AV, Neth.

SO Journal of Medicinal Chemistry (1999), 42(12), 2235-2244
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A series of 2- or 8-trifluoromethylsulfonyloxy (TfO) and 2- or 8-methylsulfonyloxy (MsO) 11-piperazinyldibenzodiazepines, -oxazepines, and -thiazepines were synthesized and evaluated in pharmacol. models for their potential clozapine-like properties. In receptor binding assays, the 2-TfO analogs (GMC2-83, GMC3-06, and previously reported GMC1-169) of the dibenzazepines have profiles comparable to that of clozapine, acting on a variety of CNS receptors except they lack M1 receptor affinity. Introduction of 2-TfO to clozapine leads to compound GMC61-39 which has a similar binding profile as that of clozapine including having M1 receptor affinity. Interestingly, the MsO analogs, as well as the 8-TfO analogs, have no or weak dopaminergic and serotonergic affinities, but all 8-sulfonyloxy analogs do have M1 affinities. In behavioral studies performed to indicate the potential antipsychotic efficacy and the propensity to induce EPS, 2-TfO analogs blocked effectively the apomorphine-induced climbing in mice in a dose-dependent manner with ED50 values (mg/kg) of 2.1 s.c. for GMC1-169, 1.3 po for GMC2-83, 2.6 s.c. for GMC3-06, and 8.2 s.c. for GMC61-39. On the other hand, they showed a clear dose separation with regard to their ED50 values (mg/kg) for indicating catalepsy in rats (>44 s.c. for GMC1-169, 28 po for GMC2-83, 30 s.c. for GMC3-06, and >50 s.c. for GMC61-39, resp.), thus implicating a more favorable therapeutic ratio (K/A, ED50 climbing/ED50 catalepsy) in comparison with typical neuroleptics such as haloperidol and isoclozapine. Furthermore, compound GMC2-83 was also demonstrated to be an orally potent DA antagonist with an ED50 value of 0.7 mg/kg po in the ex vivo L-DOPA accumulation model. The present study contributes to the SAR of 11-piperazinyldibenzazepines, and the 2-TfO analogs of 11-piperazinyldibenzazepines are promising candidates as clozapine-like atypical antipsychotics with low propensity to induce EPS.

IT 60287-08-3P 60287-33-4P 67104-22-7P

167997-02-6P 183583-24-6P 183583-25-7P

183583-27-9P 183583-29-1P 234113-90-7P

234113-92-9P 234113-95-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (sulfonyloxy)piperazinyldibenzazepines as potential clozapine-like antipsychotics)


RN 60287-08-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)


10/785,120




RN 60287-33-4 CAPLUS
CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-methoxy- (9CI) (CA INDEX NAME)



RN 67104-22-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 167997-02-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 183583-24-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 183583-25-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)




RN 183583-27-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RN 183583-29-1 CAPLUS


CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 234113-90-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 234113-92-9 CAPLUS

CN Methanesulfonic acid, trifluoro-, 8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 234113-95-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(methylsulfonyl)oxy]- (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 20 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:184239 CAPLUS

DN 130:209728

TI Integrin receptor antagonists

IN Heerding, Dirk A.; Samanen, James M.

PA SmithKline Beecham Corporation, USA

SO PCT Int. Appl., 39 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9911626 | A1 | 19990311 | WO 1998-US18379 | 19980903 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | IL 119820 | A1 | 20000217 | IL 1996-119820 | 19961212 |
| | CA 2304117 | AA | 19990311 | CA 1998-2304117 | 19980903 |
| | EP 1027337 | A1 | 20000816 | EP 1998-944735 | 19980903 |
| | R: BE, CH, DE, ES, FR, GB, IT, LI, NL | | | | |
| | JP 2001514253 | T2 | 20010911 | JP 2000-508666 | 19980903 |
| PRAI | US 1997-57529P | P | 19970904 | | |
| | US 1997-63520P | P | 19971029 | | |
| | WO 1998-US18379 | W | 19980903 | | |
| OS | MARPAT 130:209728 | | | | |
| GI | | | | | |




AB This invention relates to seven-membered tricyclic heterocycles containing at least one N atom which bind to integrins such as the vitronectin receptor and fibrinogen receptor. Such compds. are useful for inhibiting platelet aggregation and osteoclast attachment to bone. Thus, dibenzoxazepineacetic acid I was prepared in nine steps starting from 1-fluoro-2-nitrobenzene and Me 2-hydroxy-4-methoxybenzoate.

IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 54584-61-1 CAPLUS


CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




10/785,120

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 21 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:176508 CAPLUS
DN 130:296672
TI Solid support synthesis of 2-substituted dibenz[b,f]oxazepin-11(10H)-ones
via SNAr methodology on AMEBA resin
AU Ouyang, Xiaohu; Tamayo, Nuria; Kiselyov, Alexander S.
CS Small Molecule Drug Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA
SO Tetrahedron (1999), 55(10), 2827-2834
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
AB Efficient assembly of dibenz[b,f]oxazepin-11(10H)-ones utilizing the SNAr
of fluorine in 2-fluoro-5-nitrobenzoic acid with the OH of various
2-aminophenols on solid support is reported. The flexibility of this
synthesis, as well as the excellent purity (>90%) of the final products
are the distinctive characteristics of the resulting library.
IT **16398-16-6P 16398-19-9P 135810-39-8P**
223261-47-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(solid support synthesis of dibenzoxazepinones)
RN 16398-16-6 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-19-9 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA
INDEX NAME)




RN 135810-39-8 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX
NAME)



RN 223261-47-0 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 9-methyl-2-nitro- (9CI) (CA INDEX NAME)




IT 223261-48-1P 223261-49-2P 223261-50-5P
223261-51-6P 223261-52-7P 223261-53-8P
223261-54-9P 223261-55-0P 223261-56-1P
223261-57-2P 223261-58-3P 223261-59-4P
223261-60-7P 223261-61-8P 223261-62-9P
223261-63-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid support synthesis of dibenzoxazepinones)


RN 223261-48-1 CAPLUS

CN Acetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI)
(CA INDEX NAME)




RN 223261-49-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)



RN 223261-50-5 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 223261-51-6 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy-


10/785,120

(9CI) (CA INDEX NAME)




RN 223261-52-7 CAPLUS

CN Acetamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
(9CI) (CA INDEX NAME)




RN 223261-53-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-fluoro- (9CI) (CA INDEX NAME)



RN 223261-54-9 CAPLUS


CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-methyl- (9CI) (CA INDEX NAME)



RN 223261-55-0 CAPLUS


CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-methoxy- (9CI) (CA INDEX NAME)

10/785,120




RN 223261-56-1 CAPLUS

CN Acetamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-(9CI) (CA INDEX NAME)




RN 223261-57-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-58-3 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 223261-59-4 CAPLUS


CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)



10/785,120


RN 223261-60-7 CAPLUS

CN Acetamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
(9CI) (CA INDEX NAME)




RN 223261-61-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-62-9 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-methyl- (9CI) (CA INDEX NAME)



RN 223261-63-0 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 46

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 22 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:816103 CAPLUS

DN 130:52440

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay D.; Venkatesan, Aranapakam M.; Delos Santos, Efren G.

PA American Cyanamid Company, USA

SO U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 373,169, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | US 5849735 | A | 19981215 | US 1995-548805 | 19951222 |
| | ZA 9600300 | A | 19970715 | ZA 1996-300 | 19960115 |
| | CA 2210688 | AA | 19960725 | CA 1996-2210688 | 19960116 |
| | WO 9622282 | A1 | 19960725 | WO 1996-US1051 | 19960116 |
| | W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9649042 | A1 | 19960807 | AU 1996-49042 | 19960116 |
| | BR 9606977 | A | 19971104 | BR 1996-6977 | 19960116 |
| | EP 804420 | A1 | 19971105 | EP 1996-905227 | 19960116 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV | | | | |
| | CN 1190391 | A | 19980812 | CN 1996-192568 | 19960116 |
| | JP 10512865 | T2 | 19981208 | JP 1996-522448 | 19960116 |
| | IL 116777 | A1 | 20001121 | IL 1996-116777 | 19960116 |
| | TW 449584 | B | 20010811 | TW 1996-85100462 | 19960116 |
| PRAI | US 1995-373169 | B2 | 19950117 | | |
| | US 1995-548805 | A | 19951222 | | |
| | WO 1996-US1051 | W | 19960116 | | |
| OS | MARPAT 130:52440 | | | | |
| GI | | | | | |



AB The title compds. [I; Y = NH, N(Ac), N(C1-3 alkyl); AB = CH₂N(R₃), N(R₃)CH₂; R₁ = H, halo, OH, etc.; R₂ = H, OH, halo, etc.; R₃ = C(O)Ar; Ar = (un)substituted thienyl, furanyl, Ph, etc.; Z together with two carbon atoms attached = (un)substituted Ph, 5-membered aromatic (un)saturated heterocyclic ring having one heteroatom selected from O, N or S, etc.],


which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and oxytocin antagonist activity, and therefore are useful in treating diseases characterized by excess renal reabsorption of water as well as congestive heart failure, liver cirrhosis, nephrotic syndrome, CNS injuries, lung disease and hyponatremia, were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazepine with 6-[(5-fluoro-2-methylbenzoyl)aminolpyridine-3-carbonyl in the presence of Et₃N in CH₂Cl₂ afforded the title compound II which showed IC₅₀ of 0.24 μ M and 0.054 μ M against rat hepatic V1 receptors binding and rat kidney medullary V2 receptors binding, resp.

IT 22361-77-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)





RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120


L10 ANSWER 23 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:735045 CAPLUS
DN 129:343507
TI Preparation of piperazinooxazepines as dopamine D4 receptor antagonists
IN Fu, Jian-Min
PA Allelix Biopharmaceuticals Inc., Can.
SO U.S., 10 pp., Cont.-in-part of U.S. 5,602,121.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5834459 | A | 19981110 | US 1996-754014 | 19960401 |
| | US 5602121 | A | 19970211 | US 1994-354793 | 19941212 |
| | CA 2207771 | AA | 19960620 | CA 1995-2207771 | 19951208 |
| PRAI | US 1994-354793 | A2 | 19941212 | | |
| OS | MARPAT 129:343507 | | | | |
| GI | | | | | |



AB Title compds. [I; A,B = atoms to complete (un)saturated (heterocyclic) rings; R = (heteroatom-interrupted) (un)substituted alkyl; R1 = H or 1 or 2 alkyl substituents; X1 = O, NH, CO, CH2, etc.; X2 = N, CH, CH2, CO; Z = CH2 or CH2CH2; dashed line = addnl. bond when X2 = N or CH] were prepared. Thus, 2-(OHC)C6H4OK was etherified by 2-ClC6H4NO2 and the product cyclized in 3 steps to give, after piperazine condensation, dibenzoxazepine II (R = H) which was N-alkylated by BuCH2CH2Br to give II (R = CH2CH2Bu). Data for biol. activity of I were given.

IT **3158-94-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperazinooxazepines as dopamine D4 receptor antagonists)
RN 3158-94-9 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/785,120

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:682355 CAPLUS

DN 129:302376

TI Preparation of arylalkylamine as calcilytic compounds

IN Barmore, Robert M.; Bhatnagar, Pradip Kumar; Bryan, William M.; Burgess, Joelle Lorraine; Callahan, James Francis; Calvo, Raul Rolando; Del Mar, Eric G.; et al.

PA Smithkline Beecham Corporation, USA; Nps Pharmaceuticals, Inc.

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9845255 | A1 | 19981015 | WO 1998-US6928 | 19980408 |
| | W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9802951 | A | 19990316 | ZA 1998-2951 | 19980407 |
| | CA 2286454 | AA | 19981015 | CA 1998-2286454 | 19980408 |
| | AU 9868900 | A1 | 19981030 | AU 1998-68900 | 19980408 |
| | AU 721910 | B2 | 20000720 | | |
| | EP 973730 | A1 | 20000126 | EP 1998-914581 | 19980408 |
| | EP 973730 | B1 | 20040616 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI | | | | |
| | TR 9902516 | T2 | 20000221 | TR 1999-9902516 | 19980408 |
| | BR 9808491 | A | 20000523 | BR 1998-8491 | 19980408 |
| | JP 2001523223 | T2 | 20011120 | JP 1998-543055 | 19980408 |
| | AT 269300 | E | 20040715 | AT 1998-914581 | 19980408 |
| | ES 2223126 | T3 | 20050216 | ES 1998-914581 | 19980408 |
| | TW 407144 | B | 20001001 | TW 1998-87105217 | 19980722 |
| | US 6294531 | B1 | 20010925 | US 1999-402310 | 19991001 |
| | NO 9904877 | A | 19991007 | NO 1999-4877 | 19991007 |
| PRAI | US 1997-42724P | P | 19970408 | | |
| | US 1997-61327P | P | 19971008 | | |
| | US 1997-61329P | P | 19971008 | | |
| | US 1997-61330P | P | 19971008 | | |
| | US 1997-61331P | P | 19971008 | | |
| | US 1997-61333P | P | 19971008 | | |
| | WO 1998-US6928 | W | 19980408 | | |

OS MARPAT 129:302376

AB Title compds. XZY1CR7R8Y2NHCR3R4GABR5 [Y1 = covalent bond, alkylene, alkenylene, alkyl; Y2 = methylene, alkyl, CF3; Z = O, S, NH, alkyl, etc.; R3 = CH3, CH3CH2; R4 = CH3, CH3CH2; R3-R4 = cyclopropyl; R5 = C6H5, naphthyl, OH, alkoxy, cycloalkyl, CN, NO2, etc.; G = electron pair, COH, CH, CO; R7 = H, OH, alkoxy; R8 = H, alkyl; R7-R8 = carbonyl moiety; AB = CH2CH2, CH:CH, CC, covalent bond; X = (un)substituted phenylaminosulfonyl, phenylaminocarbonylalkyl, phenylcarbonylamino, phenylsulfonylamino, etc.] exhibiting calcilytic properties are prepared of treating abnormal bone or mineral homeostasis (no data).

IT 214623-53-7P 214625-44-2P 214625-45-3P

214625-46-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


10/785,120

(preparation of arylalkylamine as calcilytic compds.)

RN 214623-53-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-44-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-2-hydroxy-3-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-45-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[(1,1-dimethyl-4-phenylbutyl)amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/785,120




● HCl

RN 214625-46-4 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(1-methyl-1-phenylethoxy)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 54584-61-1P 60287-50-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of arylalkylamine as calcilytic compds.)

RN 54584-61-1 CAPLUS


CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)



RN 60287-50-5 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 3-hydroxy- (9CI) (CA INDEX NAME)

10/785,120



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:517394 CAPLUS

DN 129:245121

TI Synthesis of some substituted dibenzodiazepinones and pyridobenzodiazepinones

AU Cohen, Victor I.; Jin, Biyun; Cohen, Emil I.; Zeeberg, Barry R.; Reba, Richard C.

CS Section Radiopharmaceutical Chem., George Washington Univ. Medical Center, Washington, DC, 20037, USA

SO Journal of Heterocyclic Chemistry (1998), 35(3), 675-686

CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

AB Fluoro- and iodo-derivs. of 5-[[4-[(4-diisobutylamino)butyl]-1-phenyl]acetyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one and 11-[[4-[(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and their analogs were synthesized. The synthesis of dibenzodiazepinones was based on the reaction between 1,4-phenylenediamine and substituted benzoic acids. The intermediate pyridobenzodiazepinones were prepared by condensation of 2-chloro-3-aminopyridine with Me anthranilate and its chlorine derivative. The condensation of 4-[(halo)alkyl]phenylacetyl chloride with dibenzodiazepinones and pyridobenzodiazepinones followed by the reaction of mono- or dialkyl- or dialkenylamine provided 11-[[4-[(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones.

IT 54255-81-1P 82096-44-4P 162930-70-3P

162930-73-6P 213208-06-1P 213208-07-2P

213208-08-3P 213208-09-4P 213208-11-8P

213208-12-9P 213208-13-0P 213208-14-1P

213208-18-5P 213208-19-6P 213208-22-1P

213208-23-2P 213208-24-3P 213208-25-4P


213208-33-4P 213208-39-0P 213208-40-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)

RN 54255-81-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)



RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI) (CA INDEX NAME)

10/785,120




RN 162930-70-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)




RN 162930-73-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-06-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-07-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 213208-08-3 CAPLUS

CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-09-4 CAPLUS


CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-11-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120




RN 213208-12-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-(3-chloropropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-13-0 CAPLUS

CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-14-1 CAPLUS

CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-18-5 CAPLUS


CN Carbamic acid, [5-[[4-[[4-bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RN 213208-19-6 CAPLUS

CN Carbamic acid, [5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




(i-Bu)₂N-(CH₂)₄

RN 213208-22-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)

10/785,120



RN 213208-23-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-24-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)


10/785,120



(i-Bu)₂N-(CH₂)₄

RN 213208-25-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




EtNH-(CH₂)₃

RN 213208-33-4 CAPLUS


CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)

10/785,120




RN 213208-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄


IT 213208-35-6P 213208-41-4P 213208-42-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)

RN 213208-35-6 CAPLUS


CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 213208-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)


10/785,120



(i-Bu)₂N-(CH₂)₄

RN 213208-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)




(i-Bu)₂N-(CH₂)₄


RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:366893 CAPLUS
 DN 129:54301
 TI Preparation of tricyclic benzazepine vasopressin antagonists
 IN Albright, Jay Donald; Reich, Marvin Fred
 PA American Cyanamid Co., USA
 SO U.S., 103 pp., Cont.-in-part of U. S. 5,512,563.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| PI | US 5760031 | A | 19980602 | US 1996-637911 | 19960425 |
| | US 5512563 | A | 19960430 | US 1994-254823 | 19940613 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| PRAI | US 1993-100003 | B2 | 19930729 | | |
| | US 1994-254823 | A2 | 19940613 | | |
| | NZ 1994-264116 | A1 | 19940728 | | |
| OS | MARPAT 129:54301 | | | | |
| GI | | | | | |



I



II

AB The title compds. [I; R1 = H, Cl, F, etc.; R2 = H, Cl, Br, etc.; R1R2 = methylenedioxy, ethylenedioxy; R5 = H, Me, Et, etc.; R6 = N(Ra)COAr', CON(Ra)Ar', etc. (Ra = H, Me, Et; Ar' = (un)substituted Ph, thienyl, etc.); R7 = H, Me, Et, etc.; Z = (un)substituted fused oxazole, Ph], which exhibit antagonist activity at V1 and/or V2 receptors and in vivo vasopressin antagonist activity as well as antagonist activity at oxytocin receptors, and as such useful in treating diseases characterized by excess renal reabsorption of water (e.g., congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke), were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine in pyridine at 80° for 18 h followed by the addition of NaH afforded the compound II which showed IC50 of 2.5 μ M against rat hepatic V1 receptor binding and IC50 of 0.86 μ M against rat kidney medullary V2 receptor binding.

IT 22361-77-9

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-


10/785,120

(8CI, 9CI) (CA INDEX NAME)




RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:336533 CAPLUS
DN 128:313007
TI HPLC determination of clozapine and its related substances
AU Li, Li-Xin
CS Shanghai Institute of Pharmaceutical Industry, Shanghai, 200040, Peop.
Rep. China
SO Zhongguo Yiyao Gongye Zazhi (1998), 29(4), 173-174
CODEN: ZYGZEA; ISSN: 1001-8255
PB Zhongguo Yiyao Gongye Zazhi Bianjibu
DT Journal
LA Chinese
AB Clozapine and its related substances (ACA, CDD) was defected on Spherisorb
C8 column with DAD at 230 nm. The mobile phase was 0.02 mol/L potassium
dihydrogen phosphate solution (pH 5.9)-methanel (40:60). This method is
simple, rapid accurate and reliable.
IT **82096-44-4**
RL: ANT (Analyte); ANST (Analytical study)
(determination of clozapine by HPLC)
RN 82096-44-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)




L10 ANSWER 28 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:289524 CAPLUS
 DN 128:321569
 TI Preparation of tricyclic benzazepine vasopressin antagonists
 IN Albright, Jay Donald; Reich, Marvin Fred
 PA American Cyanamid Co., USA
 SO U.S., 101 pp., Cont.-in-part of U.S. Ser. No. 5,512,563.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5747487 | A | 19980505 | US 1996-638067 | 19960425 |
| | US 5512563 | A | 19960430 | US 1994-254823 | 19940613 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| PRAI | US 1993-100003 | B2 | 19930729 | | |
| | US 1994-254823 | A2 | 19940613 | | |
| | NZ 1994-264116 | A1 | 19940728 | | |
| OS | MARPAT 128:321569 | | | | |
| GI | | | | | |



I



II

AB The title compds. [I; Y = a bond; AB = (CH₂)₂N(R₃); R₁ = H, halo, OH, etc.; R₂ = H, halo, OH, etc.; R₁R₂ = methylenedioxy, ethylenedioxy; R₃ = C(O)Ar (wherein Ar = (un)substituted Ph, thienyl, etc.); Z = (un)substituted fused benzo, thiazole, etc.], which exhibit antagonistic activity at V₁ and/or V₂ receptors, in vivo vasopressin antagonist activity, and antagonistic activity at oxytocin receptors, and therefore useful in treating diseases characterized by excess renal reabsorption of water such as congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, liver cirrhosis, brain edema, cerebral ischemia, or cerebral hemorrhage-stroke, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine in pyridine afforded the title compound II which showed IC₅₀ of 2.5 μM against rat hepatic V₁ receptors binding and IC₅₀ of 0.86 μM against rat kidney medullary V₂ receptors binding.

IT **22361-77-9**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-(8CI, 9CI) (CA INDEX NAME)

10/785,120



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 29 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:226808 CAPLUS

DN 128:282791

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred; Sum, Fuk-wah; Du, Xuemei

PA American Cyanamid Co., USA

SO U.S., 104 pp., Cont.-in-part of U.S. 5,512,563.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5739128 | A | 19980414 | US 1996-637058 | 19960424 |
| | US 5512563 | A | 19960430 | US 1994-254823 | 19940613 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| | US 5786353 | A | 19980728 | US 1997-893497 | 19970711 |
| PRAI | US 1993-100003 | B2 | 19930729 | | |
| | US 1994-254823 | A2 | 19940613 | | |
| | NZ 1994-264116 | A1 | 19940728 | | |
| | US 1996-637058 | A3 | 19960424 | | |
| OS | MARPAT 128:282791 | | | | |
| GI | | | | | |



AB The title compds. [I; Z-containing ring = (un)substituted fused Ph; Y = NH, NCOMe; N(Cl-3 alkyl); R1 = H, halo, OH, etc.; R2 = H, Cl, Br, I, F, OH, etc.; R1R2 = methylenedioxy, ethylenedioxy; R3 = C(O)Ar (wherein Ar = (un)substituted Ph, furanyl, thienyl, pyrrolyl)] which exhibit antagonist activity at V1 and/or V2 receptors, in vivo vasopressin antagonist activity, and antagonist activity at oxytocin receptors, and are therefore useful in treating diseases characterized by excess renal reabsorption of water, were prepared Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of 4-(dimethylamino)pyridine and NaH in pyridine afforded compound II which showed IC50 of 2.5 μ M against rat hepatic V1 receptor binding and IC50 of 0.86 μ M against rat kidney medullary V2 receptor binding.

IT 22361-77-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepine vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-(8CI, 9CI) (CA INDEX NAME)

10/785,120



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:15699 CAPLUS

DN 128:88936

TI Preparation of (diazabicycloalkyl)dibenzoxepines and analogs as dopamine D4 receptor antagonists

IN Power, Patricia L.; Rakhit, Sumanas

PA Allelix Biopharmaceuticals, Can.

SO U.S., 14 pp., Cont.-in-part of U.S. 5,576,314.


CODEN: USXXAM

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|----------|
| PI | US 5703072 | A | 19971230 | US 1996-625358 | 19960401 |
| | US 5576314 | A | 19961119 | US 1994-354906 | 19941212 |
| | CA 2207546 | AA | 19960620 | CA 1995-2207546 | 19951208 |
| PRAI | US 1994-354906 | A2 | 19941212 | | |
| OS | MARPAT 128:88936 | | | | |
| GI | | | | | |



I



II

AB Title compds. [I; R1 = H, amino acid side chain residue; R2,R3= H, halo, alkyl, alkoxy, etc.; R4R5,R6R7 = atoms to complete a ring; Z = CH2 or CH2CH2; Z1 = O, SO0-2, CH2, CO, etc.; Z2 = N, CH2, CH, co, etc.; dashed line = optional addnl. bond] were prepared Thus, N-Fmoc-L-proline was condensed with H2NCH2CO2Me and the product converted in 2 steps to (S)-1,4-diazabicyclo[4.3.0]nonane which was condensed with the product of PCl5 treatment of 8-chloro-10,11-dihydrobenz[b,f][1,4]oxazepin-11-one to give title compound II. Data for biol. activity of I were given.

IT 3158-94-9P 167997-03-7P 179458-05-0P

201037-63-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (diazabicycloalkyl)dibenzoxepines and analogs as dopamine D4 receptor antagonists)

RN 3158-94-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120




RN 167997-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)




RN 179458-05-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-bromo- (9CI) (CA INDEX NAME)



RN 201037-63-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-amino- (9CI) (CA INDEX NAME)



L10 ANSWER 31 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:13962 CAPLUS

DN 128:75393

TI Preparation of tricyclic benzazepines as vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred

PA American Cyanamid Company, USA

SO PCT Int. Appl., 289 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9747624 | A1 | 19971218 | WO 1997-US9548 | 19970603 |
| | W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9732964 | A1 | 19980107 | AU 1997-32964 | 19970603 |
| PRAI | US 1996-663400 | A | 19960613 | | |
| | WO 1997-US9548 | W | 19970603 | | |
| OS | MARPAT 128:75393 | | | | |
| GI | | | | | |



AB The title compds. [I; Y = a bond, CH₂; AB = (CH₂)₂NR₃, NR₃(CH₂)₂; R₁ = H, halo, OH, etc.; R₂ = H, halo, OH, etc.; R₁R₂ = methylenedioxy, ethylenedioxy; R₃ = C(O)Ar; Ar = (un)substituted Ph, 5-indolyl, thienyl, etc.; Z = (un)substituted fused pyrazole, benzene, etc.] and their salts which exhibit vasopressin antagonist activity and are useful in treating diseases characterized by excess renal reabsorption of water, were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 6,11-dihydro-5H-dibenz[b,e]azepine in the presence of Et₃N in THF afforded the title compound II which showed IC₅₀ of 0.15 μM against rat hepatic V₁ receptor binding and IC₅₀ of 0.068 μM against rat kidney medullary V₂-receptor binding. Compound II also showed 73% inhibition of oxytocin receptor binding at 10 μM.

IT 22361-77-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)

10/785,120

RN 22361-77-9 CAPLUS

CN Dibenz[b, f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 32 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:772293 CAPLUS

DN 128:48246

TI Preparation of tricyclic benzazepines as vasopressin antagonists

IN Albright, Jay Donald; Reich, Marvin Fred

PA American Cyanamid Co., USA

SO U.S., 103 pp., Cont.-in-part of U.S. Ser. No. 639,014.



CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 5693635 | A | 19971202 | US 1996-662546 | 19960613 |
| | US 5512563 | A | 19960430 | US 1994-254823 | 19940613 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| | US 5869483 | A | 19990209 | US 1996-639014 | 19960424 |
| | WO 9747625 | A1 | 19971218 | WO 1997-US9549 | 19970603 |
| | W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, TJ, TM | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9732965 | A1 | 19980107 | AU 1997-32965 | 19970603 |
| PRAI | US 1993-100003 | B2 | 19930729 | | |
| | US 1994-254823 | A2 | 19940613 | | |
| | US 1996-639014 | A2 | 19960424 | | |
| | NZ 1994-264116 | A1 | 19940728 | | |
| | US 1996-662546 | A | 19960613 | | |
| | WO 1997-US9549 | W | 19970603 | | |
| OS | MARPAT 128:48246 | | | | |
| GI | | | | | |



AB The title compds. [I; Y = a bond; AB= (CH₂)₂NR₃, NR₃(CH₂)₂; R₁ = H, halo, OH, etc.; R₂ = H, halo, OH, etc.; R₁R₂ = methylenedioxy, ethylenedioxy; R₃ = COAr (wherein Ar = substituted Ph); Z with two carbon atoms attached represents a (un)substituted fused thiophene ring, Ph, etc.] which exhibit antagonist activity at V₁ and/or V₂ receptors, in vivo vasopressin antagonist activity, and also antagonist activity at oxytocin receptors, and are useful in treating diseases characterized by excess renal reabsorption of water, were prepared. Thus, reaction of 4-[(2-methylbenzoyl)amino]benzoyl chloride with 10,11-dihydro-5H-dibenz[b,f]azepine in the presence of NaH and 4-(dimethylamino)pyridine in pyridine afforded II which showed IC₅₀ of 2.5 μM against rat hepatic V₁

10/785,120

receptor binding and IC50 of 0.86 μ M against rat kidney medullary V2 receptor binding.


IT **22361-77-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines as vasopressin antagonists)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 33 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:735922 CAPLUS

DN 128:22824

TI Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists

IN Albright, Jay Donald; Du, Xuemei

PA American Cyanamid Co., USA

SO U.S., 107 pp., Cont.-in-part of U.S. 5,512,563.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 5686445 | A | 19971111 | US 1996-637908 | 19960425 |
| | US 5512563 | A | 19960430 | US 1994-254823 | 19940613 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| | US 5854236 | A | 19981229 | US 1997-834706 | 19970401 |
| PRAI | US 1993-100003 | B2 | 19930729 | | |
| | US 1994-254823 | A2 | 19940613 | | |
| | NZ 1994-264116 | A1 | 19940728 | | |
| | US 1996-637908 | A3 | 19960425 | | |

OS MARPAT 128:22824


AB Approx. 80 title compds., primarily N-(substituted benzoylaminobenzoyl)dibenzazepines, were prepared by N-acylation of the azepine. E.g., acylation of 10,11-dihydro-5H-dibenz[b,f]azepine with o-MeC₆H₄CONHC₆H₄COCl-p gave N-[4-(10,11-dihydro-5H-dibenz[b,f]azepin-5-ylcarbonyl)phenyl]-2-methylbenzamide. The title compds. exhibit antagonist activity at V1 and/or V2 receptors and extensive data is given for vasopressin antagonist activity.

IT 22361-77-9


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and vasopressin antagonist activity of
(benzoylaminobenzoyl)dibenzazepines)

RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 34 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:727380 CAPLUS
 DN 128:30304
 TI Synthesis and Pharmacological Evaluation of Triflate-Substituted Analogs of Clozapine: Identification of a Novel Atypical Neuroleptic
 AU Liao, Yi; DeBoer, Peter; Meier, Eddie; Wikstroem, Hkan
 CS Department of Medicinal Chemistry, University of Groningen, Groningen, NL-9713 AV, Neth.
 SO Journal of Medicinal Chemistry (1997), 40(25), 4146-4153
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 GI



AB The trifluoromethanesulfonyloxy (TfO) analogs I and II (R = OSO₂CF₃) 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine) (I; R = Cl) and its 2-chloro isomer (isoclozapine) (II; R = Cl) were prepared via their OMe and OH analogs with the conventional synthetic method of the tricyclic dibenzodiazepines and evaluated pharmacol. along with their parent drugs. The binding profile of the 2-OTf analog II (R = OSO₂CF₃) is comparable to the binding profile of I (R = Cl), although the affinity for the dopamine (DA) D₂ receptors is higher [IC₅₀ = 31 nM and 330 nM for II (R = OSO₂CF₃) and I (R = Cl), resp.]. Interestingly, no notable affinity for muscarinic receptors could be detected in II (R = OSO₂CF₃). On the contrary, the 8-OTf analog I (R = OSO₂CF₃) only displayed affinity for muscarinic M₁ receptors (IC₅₀ = 35 nM) and no affinity (IC₅₀ > 500 nM) for the other receptors tested. The 10 µmol/kg s.c. dose, but not the 10 µmol/kg po dose, of II (R = OSO₂CF₃) stimulated the output of DA. Increases of 80% and 35% in DOPAC output from the dorsal striatum were seen after s.c. and po administrations of 10 µmol/kg of II (R = OSO₂CF₃) resp. Doses up to 100 µmol/kg of I (R = OSO₂CF₃) had no effect on either parameter. Doses up to 100 µmol/kg of II (R = OSO₂CF₃) were not cataleptogenic, but significantly decreased apomorphine-induced locomotor activity. In conclusion, II (R = OSO₂CF₃) (GMC1-169) is a new clozapine-like neuroleptic candidate, which is lacking anticholinergic properties and displays a higher potency, as compared to clozapine itself.


IT 167997-02-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and neuroleptic evaluation of clozapine triflate analogs)

RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




IT 183583-24-6P 183583-25-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and neuroleptic evaluation of clozapine triflate analogs)


RN 183583-24-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)



RN 183583-25-7 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/785,120

L10 ANSWER 35 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:623152 CAPLUS

DN 127:262691

TI Preparation of nitrogenous tricyclic compounds as allergy inhibitors

IN Miyamoto, Mitsuaki; Yoshiuchi, Tatsuya; Sato, Keizo; Kaino, Makoto;
Tanaka, Masayuki; Soejima, Motohiro; Moriya, Katsuhiko; Sakuma, Yoshinori;
Yamada, Koji; Harada, Kokichi; Nishizawa, Yukio; Kobayashi, Seiichi;
Okita, Makoto; Katayama, Koichi

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 175 pp.



CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 9733871 | A1 | 19970918 | WO 1997-JP789 | 19970313 |
| | W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2248820 | AA | 19970918 | CA 1997-2248820 | 19970313 |
| | AU 9719399 | A1 | 19971001 | AU 1997-19399 | 19970313 |
| | EP 889037 | A1 | 19990107 | EP 1997-907297 | 19970313 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| | CN 1216982 | A | 19990519 | CN 1997-194202 | 19970313 |
| | NO 9804217 | A | 19981112 | NO 1998-4217 | 19980911 |
| | US 6333322 | B1 | 20011225 | US 1998-125451 | 19980921 |
| | US 2002103189 | A1 | 20020801 | US 2001-985416 | 20011102 |
| | US 6489336 | B2 | 20021203 | | |
| | US 2003171367 | A1 | 20030911 | US 2002-201952 | 20020725 |
| | US 6703388 | B2 | 20040309 | | |
| PRAI | JP 1996-55628 | A | 19960313 | | |
| | WO 1997-JP789 | W | 19970313 | | |
| | US 1998-125451 | A3 | 19980921 | | |
| | US 2001-985416 | A3 | 20011102 | | |
| OS | MARPAT 127:262691 | | | | |
| GI | | | | | |



AB The title compds. I [D = alkylene; R1 - R8 = hydrogen, hydroxy, cyano, nitro, optionally substituted carbamoyl, halogeno, lower alkyl optionally substituted by halogeno, etc.; Z = S, SO, etc. ; and Q represents, for example, NR20R21 (where R20, R21 = hydrogen, lower alkyl optionally substituted by halogeno, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl, or NR20R21 = three- to eight-membered ring)] are prepared I are effective in the prevention and treatment of diseases in which chemical transmitters such as histamine and leukotriene participate, for example, asthma, allergic rhinitis, atopic dermatitis, hives, hay fever, gastrointestinal allergy, and dietary allergy. In an in vitro test for inhibition of antigen-induced histamine release from basophils, the title compound II showed IC50 of 10 - 30 μ M.


IT **196098-27-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nitrogenous tricyclic compds. as allergy inhibitors)

RN 196098-27-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3,4-dimethyl- (9CI)
(CA INDEX NAME)



L10 ANSWER 36 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:145240 CAPLUS

DN 126:157525

TI Tricyclic inhibitors of protein farnesyltransferase

IN Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

PA Warner-Lambert Company, USA; Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

SO PCT Int. Appl., 82 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9700252 | A1 | 19970103 | WO 1996-US8528 | 19960604 |
| | W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9660342 | A1 | 19970115 | AU 1996-60342 | 19960604 |
| | US 5919780 | A | 19990706 | US 1997-981505 | 19971211 |
| PRAI | US 1995-913P | P | 19950616 | | |
| | WO 1996-US8528 | W | 19960604 | | |
| OS | MARPAT 126:157525 | | | | |
| GI | | | | | |



AB Title compds. I [wherein X = N or CR₉; Y = NR₁₀, CH₂, O, S, SO, SO₂, C:O, or CH(OH); R = H or alkyl; R₁ = heteroaryl; n = 1-5; R₂-R₁₀ = H or various substituents] are useful as inhibitors of protein farnesyltransferase (PFT), and thus for the treatment of proliferative diseases including cancer, restenosis and psoriasis, and as antiviral agents. For example, condensation of 8-chloro-5,10-dihydrodibenzo[b,e][1,4]diazepine-11-one with 3-(aminomethyl)pyridine in refluxing EtOCH₂CH₂OH gave 80% title compound II. Eighteen I were prepared and tested for PFT inhibiting and anticancer activity. In two in vitro bioassays, II had IC₅₀ values of 3.7 and 5.0 μ M against PFT.

IT **186765-25-3P**, 7,8-Dichloro-2,3-dimethoxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of tricyclic inhibitors of protein farnesyltransferase)

RN 186765-25-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7,8-dichloro-5,10-dihydro-2,3-

10/785,120

dimethoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:713039 CAPLUS

DN 126:8143

TI Preparation of sulfonyloxyisoclozapine derivatives as atypical neuroleptics.

PA Wikstroem, Haakan, Neth.; De Boer, Peter; Liao, Yi

SO PCT Int. Appl., 37 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9629316 | A1 | 19960926 | WO 1996-SE344 | 19960319 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN | | | | |
| | AU 9651305 | A1 | 19961008 | AU 1996-51305 | 19960319 |
| PRAI | SE 1995-998 | A | 19950319 | | |
| | WO 1996-SE344 | W | 19960319 | | |
| OS | MARPAT 126:8143 | | | | |
| GI | | | | | |



AB Title compds. [I; R1 = H, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cyclopropylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R2 = H, alkyl, alkenyl, alkynyl, cyclopropylalkyl, haloalkyl, hydroxylalkyl, hydroxyalkoxyalkyl, 1-(alkyl-2-imidazolidinonyl); X = NH, NR1, O, S, SO, SO2], were prepared. The compds. of this invention possess affinity to one or several receptor systems, e.g. DA (D1-D4), α 1, muscarinic (M1-M4) and 5-HT (5-HT2A, 5-HT2C and 5-HT7). Thus, (I; X = NH; R1 = CF3; R2 = Me), prepared starting from 5-methoxy-2-aminobenzoic acid and 2-bromonitrobenzene via cyclization of 2-(2-aminophenyl)amino-5-methoxybenzoic acid, s.c. in rats gave a 94% increase in dopamine.

IT 60287-08-3P 167997-02-6P 183583-24-6P

183583-25-7P 183583-27-9P 183583-29-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonyloxyisoclozapine derivs. as atypical neuroleptics)

RN 60287-08-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)

10/785,120




RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA INDEX NAME)




RN 183583-24-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-hydroxy- (9CI) (CA INDEX NAME)



RN 183583-25-7 CAPLUS


CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl ester (9CI) (CA INDEX NAME)



RN 183583-27-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-[(methanesulfonyl)oxy]- (9CI) (CA INDEX NAME)

10/785,120



RN 183583-29-1 CAPLUS

CN Methanesulfonic acid, trifluoro-, 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl ester (9CI) (CA INDEX NAME)



L10 ANSWER 38 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:567275 CAPLUS

DN 125:221884

TI Preparation of tricyclic benzazepines and benzodiazepines as vasopressin antagonists

IN Albright, Jay Donald; Venkatesan, Aranapakam Mudumbai; Delos Santos, Efren Guillermo

PA American Cyanamid Company, USA

SO PCT Int. Appl., 357 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9622282 | A1 | 19960725 | WO 1996-US1051 | 19960116 |
| | W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5849735 | A | 19981215 | US 1995-548805 | 19951222 |
| | AU 9649042 | A1 | 19960807 | AU 1996-49042 | 19960116 |
| | BR 9606977 | A | 19971104 | BR 1996-6977 | 19960116 |
| | EP 804420 | A1 | 19971105 | EP 1996-905227 | 19960116 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV | | | | |
| | JP 10512865 | T2 | 19981208 | JP 1996-522448 | 19960116 |
| PRAI | US 1995-373169 | A | 19950117 | | |
| | US 1995-548805 | A | 19951222 | | |
| | WO 1996-US1051 | W | 19960116 | | |
| OS | MARPAT 125:221884 | | | | |
| GI | | | | | |



AB The title compds. [I; Y = (CH₂)_n (wherein n = 0-2), O, S, etc.; AB = (N-substituted) (CH₂)_mNH, NH(CH₂)_m (wherein m = 1-2); R₁, R₂ = H, halo, OH, etc.; Z = (substituted) fused Ph, 5-membered fused heteroaryl, etc.] which exhibit antagonist activity at V₁ and/or V₂ receptors and therefore useful as diuretics and antihypertensives, and in the treatment and/or prevention of congestive heart failure, liver cirrhosis, brain edema, cerebral ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding, etc., were prepared. Thus, reaction of 10,11-dihydrodibenz[b,f][1,4]oxazepine with 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride in the presence of Et₃N in CH₂Cl₂ afforded the desired product II which showed IC₅₀ of 0.24 μM against rat hepatic V₁ receptors and of 0.054 μM

10/785,120

against rat kidney medullary V2 receptors.


IT **22361-77-9**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic benzazepines and benzodiazepines as vasopressin antagonists)

RN 22361-77-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 39 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1996:494734 CAPLUS
DN 125:140671
TI Compound produced by a Micromonospora strain
IN Ohkuma, Hiroaki; Kobaru, Seikichi
PA Bristol-Myers Squibb Company, USA
SO U.S., 14 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5541181 | A | 19960730 | US 1994-249518 | 19940526 |
| PRAI | US 1994-249518 | | 19940526 | | |
| OS | MARPAT 125:140671 | | | | |
| GI | | | | | |



I

AB Disclosed is the novel compound BU-4664L (I) and derivs. thereof. The compound is produced by fermentation of Micromonospora sp. M990-6. The compound

possesses anti-inflammatory and/or anti-tumor activities.


IT **179981-41-0P 179981-42-1P**

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 179981-41-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,7,9-tris(acetyloxy)-5,10-dihydro-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179981-42-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,7,9-trimethoxy-5-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, (E,E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 179981-43-2P

RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(anti-inflammatory and anti-tumor compound BU-4664L from Micromonospora)

RN 179981-43-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4,7,9-trimethoxy- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 40 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:486143 CAPLUS

DN 125:158639

TI Dopamine receptor ligands

IN Tehim, Ashok; Fu, Jian-min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 172,208, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5538965 | A | 19960723 | US 1994-355297 | 19941212 |
| | CA 2179306 | AA | 19950629 | CA 1994-2179306 | 19941214 |
| | CA 2179306 | C | 20001107 | | |
| | US 5798350 | A | 19980825 | US 1996-642264 | 19960503 |
| | US 6103715 | A | 20000815 | US 1998-139715 | 19980825 |
| PRAI | US 1993-172208 | B2 | 19931223 | | |
| | US 1994-355297 | A3 | 19941212 | | |
| | US 1996-642264 | A3 | 19960503 | | |
| OS | MARPAT 125:158639 | | | | |
| GI | | | | | |



I

AB D4 receptor-selective compds. such as 11-(4-piperonyl)-1-piperazinyldibenz[b,f][1,4]oxazepine (I) and other dibenzoxazepine, dibenzodiazepine, dibenzothiazepine, and dibenzothiepine derivs. were prepared Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, is also described.


IT **82096-44-4P 167996-99-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dopamine receptor ligands)

RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)

10/785,120



RN 167996-99-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA
INDEX NAME)



L10 ANSWER 41 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476853 CAPLUS

DN 125:142798

TI Alkyl-substituted oxazepine compounds having dopamine receptor affinity

IN Fu, Jian-Min

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9618621 | A1 | 19960620 | WO 1995-IB1108 | 19951208 |
| | W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5602121 | A | 19970211 | US 1994-354793 | 19941212 |
| | CA 2207771 | AA | 19960620 | CA 1995-2207771 | 19951208 |
| | AU 9539345 | A1 | 19960703 | AU 1995-39345 | 19951208 |
| PRAI | US 1994-354793 | A | 19941212 | | |
| | WO 1995-IB1108 | W | 19951208 | | |

OS MARPAT 125:142798

GI For diagram(s), see printed CA Issue.

AB The compds. are I, wherein: A and B are independently selected, optionally substituted, unsatd. 5- or 6-membered, homo- or heterocyclic rings; X1 is selected from CH₂, O, NH, S, C=O, CH-OH, CH-N(C1-4alkyl)₂, C=CHCl, C=CHCN, N-C1-4alkyl, N-acetyl, SO₂ and SO; X2--- is selected from N-, CH₂-, CH= and C(OH); Y is selected from N and CH; R1 represents C1-4alkyl; n is 0, 1 or 2; q is 1 or 2; and Z is C5-10alkyl optionally substituted with OH, halo, C1-4alkyl or C1-4alkoxy and optionally incorporating a heteroatom selected from O, N and S; and acid addition salts, solvates and hydrates thereof. Their use as ligands for dopamine receptor identification and in a drug screening program, and as pharmaceuticals to treat indications in which D4 receptor stimulation is implicated, such as schizophrenia, is also described.


IT 3158-94-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(in manufacture of alkyl-substituted oxazepine compds. having dopamine receptor affinity)

RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 42 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476852 CAPLUS

DN 125:142797

TI Preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists

IN Power, Patricia L.; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 41 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9618630 | A1 | 19960620 | WO 1995-IB1110 | 19951208 |
| | W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5576314 | A | 19961119 | US 1994-354906 | 19941212 |
| | CA 2207546 | AA | 19960620 | CA 1995-2207546 | 19951208 |
| | AU 9539347 | A1 | 19960703 | AU 1995-39347 | 19951208 |
| | EP 797577 | A1 | 19971001 | EP 1995-937148 | 19951208 |
| | EP 797577 | B1 | 20000726 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV | | | | |
| | AT 194988 | E | 20000815 | AT 1995-937148 | 19951208 |
| PRAI | US 1994-354906 | A | 19941212 | | |
| | WO 1995-IB1110 | W | 19951208 | | |
| OS | MARPAT 125:142797 | | | | |
| GI | | | | | |



I



II

AB Bicyclic nonane and decane compds., i.e., octahydropyrrolo[1,2-a]pyrazine and octahydro-1H-pyrrolo[1,2-a][1,4]diazepine derivs. I (A, B = ring-forming group; R1 = H, α -carbon of amino acid side-chain; R2, R3 = H, hydroxy, amino, etc.; n = 1,2; X2 = O, S, methine, etc.; X2 = imino, methylene, carbonyl) were disclosed as D4 receptor-selective compds. The use of I as ligands for dopamine receptor identification and the use of I in drug screening programs and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia,

10/785,120

were also described. The target compds. I were analogs of clozapine. An example compound is (R)-11-(octahydropyrrolo[1,2-a]pyrazinyl-2-yl)dibenz[b,f][1,4]oxazepine (II).


IT **167997-03-7**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists)

RN 167997-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)




IT **3158-94-9P 179458-05-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[1,2-a]pyrazine and pyrrolo[1,2-a][1,4]diazepine derivs. as dopamine agonists or antagonists)


RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 179458-05-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-bromo- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 43 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:476645 CAPLUS

DN 125:142792

TI Substituted tetracyclic oxazepine and thiazepine derivatives with 5-HT2 receptor affinity.

IN Fernandez-Gadea, Francisco Javier; Sipido, Victor Karel; Andres-Gil, Jose Ignacio; Meert, Theo Frans

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 28 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9614321 | A1 | 19960517 | WO 1995-EP4197 | 19951025 |
| | W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | TW 449601 | B | 20010811 | TW 1995-84111064 | 19951020 |
| | CA 2203664 | AA | 19960517 | CA 1995-2203664 | 19951025 |
| | AU 9539250 | A1 | 19960531 | AU 1995-39250 | 19951025 |
| | AU 699545 | B2 | 19981203 | | |
| | EP 789702 | A1 | 19970820 | EP 1995-937007 | 19951025 |
| | EP 789702 | B1 | 20010207 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | CN 1162314 | A | 19971015 | CN 1995-195988 | 19951025 |
| | CN 1065245 | B | 20010502 | | |
| | JP 10508309 | T2 | 19980818 | JP 1995-515010 | 19951025 |
| | RU 2161159 | C2 | 20001227 | RU 1997-108688 | 19951025 |
| | AT 199088 | E | 20010215 | AT 1995-937007 | 19951025 |
| | ES 2155899 | T3 | 20010601 | ES 1995-937007 | 19951025 |
| | PT 789702 | T | 20010731 | PT 1995-937007 | 19951025 |
| | PL 183618 | B1 | 20020628 | PL 1995-319870 | 19951025 |
| | ZA 9509216 | A | 19970430 | ZA 1995-9216 | 19951031 |
| | IL 115820 | A1 | 19990620 | IL 1995-115820 | 19951031 |
| | US 5773433 | A | 19980630 | US 1997-817989 | 19970425 |
| | FI 9701855 | A | 19970430 | FI 1997-1855 | 19970430 |
| | FI 113270 | B1 | 20040331 | | |
| | NO 9702018 | A | 19970430 | NO 1997-2018 | 19970430 |
| | NO 308036 | B1 | 20000710 | | |
| | GR 3035666 | T3 | 20010629 | GR 2001-400516 | 20010329 |
| PRAI | EP 1994-203177 | A | 19941102 | | |
| | US 1995-454993 | A1 | 19950531 | | |
| | EP 1995-937007 | A | 19951025 | | |
| | WO 1995-EP4197 | W | 19951025 | | |
| OS | CASREACT 125:142792; MARPAT 125:142792 | | | | |
| GI | | | | | |



AB The invention concerns title compds. I [R1, R2 = H, C1-6 alkyl or alkylcarbonyl, trihalomethylcarbonyl, C1-6 hydroxyalkyl, C1-6 alkoxy, CO2H, C1-6 alkylcarbonyloxy, C1-6 alkoxy carbonyl, or aryl; or R1 and R2 form various N heterocycles; R3-R10 = H, halo, cyano, OH, CF3, CF3O, CO2H, NO2, (di)(alkyl)amino, C1-6 alkylcarbonylamino, aminosulfonyl, (di)alkylaminosulfonyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkoxy carbonyl; R11 = H, C1-6 alkyl, CF3; R12 = H, C1-6 alkyl, cyano, or CF3; n = 0-6; and X = O, S, S(:O) or S(:O)2], and their pharmaceutically acceptable salts, stereoisomeric forms, and N-oxides. I show activity in 5-HT2 receptor binding tests in vitro (no data), and may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders. For example, 1,3-dipolar cycloaddn. of dibenzoxazepine oxide II with the corresponding allylic amine gave cis-isomeric title compound III [R = COCF3], which was hydrolyzed with K2CO3 in aqueous MeOH to give preferred title compound III [R = H], the latter isolated as its (2:3) oxalate salt in 47% yield. III was active in the "elevated and illuminated plus maze test" in rats, with a highest/lowest active dose ratio of ≥ 4 . I were also active as antagonists of mCPP-induced effects in rats. Examples include preps. of over 50 compds. I and several precursors, plus 4 formulations and the above bioassays.

IT **3158-88-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of tetracyclic oxazepine and thiazepine derivs. with 5-HT2 receptor affinity)

RN 3158-88-1 CAPLUS

CN Dibenz[*b,f*][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120



10/785,120

L10 ANSWER 44 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:473239 CAPLUS

DN 125:142799

TI Preparation of (4-methyl-1-piperazinyl)dibenzo[b,e][1,4]diazepines and (4-methyl-1-piperazinyl)dibenzo[b,f]thiepins as dopaminergic neurotransmitter agonists or antagonists

IN Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 31 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9618622 | A1 | 19960620 | WO 1995-IB1109 | 19951208 |
| | W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5700445 | A | 19971223 | US 1994-354905 | 19941212 |
| | CA 2207494 | AA | 19960620 | CA 1995-2207494 | 19951208 |
| | AU 9539346 | A1 | 19960703 | AU 1995-39346 | 19951208 |
| | US 5968478 | A | 19991019 | US 1997-948051 | 19971009 |
| PRAI | US 1994-354905 | A | 19941212 | | |
| | WO 1995-IB1109 | W | 19951208 | | |
| OS | MARPAT 125:142799 | | | | |
| GI | | | | | |



I



II



III

AB Piperazine derivs. I (X1 = methine, amino group, O, S: X2 = methylene,


methine, imino; R1-R8 = H, alkyl, halo, cyano, nitro, etc.) were disclosed. I are dopaminergic D4 receptor agonists and/or antagonists. The use of I as ligands for dopamine receptor identification and their use in drug screening programs and as pharmaceuticals to treat indications in which the D4 receptor is implicated, such as schizophrenia, were described. Example compds. were 4-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (II) and 10-(4-methyl-1-piperazinyl)-10-oxodibenzo[b,f]thiepin-2-carbonitrile (III).

IT 162930-70-3 167996-99-8, 4-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine 167997-00-4 167997-01-5 167997-04-8 179385-64-9

RL: RCT (Reactant); RACT (Reactant or reagent)
((piperazinyl)dibenzo[b,e][1,4]diazepines and
(piperazinyl)dibenzo[b,f]thiepins as dopaminergic neurotransmitter
agonists or antagonists)


RN 162930-70-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) (CA INDEX NAME)




RN 167996-99-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 167997-00-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 167997-01-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,7,8-trichloro-5,10-dihydro- (9CI)


10/785,120

(CA INDEX NAME)




RN 167997-04-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-4-carbonitrile, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 179385-64-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4,7,8-trichloro-5,10-dihydro- (9CI) (CA INDEX NAME)



L10 ANSWER 45 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:473238 CAPLUS

DN 125:142796

TI Preparation of (piperazinyl)dibenzoxazepines as 5-HT₂ receptor ligands

IN Tehim, Ashok; Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 27 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9618629 | A1 | 19960620 | WO 1995-IB1111 | 19951208 |
| | W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5602124 | A | 19970211 | US 1994-354765 | 19941212 |
| | CA 2207613 | AA | 19960620 | CA 1995-2207613 | 19951208 |
| | AU 9539348 | A1 | 19960703 | AU 1995-39348 | 19951208 |
| | US 5824676 | A | 19981020 | US 1996-763255 | 19961210 |
| PRAI | US 1994-354765 | A | 19941212 | | |
| | WO 1995-IB1111 | W | 19951208 | | |
| OS | MARPAT 125:142796 | | | | |
| GI | | | | | |



I



II

AB The piperazine derivs, I (A, B = ring-forming group; X1 = O, S, etc.; X2 = imino, methine, carbonyl, etc.; R1 = alkyl, etc.; R2, R3, R4 = H, alkyl) were disclosed as 5-HT₂ receptor-selective compds. The compds. I are analogs of clozapine. The use of I in the serotonin 5-HT₂ receptor identification and use in drug screening programs and as pharmaceuticals to treat indications in which the 5-HT₂ receptor is implicated, such as hypertension, thrombosis, migraine, vasospasm, ischemia, depression, anxiety, schizophrenia, sleep disorders and appetite disorders were also described.

IT **3158-88-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (piperazinyl)dibenzoxazepines as serotonergic neurotransmitter agonists of antagonists)

RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 46 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:927367 CAPLUS

DN 124:117270

TI Pictet-Spengler reaction in trifluoroacetic acid. Large scale synthesis of pyridoindolobenzodiazepine as an atypical antipsychotic agent

AU Zhang, Lin-hua; Meier, W.; Wats, E.; Costello, T. D.; Ma, P.; Ensinger, C. L.; Rodgers, J. M.; Jacobson, I. C.; Rajagopalan, P.

CS DuPont Merck Pharmaceutical Company, Deepwater, NJ, 08023-0999, USA

SO Tetrahedron Letters (1995), 36(46), 8387-90

CODEN: TELEAY; ISSN: 0040-4039


PB Elsevier

DT Journal

LA English

OS CASREACT 124:117270

GI



AB Traditional syntheses of benzodiazepines involve a Bischler-Napieralski reaction which is a three step process and gives low overall yields. An attractive alternative is to construct the diazepine ring under Pictet-Spengler conditions. This paper reports the synthesis of a novel pyridoindolobenzodiazepine, I, as a potent atypical antipsychotic agent. The key step in the synthesis is the ring formation of the diazepine ring from pyridoindole II in neat trifluoroacetic acid.

IT 90353-71-2P 90353-75-6P 154557-90-1P


173034-10-1P 173034-11-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridoindolobenzodiazepines via Pictet-Spengler reaction in trifluoroacetic acid)

RN 90353-71-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)



10/785,120


RN 90353-75-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-
(9CI) (CA INDEX NAME)




RN 154557-90-1 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,
11-chloro-1,2,3,4-tetrahydro-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 173034-10-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-amino-8-chloro-5,10-dihydro-2-methyl-
(9CI) (CA INDEX NAME)



RN 173034-11-2 CAPLUS

CN Pyrido[3',4':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-2,11-dimethyl- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 47 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:898877 CAPLUS

DN 123:313792

TI Preparation of tricyclic benzazepine vasopressin antagonists

IN Albright, Jay D.; Reich, Marvin F.; Sum, Fuk-Wah; Du, Xuemei

PA American Cyanamid Co., USA

SO Can. Pat. Appl., 288 pp.



CODEN: CPXXEB

DT Patent


LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | CA 2128955 | AA | 19950130 | CA 1994-2128955 | 19940727 |
| | EP 640592 | A1 | 19950301 | EP 1994-111040 | 19940715 |
| | EP 640592 | B1 | 19981230 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | AT 175198 | E | 19990115 | AT 1994-111040 | 19940715 |
| | ES 2125377 | T3 | 19990301 | ES 1994-111040 | 19940715 |
| | SK 281194 | B6 | 20010118 | SK 1994-880 | 19940720 |
| | IL 110436 | A1 | 20031210 | IL 1994-110436 | 19940725 |
| | FI 9403542 | A | 19950130 | FI 1994-3542 | 19940728 |
| | FI 108433 | B1 | 20020131 | | |
| | NO 9402817 | A | 19950130 | NO 1994-2817 | 19940728 |
| | NO 308601 | B1 | 20001002 | | |
| | AU 9468776 | A1 | 19950209 | AU 1994-68776 | 19940728 |
| | AU 676737 | B2 | 19970320 | | |
| | ZA 9405604 | A | 19950309 | ZA 1994-5604 | 19940728 |
| | JP 07179430 | A2 | 19950718 | JP 1994-195886 | 19940728 |
| | JP 3630449 | B2 | 20050316 | | |
| | HU 71548 | A2 | 19951228 | HU 1994-2223 | 19940728 |
| | RU 2149160 | C1 | 20000520 | RU 1994-27580 | 19940728 |
| | NZ 299340 | A | 20000825 | NZ 1994-299340 | 19940728 |
| | CN 1106802 | A | 19950816 | CN 1994-108768 | 19940729 |
| | CN 1064354 | B | 20010411 | | |
| | PL 181918 | B1 | 20011031 | PL 1994-304496 | 19940729 |
| | TW 402592 | B | 20000821 | TW 1994-83108599 | 19940916 |
| | HK 1011362 | A1 | 20010727 | HK 1998-112373 | 19981127 |
| | FI 2001001100 | A | 20010525 | FI 2001-1100 | 20010525 |
| | FI 111077 | B1 | 20030530 | | |
| | FI 2001001101 | A | 20010525 | FI 2001-1101 | 20010525 |
| | FI 111075 | B1 | 20030530 | | |
| | FI 2001001102 | A | 20010525 | FI 2001-1102 | 20010525 |
| | FI 111076 | B1 | 20030530 | | |
| PRAI | US 1993-100003 | A | 19930729 | | |
| OS | NZ 1994-264116 | A1 | 19940728 | | |
| GI | MARPAT 123:313792 | | | | |



- AB The title compds. [I; AB = (CH₂)_mNR₃, (un)substituted R₃N(CH₂)_m; R₃ = (un)substituted arylcarbonyl, (un)substituted 5-indolylcarbonyl, etc.; m = 1, 2; R₁ = H, halogen, OH, alkylthio, SH, acyl, etc.; R₂ = H, Cl, F, Br, I, alkyl, alkoxy; Z = (un)substituted fused Ph, (un)substituted 5-member heteroarom. ring, etc.], useful as vasopressin antagonists for diseases requiring diuretic application, are prepared Thus, dibenzazepine II was prepared and demonstrated a IC₅₀ for human V₂ receptors of 0.86 μM.
- IT **22361-77-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tricyclic benzazepine vasopressin antagonists from)
- RN 22361-77-9 CAPLUS
- CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo-
(8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:804461 CAPLUS

DN 123:198834

TI N-Heterobicycyl-piperazinyl or -piperidinyl tricyclic derivatives useful as dopamine receptor ligands

IN Tehim, Ashok; Fu, Jian-Min; Rakhit, Sumanas

PA Allelix Biopharmaceuticals Inc., Can.

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9517400 | A1 | 19950629 | WO 1994-CA687 | 19941214 |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN | | | | |
| | RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2179306 | AA | 19950629 | CA 1994-2179306 | 19941214 |
| | CA 2179306 | C | 20001107 | | |
| | AU 9511899 | A1 | 19950710 | AU 1995-11899 | 19941214 |
| | EP 736024 | A1 | 19961009 | EP 1995-902734 | 19941214 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 09506868 | T2 | 19970708 | JP 1994-517063 | 19941214 |
| PRAI | US 1993-172208 | A | 19931223 | | |
| | WO 1994-CA687 | W | 19941214 | | |

OS CASREACT 123:198834; MARPAT 123:198834

GI For diagram(s), see printed CA Issue.

AB Dopamine D4 receptor-selective compds. are disclosed, specifically I [rings A, B = (un)substituted, (un)saturated 5- or 6-membered, homo- or heterocyclic rings; X1 = CH₂, O, NH, S, CO, CH(OH), CH[CH(C1-4-alkyl)2], C:CHCl, C:CHCN, N(C1-4-alkyl), NAc, SO₂, SO; X2 = N:, CH₂CH:, CO, O, S; R1 = C1-4 alkyl; Y = CH, N; n = 0-2; q = 1-2; R2 = C1-6 alkyl bridge optionally incorporating N, O and S; ring D = cyclohexane or benzene nucleus; ring E = (un)saturated 5- or 6-membered heterocycle incorporating 1-3 of O, N, and/or S and (un)substituted by 1-2 of halo, C1-4 alkyl, haloalkyl] and their acid addition salts, solvates, and hydrates. Their uses as ligands for dopamine receptor identification, in a drug screening program, and as pharmaceuticals for, e.g., schizophrenia, are also described. Eighteen compds. I were claimed, prepared, and/or tested. Various salts and precursors were also prepared For example, condensation of 8-chlorodibenz[b,f][1,4]oxazepin-11(10H)-one [preparation briefly described] with 1-piperonylpiperazine in refluxing PhMe in the presence of TiCl₄ gave title compound II. As the most preferred embodiment of the invention, II exhibited better D4 affinity and selectivity than the standard D4 antagonist clozapine. For example, II had D4 receptor Ki of 4, vs. 23 for clozapine, and a D2/D4 ratio of 23.8, vs. 10 for clozapine.


IT **3158-94-9**, 4-Chlorodibenz[b,f][1,4]oxazepin-11(10H)-one
82096-44-4, 2-Chloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one
90353-73-4, 3-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine
167996-99-8, 4-Chloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine
167997-00-4, 2-Trifluoromethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine
167997-01-5, 2,7,8-Trichloro-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine
167997-02-6, 2-Methoxy-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine
167997-03-7, 4-Nitrodibenz[b,f][1,4]oxazepin-11(10H)-one
167997-04-8, 4-Cyanodibenz[b,f][1,4]oxazepin-11(10H)-one

10/785,120

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of piperazinyl and piperidinyl tricyclics as
dopamine receptor ligands)


RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX
NAME)




RN 82096-44-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)




RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)



RN 167996-99-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-chloro-5,10-dihydro- (9CI) (CA
INDEX NAME)



10/785,120


RN 167997-00-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-(trifluoromethyl)-
(9CI) (CA INDEX NAME)




RN 167997-01-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,7,8-trichloro-5,10-dihydro- (9CI)
(CA INDEX NAME)




RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA
INDEX NAME)



RN 167997-03-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-nitro- (9CI) (CA INDEX NAME)



RN 167997-04-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-4-carbonitrile, 10,11-dihydro-11-oxo- (9CI) (CA
INDEX NAME)

10/785,120



L10 ANSWER 49 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:570871 CAPLUS

DN 122:314588

TI Preparation of sulfonamide and sulfonic ester derivatives each having tricyclic heterocyclic ring as antitumor agents

IN Yoshino, Hiroshi; Ueda, Norihiro; Niijima, Jun; Haneda, Toru; Kotake, Yoshihiko; Yoshimatsu, Kentaro; Watanabe, Tatsuo; Nagasu, Takeshi; Tsukahara, Naoko; et al.

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9503279 | A1 | 19950202 | WO 1994-JP1231 | 19940726 |
| | W: CA, FI, NO, RU, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2144854 | AA | 19950202 | CA 1994-2144854 | 19940726 |
| | EP 679641 | A1 | 19951102 | EP 1994-921819 | 19940726 |
| | EP 679641 | B1 | 20021002 | | |
| | R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE | | | | |
| | JP 08081441 | A2 | 19960326 | JP 1994-174643 | 19940726 |
| | JP 3690825 | B2 | 20050831 | | |
| | AT 225334 | E | 20021015 | AT 1994-921819 | 19940726 |
| | NO 9501108 | A | 19950523 | NO 1995-1108 | 19950323 |
| | US 5834462 | A | 19981110 | US 1995-397254 | 19950323 |
| | FI 9501416 | A | 19950517 | FI 1995-1416 | 19950324 |
| | US 5854274 | A | 19981229 | US 1996-760738 | 19961205 |
| | US 5846969 | A | 19981208 | US 1997-873033 | 19970611 |
| PRAI | JP 1993-202466 | A | 19930726 | | |
| | JP 1994-158870 | A | 19940711 | | |
| | WO 1994-JP1231 | W | 19940726 | | |
| | US 1995-397254 | A3 | 19950323 | | |
| | US 1996-760738 | A3 | 19961205 | | |

OS MARPAT 122:314588

GI For diagram(s), see printed CA Issue.

AB N-heterocyclarylarylsulfonamide and heterocyclaryl arylsulfonate derivs. each having a tricyclic hetero ring, represented by general formula G-SO₂-L-M [G = a 5- or 6-membered aromatic ring; L = O or NR₁, wherein R₁ = H or lower alkyl; M = a tricyclic structure selected from the members Q - Q₅, wherein rings A and B represent each a 5 or 6-membered unsatd. ring; X = NR₂ (wherein R₂ = H or lower alkyl) or NHCO; Y = O, S(O)_n, CR₃R₄, CO, NR₅, CHR₆CHR₇, CR₈:R₉, NR₁₀CO, N:CR₁₁, OCHR₁₂, S(O)_nCH₁₃, or NR₁₄CHR₁₅; Z = N or CR₁₆, wherein n represents 0, 1 or 2; R₃ - R₁₃, R₁₅, R₁₆ = H or lower alkyl; R₁₄ = H, lower alkyl, or lower acyl] are prepared Thus, 107 mg 1-amino-10H-phenothiazine was dissolved in pyridine and a solution of 115 mg 4-methoxybenzenesulfonyl chloride in THF was added followed by stirring the mixture overnight at room temperature to give, after silica gel chromatog., a

title compound (I) (115 mg). I and phenothiazin-3-one derivative (II) showed IC₅₀ of 0.11 and 0.016 µg/mL against KB cells (human nasal cavity cancer). A total of 49 I were prepared

IT **163308-29-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate for preparation of N-heterocyclarylarylsulfonamide as antitumor agent)

RN 163308-29-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-amino-2-fluoro-5,10-dihydro- (9CI)

10/785,120

(CA INDEX NAME)




IT **163308-03-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclaryl sulfonamide as antitumor agent)

RN 163308-03-0 CAPLUS

CN Benzenesulfonamide, N-(2-fluoro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxy- (9CI) (CA INDEX NAME)



L10 ANSWER 50 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:380741 CAPLUS

DN 122:290829

TI Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) Derivatives. 3

AU Breslin, Henry J.; Kukla, Michael J.; Ludovici, Donald W.; Mohrbacher, Richard; Ho, Winston; Miranda, Milton; Rodgers, James D.; Hitchens, T. Kevin; Leo, Gregory; et al.

CS Janssen Research Foundation, Spring House, PA, 19477, USA

SO Journal of Medicinal Chemistry (1995), 38(5), 771-93


CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

GI



AB 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) (I, R = H, 5-Et, 7-Ph, etc.; X = S, O; Y = 8-Cl, 9-Cl; Z = H, 3,3-dimethylallyl, Pr, etc.) have been shown to significantly inhibit HIV-1 replication in vitro by interfering with the virus's reverse transcriptase enzyme. We describe our synthetic endeavors around 4, 5, and 7 mono- and disubstitutions of I and discuss HIV-1 inhibitory structure-activity relationships. On the basis of inhibition of HIV-1 replication in MT-4 cells, we found that 5-mono-Me-substituted analogs and 7-mono-Me-substituted analogs of I were comparable as being consistently the most active compds. Although generally less active, the 4,5,7-unsubstituted, 4-mono-substituted, cis- and trans-5,7-di-Me-substituted, and cis-4,5-di-Me-substituted analogs of I also exhibited significant activity. The remaining trans-4,5-di-Me-substituted, cis- and trans-4,7-di-Me-substituted, and all 4,5-, 5,6-, 6,7-, and 7,8-fused disubstituted analogs of I possessed no noticeable desired activity.


IT 162930-70-3P 162930-73-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and anti-HIV-1 activity of imidazobenzodiazepinones)

RN 162930-70-3 CAPLUS


| | | |
|----|---|-----|
| CN | 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-nitro- (9CI) | (CA |
| | INDEX NAME) | |



10/785,120

RN 162930-73-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5,10-dihydro- (9CI) (CA
INDEX NAME)



L10 ANSWER 51 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:534165 CAPLUS

DN 121:134165

TI Preparation of 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzox(thi)azepine compounds, and methods for treating pain

IN Husa, Robert K.; Rafferty, Michael F.; Hagen, Timothy J.; Hallinan, E. Ann

PA G. D. Searle and Co., USA

SO U.S., 27 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5304644 | A | 19940419 | US 1992-869563 | 19920415 |
| | US 5461046 | A | 19951024 | US 1993-126826 | 19930924 |
| PRAI | US 1992-869563 | A1 | 19920415 | | |
| OS | MARPAT 121:134165 | | | | |
| GI | | | | | |



AB Title compds. I (R1 = H, HO, alkyl, haloalkyl, alkoxy, HO2C, alkoxy carbonyl, amino, aminocarbonyl, (alkyl)(dialkyl)amino, amido, halo, NC, O2N, F3C, etc.; R2 = H, halo; X = O, S, with the proviso that R1 is not Cl at position 8 when X is O and R2 is H) or a salt, ester or amide thereof, are prepared 4-Chloro-3-nitrobenzotrifluoride and salicylaldehyde K salt were were reacted to give 2-[2-nitro-4-(trifluoromethyl)phenoxy]benzaldehyde which in EtOH was hydrogenated over Raney Ni to give 8-(trifluoromethyl)-10,11-dihydrodiben[b,f]oxazepine to which was added phosgene in MePh followed by 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide to give I (R1 = 8-F3C, R2 = H, X = O) which in a writhing assay at 30 mg/kg was the most potent. I were also tested for prostaglandin antagonism.


IT 3158-94-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of analgesics)


RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 52 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:270470 CAPLUS
 DN 120:270470
 TI Pyridoindolobenzodiazepines and derivatives as antipsychotics
 IN Rajagopalan, Parthasarathi
 PA The Du Pont Merck Pharmaceutical Co., USA
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9403455 | A1 | 19940217 | WO 1993-US6823 | 19930723 |
| | W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5321023 | A | 19940614 | US 1992-921051 | 19920729 |
| | AU 9346853 | A1 | 19940303 | AU 1993-46853 | 19930723 |
| | EP 652878 | A1 | 19950517 | EP 1993-917295 | 19930723 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | HU 69393 | A2 | 19950928 | HU 1995-193 | 19930723 |
| | JP 08500579 | T2 | 19960123 | JP 1993-505349 | 19930723 |
| | BR 9306896 | A | 19981208 | BR 1993-6896 | 19930723 |
| | ZA 9305486 | A | 19950130 | ZA 1993-5486 | 19930729 |
| | CN 1100424 | A | 19950322 | CN 1993-109416 | 19930729 |
| | FI 9500303 | A | 19950124 | FI 1995-303 | 19950124 |
| | NO 9500327 | A | 19950127 | NO 1995-327 | 19950127 |
| PRAI | US 1992-921051 | A | 19920729 | | |
| | WO 1993-US6823 | W | 19930723 | | |
| OS | MARPAT 120:270470 | | | | |
| GI | | | | | |



AB Pyrido[4',3':2,3]indolo-[1,7-ab][1,5]benzodiazepines [I; R = H, C1-10 alkyl, C3-7 cycloalkyl, hydroxyalkyl, amidoalkyl, aminoalkyl, (CH₂)_n-adamantyl, etc.; n = 1-8; R₁, R₂, R₄, and R₅ are independently selected from H, C1-3 alkyl, CF₃, Cl, F, Br, OH, CN, OMe, S(O)_pR₇; P = 0-2; R₇ = H, C1-3 alkyl, Ph; R₃ = H, C1-3 alkyl, cycloalkyl, cycloalkylalkyl, aralkyl, heteroarylalkyl, CO₂Me, CO₂Et; X = O, S, 2H], pharmaceutical compns. containing these compds., and methods of using these compds. to treat physiol. or drug induced psychosis and/or dyskinesia are claimed. In an example, I (R = R₄ = Me, R₁ = R₃ = R₅ = H, R₂ = Cl, CF₃, X = 2H, O) gave ED₅₀ values of ≤ 20 mg/kg in overcoming catalepsy in rats.


IT 154557-90-1P 154557-91-2P 154557-92-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)

10/785,120

(preparation, antidyskinetic and antipsychotic activity, and reduction of)


RN 154557-90-1 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,
11-chloro-1,2,3,4-tetrahydro-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 154557-91-2 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,
11-chloro-1,2,3,4-tetrahydro-6-methyl- (9CI) (CA INDEX NAME)



RN 154557-92-3 CAPLUS

CN Benzo[b]pyrido[3',4':4,5]pyrrolo[3,2,1-jk][1,4]benzodiazepin-8(9H)-one,
1,2,3,4-tetrahydro-3,6-dimethyl-11-(trifluoromethyl)- (9CI) (CA INDEX
NAME)




IT 154557-99-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methylpiperidone)


RN 154557-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-8-methyl-5-
nitroso- (9CI) (CA INDEX NAME)


10/785,120



L10 ANSWER 53 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:407902 CAPLUS
 DN 117:7902
 TI Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2.
 Tricyclic pyridobenzoxazepinones and dibenzoxazepinones
 AU Klunder, Janice M.; Hargrave, Karl D.; West, M.; Cullen, Ernest; Pal,
 Kollol; Behnke, Mark L.; Kapadia, Suresh R.; McNeil, Daniel W.; Wu, Joe
 C.; Chow, Grace C.
 CS Boehringer Ingelheim Pharm., Ridgefield, CT, 06877, USA
 SO Journal of Medicinal Chemistry (1992), 35(10), 1887-97
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 117:7902
 GI




AB Dibenzo[b,f][1,4]oxazepin-11(10H)-ones, e.g., I, pyrido[2,3-
 b][1,4]benzoxazepin-6(5H)-ones, e.g., II, and pyrido[2,3-
 b][1,5]benzoxazepin-5(6)-ones (III) inhibited human immunodeficiency virus
 type 1 reverse transcriptase with IC50 values as low as 19 nM. A-ring
 substitution had a profound effect on activity, with appropriate
 substituents at the positions ortho and para to the lactam N providing
 dramatically enhanced potency. Substitution in the C-ring is generally
 neutral or detrimental to activity. I-III are specific for HIV-1 RT,
 showing no activity for other viral reverse transcriptase enzymes.
 IT **140412-92-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and HIV-1 inhibition activity of)
 RN 140412-92-6 CAPLUS
 CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-amino-9-methyl- (9CI) (CA INDEX
 NAME)



IT **135810-39-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and alkylation of)
 RN 135810-39-8 CAPLUS
 CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX
 NAME)

10/785,120



L10 ANSWER 54 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:194275 CAPLUS

DN 116:194275

TI Reaction of tetrafluorodibenz[b,f][1,4]oxazepin-11(10H)-ones with nucleophiles

AU Konstantinova, A. V.; Yakovleva, O. D.; Gerasimova, T. N.

CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR


SO Khimiya Geterotsiklicheskikh Soedinenii (1991), (9), 1259-61

CODEN: KGSSAQ; ISSN: 0453-8234

DT Journal

LA Russian

GI




AB The nucleophilic substitution reactions of the title compound I (R = R2 = F; R1 = H) with NaOMe/MeOH or piperidine gave I (R2 = OMe or piperidino). In excess piperidine a 1,3-dipiperidino derivative was formed. I (R = R2 = H; R1 = F) did not react with NaOMe/MeOH or piperidine.

IT **140406-57-1P 140406-58-2P 140406-59-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 140406-57-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,4-trifluoro-3-methoxy- (9CI)
(CA INDEX NAME)



RN 140406-58-2 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,4-trifluoro-3-(1-piperidinyl)-
(9CI) (CA INDEX NAME)

10/785,120



RN 140406-59-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-difluoro-1,3-di-1-piperidinyl-
(9CI) (CA INDEX NAME)




IT 123959-09-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with methoxide or piperidine)

RN 123959-09-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA
INDEX NAME)



L10 ANSWER 55 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:583381 CAPLUS

DN 115:183381

TI Preparation of dibenz[b,f][1,4]oxazepin (and thiazepin)-11(10H)-ones and -thiones for prevention and treatment of AIDS

IN Hargrave, Karl D.; Schmidt, Guenther; Engel, Wolfhard; Schromm, Kurt

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Thomae, Dr. Karl, G.m.b.H.

SO Can. Pat. Appl., 41 pp.


CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------|---|------|----------|-----------------|----------|
| <hr/> | | | | | |
| PI | CA 2024040 | AA | 19910301 | CA 1990-2024040 | 19900827 |
| | CA 2024040 | C | 20020219 | | |
| | EP 419861 | A2 | 19910403 | EP 1990-116339 | 19900827 |
| | EP 419861 | A3 | 19920610 | | |
| | EP 419861 | B1 | 19951102 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | AT 129637 | E | 19951115 | AT 1990-116339 | 19900827 |
| | JP 03163021 | A2 | 19910715 | JP 1990-226409 | 19900828 |
| | JP 2862980 | B2 | 19990303 | | |
| | HU 57589 | A2 | 19911230 | HU 1990-5511 | 19900828 |
| | HU 211077 | B | 19951030 | | |
| | ZA 9006834 | A | 19920527 | ZA 1990-6834 | 19900828 |
| | KR 165108 | B1 | 19990218 | KR 1990-13273 | 19900828 |
| | AU 9061916 | A1 | 19910307 | AU 1990-61916 | 19900829 |
| | AU 639255 | B2 | 19930722 | | |
| | US 5571806 | A | 19961105 | US 1994-271350 | 19940706 |
| PRAI | US 1989-400254 | A | 19890829 | | |
| | US 1990-582773 | B1 | 19900803 | | |
| | US 1992-879652 | B1 | 19920506 | | |
| | US 1993-53948 | B1 | 19930428 | | |
| OS | MARPAT 115:183381 | | | | |
| GI | | | | | |



AB The title compds. [I; X, Z = O, S; R1 = H, C1-6 alkyl, C2-6 alkenyl, alkynyl, C3-6 cycloalkyl, etc.; R2 = H, Me, halo; R3 = H, C1-4 alkyl, halo, OH, C1-3 alkoxy, etc.; R4 = H, Me, halo; R5 = H, C1-4 alkyl, OH, C1-3 alkoxy, alkylthio, etc.] are prepared, tested, and formulated. To a solution of I (R1-R5 = H, X = Z = O) in DMF was added a 50% dispersion of NaH in mineral oil, the resulting mixture was stirred with PrBr to give 87% I (R1 = Pr, R2-R5 = H, X = Z = O), which showed 100% reverse transcriptase inhibition at 10 µg/mL. Also prepared and tested were 49 addnl. I. Capsule, parenteral solution, and nasal solution formulations were given.

IT 135810-39-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of HIV inhibitor)

10/785,120

RN 135810-39-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methyl-2-nitro- (9CI) (CA INDEX NAME)



IT 23474-55-7P 23474-59-1P 23474-63-7P


23474-66-0P 135810-51-4P 135810-53-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as HIV inhibitor for prevention and treatment of AIDS)


RN 23474-55-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)




RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)



RN 23474-63-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)



RN 23474-66-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120




RN 135810-51-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylamino)- (9CI) (CA INDEX NAME)




RN 135810-53-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methyl- (9CI) (CA INDEX NAME)



10/785,120


L10 ANSWER 56 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:247246 CAPLUS
DN 114:247246
TI Synthesis of fluorosubstituted 10,11-dihydrodibenz[b,f][1,4]oxazepines
AU Konstantinova, A. V.; Zborovskaya, O. D.; Gerasimova, T. N.
CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1990), (12), 1679-82
CODEN: KGSSAQ; ISSN: 0453-8234
DT Journal
LA Russian
OS CASREACT 114:247246
GI



AB Fluorinated dibenzoxazepinones I (X = F; Y = H and vice versa; R = H; Z = CO) were alkylated with Me₂N(CH₂)₃Cl.HCl to give I [R = (CH₂)₃NMe₂]. Also, the reaction of dibenzoxazepines I (R = H; X = CH₂) with CO₂Cl₂ and subsequent amination with NH₃ or Me₂NH or reaction with NH₂NH₂ followed by acetylation gave I (R = CONH₂, CONMe₂) or I (R = CONHNHAc), resp.

IT **123959-09-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of, with (dimethylamino)chloropropane hydrochloride)

RN 123959-09-1 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA INDEX NAME)



L10 ANSWER 57 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:632774 CAPLUS

DN 111:232774

TI Preparation of tricyclic lactams and analogs as muscarinic antagonists

IN Turconi, Marco; Donetti, Arturo; Cereda, Enzo; Quintero, Myrna Gil; Schiavi, Giovanni Battista; Micheletti, Rosamaria

PA Istituto De Angeli S.p.A., Italy

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 309422 | A2 | 19890329 | EP 1988-830374 | 19880919 |
| | EP 309422 | A3 | 19900110 | | |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| DD | 282689 | A5 | 19900919 | DD 1988-319831 | 19880915 |
| DK | 8805226 | A | 19890322 | DK 1988-5226 | 19880920 |
| FI | 8804305 | A | 19890322 | FI 1988-4305 | 19880920 |
| NO | 8804174 | A | 19890322 | NO 1988-4174 | 19880920 |
| JP | 01132567 | A2 | 19890525 | JP 1988-236178 | 19880920 |
| AU | 8822380 | A1 | 19890323 | AU 1988-22380 | 19880921 |
| PRAI | IT 1987-21978 | A | 19870921 | | |

OS MARPAT 111:232774

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = H, halo; X = N, CH; W = NHCO, CH:CH, (CH₂)₂, O, S; R₁ = H, C1-4 alkyl; n = 0, 1; Y = S, CH; A = C, N; B = CH when A ≠ N, CO₂, CO, CH₂; m = 0-3; Z = NH, CO, CO₂, CH, bond; p, q = 0, 1; Q = (homo)piperazinyl, piperidinyl, trotyl, tetrahydropyrimidinyl, the above groups may be substituted by a C1-4 alkyl or an amino; R = CR₂:NR₃; R₂ = H, C1-4 alkyl, (C1-4 alkyl- or Ph-substituted) amino; R₃ = C1-8 alkyl, H (provided that the bond of QR is a C-C bond or AB = C:CH); R₂R₃ = atoms to form a 5-membered ring] are prepared for treatment of motility disorders of the gastrointestinal or urogenital tract and peptic ulcer disorders. A mixture of 5,10-dihydro-5-[2-piperazin-1-yl]acetyl-11H-dibenzo[b,e][1,4]-diazepin-11-one and H₂NC(:NH)SMe.H₂SO₄ in EtOH was refluxed to give the 4-guanylpiperazinyl analog isolated as its 2 HCl salt. The latter salt showed a dissociation constant (K_D) of 6 nM for displacement of 3H-pirenzepine from cerebral cortex homogenate of rats. Tablets were formulated containing I 20, lactose 247, cornstarch 30, and Mg stearate 3 mg.

IT **122859-65-8P 122859-68-1P 122859-69-2P**
122860-39-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of muscarinic antagonists)

RN 122859-65-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-methyl-5-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)

10/785,120




RN 122859-68-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 122859-69-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(chloroacetyl)-5,10-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 122860-39-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(nitroamino)methyl]-1-piperazinyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




IT **122858-73-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as muscarinic antagonist)

RN 122858-73-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]acetyl]-5,10-dihydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L10 ANSWER 58 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:632756 CAPLUS

DN 111:232756

TI 11-Substituted polyfluorinated dibenz[b,f][1,4]oxazepines

AU Konstantinova, A. V.; Gerasimova, T. N.; Kozlova, M. M.; Petrenko, N. I.

CS Novosib. Inst. Org. Khim., Novosibirsk, USSR

SO Khimiya Geterotsiklicheskikh Soedinenii (1989), (4), 539-42



CODEN: KGSSAQ; ISSN: 0453-8234

DT Journal

LA Russian

OS CASREACT 111:232756

GI




AB Tetrafluorodibenzoxazepinones I (X = F, Y = H; X = H, Y = F), prepared by oxidation of the corresponding dibenzoxazepinones with Na₂Cr₂O₇ in AcOH, were chlorinated with POCl₃ to give 73 and 95% chloro derivs. II (same X, Y), resp. Amination of the latter by piperidine gave the corresponding piperidine derivs.

IT 123959-09-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

RN 123959-09-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,3,4-tetrafluoro- (9CI) (CA INDEX NAME)



L10 ANSWER 59 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:492960 CAPLUS

DN 109:92960

TI Synthesis and structure of 7,9-dinitro-5-phenyl-1,4-benzodiazepine derivatives and benzo[b] analogs

AU Dvorkin, A. A.; Simonov, Yu. A.; Ivanov, E. I.; Fedorova, G. V.; Ivanova, R. Yu.

CS Fiz. Khim. Inst., Odessa, USSR

SO Zhurnal Obshchei Khimii (1987), 57(11), 2613-17


CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Russian

OS CASREACT 109:92960

GI



AB Cyclocondensation of o-H₂NC₆H₄NH₂ and H₂NCH₂CH₂NH₂ with benzoic acid derivs. I (R₁ = R₃ = NO₂, R₂ = Ph, OMe) gave 65 and 72% benzodiazepines II and III and 68 and 79% benzo[b]-analogs IV and V.


IT **22177-14-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)



RN 22177-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)
(CA INDEX NAME)

10/785,120




L10 ANSWER 60 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1987:489483 CAPLUS
 DN 107:89483
 TI 2-[10,11-Dihydro-11-oxodibenz[b,f][1,4]oxazepin-7 or 8-yl]propanoic acids
 as potential anti-inflammatory agents
 AU Chakrabarti, Jiban K.; Hicks, Terence A.
 CS Lilly Res. Cent. Ltd., Windlesham/Surrey, GU20 6PH, UK
 SO European Journal of Medicinal Chemistry (1987), 22(2), 161-3
 CODEN: EJMCA5; ISSN: 0223-5234
 DT Journal
 LA English
 OS CASREACT 107:89483
 GI




AB I (R = o-Cl, o-O₂N, o-H₂N, or m-F) were prepared by the reaction of appropriately substituted o-aminophenols with o-halobenzoyl chlorides in the presence of 1 equivalent of aqueous NaOH and cyclization of the resulting
 II
 (R = 2-Cl, 2-NO₂, 2-NH₂ or 3-F, X = F or Cl) as di-Na salts followed by neutralization. The compds. were administered in mice in oral doses up to 1600 mg/kg. The compds. were not potent inhibitors of adjuvant-induced arthritis in rats and effects, where seen, were only moderate. I (R = 3-F; 7- or 8-CHMeCO₂H) showed moderately weak in vitro reduction of cyclooxygenase products of arachidonic acid in guinea pig peritoneal polymorphonuclear leukocytes. The compds. were 300-fold less potent than indomethacin.
 IT **109790-28-5P 109790-29-6P 109790-30-9P**
109790-31-0P 109790-32-1P 109823-13-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiinflammatory agent)
 RN 109790-28-5 CAPLUS
 CN Dibenz[b,f][1,4]oxazepine-7-acetic acid, 3-fluoro-10,11-dihydro- α -methyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 109790-29-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 2-chloro-10,11-dihydro- α -methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 109790-30-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 10,11-dihydro- α -methyl-2-nitro-11-oxo- (9CI) (CA INDEX NAME)




RN 109790-31-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 2-amino-10,11-dihydro- α -methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 109790-32-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-fluoro- (9CI) (CA INDEX NAME)



10/785,120

RN 109823-13-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-acetic acid, 3-fluoro-10,11-dihydro- α -methyl-11-oxo- (9CI) (CA INDEX NAME)



L10 ANSWER 61 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1986:442760 CAPLUS

DN 105:42760

TI Synthesis of 10,11-dihydrodibenz[b,f][1,4]oxazepine derivatives as potential anticonvulsant and psychotropic agents

AU Nagarajan, K.; David, J.; Bhat, G. A.

CS Res. Cent., Hindustan Ciba-Geigy Ltd., Bombay, 400 063, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1985), 24B(8), 840-4



CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 105:42760

GI




AB Dihydrobenzoxazepines I ($Z = O, S$; $R = H_2N, MeNH, EtNH, PrNH$, cyclohexylamino, $PhNH$, Me_2N , H_2NNH , EtO , Me , CF_3 , $ClCH_2$, morpholinomethyl, Et_2NCH_2 ; $R_1 = H, NO_2, NH_2, AcNH$) and II ($Z_1 = O, H_2$; $R_2 = NH_2, NO_2$; $R_3 = H, Me$), most of them carrying either a nitro or amino group at position-2, have been synthesized as analogs of carbamazepine and evaluated as anticonvulsants associated with potential neuroleptic activity. I ($Z, R, R_1 = O, AcNHNH, NO_2$; O, Me_2N, NH_2) have moderate activity in the electroshock test but are inactive against chemoshock. I ($Z = S, R = NH_2, R_1 = H$) is active against electroshock as well as against strychnine-induced seizures, has some analgesic activity and also exhibits neuroleptic properties, but its overall profile does not present any advantages over carbamazepine.

IT 23474-59-1P 23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticonvulsant and psychotropic activities of)

RN 23474-59-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 62 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:435135 CAPLUS
 DN 105:35135
 TI Piperazinylnaphthoxazepines with CNS depressant properties
 AU Nagarajan, Kuppuswamy; David, Joy; Kulkarni, Yashwant S.; Hendi, Shivakumar B.; Shenoy, Sharada J.; Upadhyaya, Pramod
 CS Res. Cent., Hindustan Ciba-Geigy Ltd., Bombay, 400063, India
 SO European Journal of Medicinal Chemistry (1986), 21(1), 21-6
 CODEN: EJMCA5; ISSN: 0223-5234
 DT Journal
 LA English
 OS CASREACT 105:35135
 GI



AB Several piperazinylnaphthoxazepines were synthesized and tested for central nervous system (CNS)-depressant, anticonvulsant, and antimescaline (tranquilizing) activities in mice. 13-(4-Methyl-1-piperazinyl)benzo[b]naphth[2,3-f][1,4]oxazepine maleate (I maleate) [103086-38-0] and 13-(4-methyl-1-piperazinyl)benzo[b]naphth[1,2-f][1,4]oxazepine maleate (II maleate) [103086-50-6] had strong CNS-depressant and antimescaline activity, but provided little or no protection against electroshock convulsions. III [103086-33-5] had only moderate antimescaline and CNS-depressant action, but protected the animals against electroshock convulsions. Structure-activity relation of the psychoactive agents are discussed.


IT 103086-27-7P 103086-33-5P 103086-64-2P
 103086-65-3P 103116-81-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and central nervous system activity of)

RN 103086-27-7 CAPLUS


CN Benzo[f]naphth[1,2-b][1,4]oxazepin-8(7H)-one, 10-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 103086-33-5 CAPLUS

CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-amino- (9CI) (CA INDEX NAME)




RN 103086-64-2 CAPLUS

CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-nitro- (9CI) (CA INDEX NAME)



RN 103086-65-3 CAPLUS


CN Benzo[f]naphth[2,1-b][1,4]oxazepin-12(13H)-one, 10-chloro- (9CI) (CA INDEX NAME)



RN 103116-81-0 CAPLUS


CN Benzo[f]naphth[2,3-b][1,4]oxazepin-13(12H)-one, 2-chloro- (9CI) (CA INDEX NAME)

10/785,120




10/785,120

L10 ANSWER 63 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:148838 CAPLUS
DN 104:148838
TI A new facile synthesis of 11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepines
AU Giani, R. P.; Borsa, M.; Parini, E.; Tonon, G. C.
CS Res. Dev. Dep., Dompe Farm. S.p.A., Milan, I-20122, Italy
SO Synthesis (1985), (5), 550-2
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
OS CASREACT 104:148838
GI




AB The title compds. I (R = 3-NO₂, 2-NO₂, 3-Cl, H, 2-Cl; R₁ = H, 4-NO₂; R₂ = H, 7-Me, 7-Cl; R₃ = H, 8-Me, 8-Cl) were prepared in 3-41% yield by heating chlorobenzoic acids II with phenylenediamines III in a PhCl suspension of Cu powder.
IT 22177-14-6P 54255-81-1P 82096-44-4P
90353-73-4P 101382-96-1P 101382-98-3P
101382-99-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22177-14-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)
(CA INDEX NAME)




RN 54255-81-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)

10/785,120




RN 82096-44-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)




RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)



RN 101382-96-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-nitro- (9CI) (CA
INDEX NAME)



RN 101382-98-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethyl-2-nitro-
(9CI) (CA INDEX NAME)

10/785,120



RN 101382-99-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7,8-dimethyl-
(9CI) (CA INDEX NAME)



L10 ANSWER 64 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1985:166786 CAPLUS

DN 102:166786

TI Dibenzodiazepines

PA Hoechst-Roussel Pharmaceuticals, Inc., USA

SO Jpn. Kokai Tokkyo Koho, 47 pp.


CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | JP 59219285 | A2 | 19841210 | JP 1984-97691 | 19840517 |
| | US 4761411 | A | 19880802 | US 1983-495569 | 19830518 |
| | HU 37432 | A2 | 19851228 | HU 1984-1858 | 19840514 |
| | HU 193010 | B | 19870828 | | |
| | EP 129692 | A2 | 19850102 | EP 1984-105509 | 19840515 |
| | EP 129692 | A3 | 19870729 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | FI 8401965 | A | 19841119 | FI 1984-1965 | 19840516 |
| | FI 77865 | B | 19890131 | | |
| | FI 77865 | C | 19890510 | | |
| | ES 532509 | A1 | 19850801 | ES 1984-532509 | 19840516 |
| | DK 8402469 | A | 19841119 | DK 1984-2469 | 19840517 |
| | AU 8428347 | A1 | 19841122 | AU 1984-28347 | 19840517 |
| | AU 575830 | B2 | 19880811 | | |
| | ZA 8403722 | A | 19850130 | ZA 1984-3722 | 19840517 |
| | CA 1244414 | A1 | 19881108 | CA 1984-454542 | 19840517 |
| | US 4663453 | A | 19870505 | US 1985-770046 | 19850828 |
| | US 4723003 | A | 19880202 | US 1986-929697 | 19861112 |
| | US 4723007 | A | 19880202 | US 1986-929705 | 19861112 |
| | US 4761412 | A | 19880802 | US 1986-929700 | 19861112 |
| | US 4764616 | A | 19880816 | US 1986-929696 | 19861112 |
| | FI 8800925 | A | 19880229 | FI 1988-925 | 19880229 |
| PRAI | US 1983-495569 | A | 19830518 | | |
| | FI 1984-1965 | A | 19840516 | | |
| | US 1984-639569 | A2 | 19840810 | | |
| | US 1985-770046 | A3 | 19850828 | | |
| OS | CASREACT 102:166786; MARPAT 102:166786 | | | | |
| GI | | | | | |



I



II

AB Title compds. I (R, R4 = H, halo, CF3, alkyl, alkoxy, alkylthio, alkylsulfonyl; R1 = H, R2R3 = alkylene, CH:CH; R3 = H, R1R2 = alkylene, CH:CH; R5 = amino) and their salts were prepared Thus, treating 5-chloroindoline with 2-FC6H4CONH2 in Me2SO in the presence of NaH gave indoline II (R6 = H), which was nitrated and reduced to give II (R6 = NH2). The latter compound was cyclized with HCl-Et2O and condensed with

10/785,120


N-methylpiperazine to give I (R = R₁ = H, R₂R₃ = CH:CH, R₄ = 4-Cl, R₅ = N-methylpiperazinyl). 9-Methyl-6-(4-methylpiperazinyl)-1,2-dihydrobenzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepine had antipsychotic ED₅₀ of 25.5 mg/kg orally in mice and analgesic ED₅₀ of 0.34 mg/kg s.c. in mice.

IT **96015-18-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96015-18-8 CAPLUS


CN Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepin-6(7H)-one,
4-chloro-1,2-dihydro- (9CI) (CA INDEX NAME)




10/785,120

L10 ANSWER 65 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:407218 CAPLUS
DN 101:7218
TI Pyridoindolobenzodiazepine tranquilizers
IN Rajagopalan, Parthasarathi
PA du Pont de Nemours, E. I., and Co. , USA
SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------------------------|------|----------|-----------------|----------|
| PI | US 4438120 | A | 19840320 | US 1982-441376 | 19821112 |
| PRAI | US 1982-441376 | | 19821112 | | |
| OS | CASREACT 101:7218; MARPAT 101:7218 | | | | |
| GI | | | | | |



I



III


AB Pyridoindolobenzodiazepines I [R = H, (un)substituted alkyl; R1, R2, R4, R5 = H, CF3, Me, Et, halo; R3 = H, alkyl; X = H2, O, S] and their trans-4a,14a dihydro derivs. (II) were prepared Thus, the dibenzodiazepinone III (R6 = H) was nitrosated to give III (R6 = NO) which was treated with Zn-HOAc and 4-piperidone to give I (R = R1 = R3 = R4 = R5 = H, R2 = Cl; X = O; IV). IV was acetylated to give I (R = Ac, R1 = R3 = R4 = R5 = H, R2 = Cl, X = O; IV) which was reduced by B2H6 in THF, then refluxed with 6N HCl to give II.2HCl (R = Et, R1 = R3 = R4 = R5 = H, R2 = Cl, X = H2; V). In the conditioned avoidance response test with mice, the ED50 for IV and V were 29 and 0.3 mg/kg orally, resp.

IT 82096-44-4 90353-73-4 90353-74-5
90353-75-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(nitrosation of)

RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)



10/785,120


RN 90353-73-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)




RN 90353-74-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 90353-75-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl- (9CI) (CA INDEX NAME)




IT 90353-29-0P 90353-35-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and borane reduction of)

RN 90353-29-0 CAPLUS


CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
3-acetyl-11-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

10/785,120



RN 90353-35-8 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(1-oxohexyl)- (9CI) (CA INDEX
NAME)




IT 90353-38-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of, by borane)

RN 90353-38-1 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-1,2,3,4-tetrahydro-3-(phenylacetyl)- (9CI) (CA INDEX NAME)



IT 90340-27-5P 90340-29-7P 90340-30-0P
90340-33-3P 90340-34-4P 90340-35-5P


90340-37-7P 90340-38-8P 90340-40-2P

90340-55-9P 90340-56-0P 90340-57-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tranquilizer activity of)


RN 90340-27-5 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 90340-29-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
12-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 90340-30-0 CAPLUS


CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
5-chloro-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)




RN 90340-33-3 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


10/785,120



RN 90340-34-4 CAPLUS
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)




RN 90340-35-5 CAPLUS
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6,11-dichloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)




RN 90340-37-7 CAPLUS
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX
NAME)

10/785,120




RN 90340-38-8 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-1,2,3,4-tetrahydro-3-methyl-6-(trifluoromethyl)- (9CI) (CA
INDEX NAME)



RN 90340-40-2 CAPLUS


CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
5-chloro-1,2,3,4-tetrahydro-3,11-dimethyl- (9CI) (CA INDEX NAME)



RN 90340-55-9 CAPLUS


CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
5-chloro-3-hexyl-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 90340-56-0 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-3-hexyl-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 90340-57-1 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-3-hexyl-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



IT 90340-36-6P 90353-30-3P 90353-67-6P

90353-68-7P 90353-70-1P 90353-71-2P


90353-72-3P 90353-96-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 90340-36-6 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
12-chloro-1,2,3,4-tetrahydro-3-methyl- (9CI) (CA INDEX NAME)


10/785,120



RN 90353-30-3 CAPLUS
CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
3-acetyl-11-chloro-1,2,3,4-tetrahydro-6-(trifluoromethyl)- (9CI) (CA
INDEX NAME)




RN 90353-67-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-
(9CI) (CA INDEX NAME)




RN 90353-68-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-nitroso-
(9CI) (CA INDEX NAME)

10/785,120




RN 90353-70-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)




RN 90353-71-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)



RN 90353-72-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 90353-96-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/785,120




IT **90340-41-3P 90340-42-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, acylation, and tranquilizer activity of)


RN 90340-41-3 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 6-chloro-1,2,3,4-tetrahydro-11-methyl- (9CI) (CA INDEX NAME)



RN 90340-42-4 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 11-chloro-1,2,3,4-tetrahydro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT **90340-28-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, borane reduction, and tranquilizer activity of)

RN 90340-28-6 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one, 11-chloro-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




IT 90353-67-6 90353-68-7 90353-70-1
90353-71-2 90353-72-3 90353-78-9
90353-79-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction and reaction of, with piperidones, pyridoindolobenzodiazepines
from)


RN 90353-67-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-
(9CI) (CA INDEX NAME)



RN 90353-68-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-nitroso-
(9CI) (CA INDEX NAME)



RN 90353-70-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methyl-5-nitroso-
(9CI) (CA INDEX NAME)

10/785,120




RN 90353-71-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)




RN 90353-72-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-nitroso-8-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 90353-78-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-chloro-5,10-dihydro-2-methyl-5-nitroso- (9CI) (CA INDEX NAME)



RN 90353-79-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,8-dichloro-5,10-dihydro-5-nitroso- (9CI) (CA INDEX NAME)

10/785,120




IT 90353-92-7 90353-94-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of, by borane)


RN 90353-92-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX
NAME)




RN 90353-94-9 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(phenylacetyl)- (9CI) (CA INDEX
NAME)



10/785,120


L10 ANSWER 66 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:407128 CAPLUS
DN 101:7128
TI Synthesis of carbon-14-labeled 10-[3-(dimethylamino)propyl]-2-nitrodibenz[b,f][1,4]oxazepin-11(10H)one (nitroxazepine) hydrochloride
AU Maller, R. K.; Nagarajan, K.
CS Res. Cent., Ciba-Geigy, Bombay, 400 063, India
SO Journal of Labelled Compounds and Radiopharmaceuticals (1983), 20(12), 1339-48
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
OS CASREACT 101:7128
GI



AB The title antidepressant compound I was prepared labeled in the 11-position with ¹⁴C in an overall yield of 12% and sp. activity 0.95 μ Ci/mg starting from Na¹⁴CN, and ¹⁴C-labeled in one terminal Me group in 20% overall yield and sp. activity 1.84 μ Ci/mg starting from desmethylnitroxazepine. The 11-¹⁴C atom was introduced by treating diazotized 2-ClC₆H₄NH₂ with Cu₂(¹⁴CN)₂, prepared in situ from Cu₂Cl₂ and K¹⁴CN, to give 2-ClC₆H₄¹⁴CN.

IT **90425-08-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and condensation of, with (dimethylamino)propyl chloride)


RN 90425-08-4 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one-11-¹⁴C, 2-nitro- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 67 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1984:209889 CAPLUS
DN 100:209889
TI Dibenzoxazepine derivatives
PA Chugai Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------|------|----------|-----------------|----------|
| PI | JP 58225074 | A2 | 19831227 | JP 1982-108516 | 19820625 |
| | JP 03059068 | B4 | 19910909 | | |
| PRAI | JP 1982-108516 | | 19820625 | | |
| OS | CASREACT 100:209889 | | | | |
| GI | | | | | |



AB Ten anti-ulcer (no data) dibenzoxazepine derivs. I [R₁ = H, halo, alkoxy, alkyl; n = 1, 2; NR₂R₃ = NH(CH₂)_mNR₄R₅ (R₄, R₅ = alkyl; NR₄R₅ may form a heterocyclic ring; m = 2, 3), 4-methyl(homo)piperazino] and their HCl salts were prepared by reaction of II with R₂R₃NH. Thus, refluxing 3.4 g II (R₁ = 2- and 4-Me₂CH, n = 2) with 10 mL SOCl₂ in C₆H₆ 3 h gave the chloride, which (in CHCl₃) was added to a mixture of 3 g N-methylpiperazine and 15 mL 10% aqueous NaOH with ice cooling and the whole stirred 1 h with ice cooling and 2 h at room temperature to give 85.4% I (R₁ = 2- and 4-Me₂CH, n =


2, NR₂R₃ = 4-methylpiperazino).

IT **81679-38-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

RN 81679-38-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




IT **90174-23-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and amidation of)

RN 90174-23-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carbonyl chloride, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




IT 90174-02-0P 90174-04-2P 90174-05-3P
 90174-06-4P 90174-07-5P 90174-08-6P
 90174-09-7P 90174-10-0P 90174-11-1P
 90174-12-2P 90174-14-4P 90174-15-5P
 90174-16-6P 90174-17-7P 90174-18-8P
 90174-19-9P 90174-20-2P 90174-21-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 90174-02-0 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-04-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-05-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-06-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-4-methoxy-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-07-5 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 90174-08-6 CAPLUS


CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 90174-09-7 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)

10/785,120




RN 90174-10-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 90174-11-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 90174-12-2 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 90174-14-4 CAPLUS

10/785,120


CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-15-5 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-16-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-4-methoxy-11-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 90174-17-7 CAPLUS


CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenzo[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/785,120




● HCl

RN 90174-18-8 CAPLUS
CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 90174-19-9 CAPLUS
CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 90174-20-2 CAPLUS
CN Dibenz[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/785,120



● HCl

RN 90174-21-3 CAPLUS
CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

10/785,120

L10 ANSWER 68 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:191915 CAPLUS

DN 100:191915

TI Dibenzoxazepinone derivatives

PA Chugai Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 58225073 | A2 | 19831227 | JP 1982-108515 | 19820625 |
| | JP 03059067 | B4 | 19910909 | | |
| PRAI | JP 1982-108515 | | 19820625 | | |
| GI | | | | | |




AB Sixteen anti-ulcer (no data) dibenzoxazepinones I (R₁ = H, alkyl, alkoxy; n = 1, 2; R₂ = alkyl, alkenyl, aralkyl; R₃ = H, alkyl) were prepared by reaction of II with R₂X (X = halo) optionally followed by hydrolysis. Thus, 3.86 g MeI and 5.6 g K₂CO₃ were added to 5 g II (R₁ = 2- and 4-Me₂CH, n = 2, R₃ = Et) in Me₂CO to give, after refluxing 30 h, 86% I (R₁ = 2- and 4-Me₂CH, n = 2, R₂ = Me, R₃ = Et). Treatment of the latter with refluxing 50 mL 10% aqueous NaOH in EtOH 2 h gave 92% I (R₁ = 2- and 4-Me₂CH, n = 2, R₂ = Me, R₃ = H).

IT 81679-30-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(methylation of)



RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 69 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1984:156648 CAPLUS
 DN 100:156648
 TI Dibenz[b,f][1,4]oxazepine derivatives
 PA Chugai Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | JP 58208278 | A2 | 19831203 | JP 1982-91265 | 19820531 |
| | JP 03059065 | B4 | 19910909 | | |
| PRAI | JP 1982-91265 | | 19820531 | | |
| GI | | | | | |




AB Dibenzo[b,f][1,4]oxazepine derivs. I [Rn = H, 3-Me, 4-Me, 2-Br, 2-Cl, 4-MeO, 2,4-(Me2CH)2, 2,4-Cl2, 2,4-Br2] were prepared by lactamization of II (R1 = alkyl) in the presence of strong bases. Thus, heating 1.5 g II [Rn = 4,6-(Me2CH)2, R1 = Et] with 145 mg 60% NaH in DMF 1 h at 70° gave 77% I [Rn = 2,4-(Me2CH)2].

IT **81679-23-4P 81679-24-5P 81679-25-6P**
81679-26-7P 81679-27-8P 81679-28-9P
81679-29-0P 81679-30-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 81679-23-4 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-24-5 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-25-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-26-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-27-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-28-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 81679-29-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 70 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:80806 CAPLUS

DN 100:80806

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat. Part II.
Metabolism in vitro

AU Furnival, B.; Harrison, J. M.; Newman, J.; Upshall, D. G.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 361-72

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB Dibenz[b,f]-1,4-oxazepine (I) [257-07-8] is metabolized by rat liver fractions by (a) ring opening and reduction to 2-amino-2'-hydroxymethyldiphenyl ether [88373-14-2] and (b) oxidation at C11 to give a cyclic lactam [3158-85-8]. Reaction a is NADPH-dependent, decreased by dialysis and methylene blue, and reaction b is heat-resistant, inactivated by dialysis, inhibited by cyanide, p-chloromercuribenzoate, amytal and menadione, and stimulated by methylene blue, phenazine methosulfate and 2,6-dichlorophenol indophenol. Reaction a is similar to that of aldehyde reductase (EC 1.1.1.2) [9028-12-0] and reaction b to that of aldehyde oxidase (EC 1.2.3.1) [9029-07-6]. Reaction a is also catalyzed by an NADH-dependent enzyme in liver microsomes and subsequent hydroxylation of the lactam also occurs in this cell fraction. Some extrahepatic metabolism of I occurs via the same routes in kidney, small intestine, and lung, though the yield is limited. Digestive gland extract of *Helix pomatia* converts I to its lactam. The metabolism of I in vitro is similar to that predicted from observations in vivo.


IT 60287-09-4 88373-19-7

RL: FORM (Formation, nonpreparative)

(formation of, as dibenzoxazepine metabolite by liver in vitro)


RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)



L10 ANSWER 71 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:30556 CAPLUS

DN 100:30556

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat. Part III. The intermediary metabolites

AU French, M. C.; Harrison, J. M.; Newman, J.; Upshall, D. G.; Powell, G. M.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 373-81

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB The fates of several intermediates of dibenz[b,f]-1,4-oxazepine (CR) [257-07-8] metabolism in vivo and in vitro in rats were examined to establish the metabolic and excretory sequence of CR. The ring-opened 2-amino-2'-hydroxymethyldiphenyl ether (amino alc.) [88373-14-2] added to isolated perfused rat liver was rapidly cleared in bile as a mixture of highly polar conjugates, whereas the major route of excretion in vivo was as the 4- [88373-19-7], 7- [88373-20-0] and 9-hydroxylactam sulfate [88373-18-6] in urine. The lactam of CR [3158-85-8] was eliminated exclusively in urine giving the same products as obtained for CR, but the distribution of metabolites of the C10-C11 dihydro derivative of CR [2244-60-2] was unlike that of the parent compound indicating that it occupies only a peripheral role in the fate of CR in vivo. A mixture of 7- [60287-11-8], 4- [60287-09-4] and 9-hydroxylactam [60287-13-0] derivs. derived from the enzymic hydrolysis of urinary sulfates was rapidly removed from blood, sulfated and secreted as sulfates into blood both in vivo and in isolated perfused liver. Little biliary excretion occurred. When the urinary sulfates of the hydroxylactams were administered i.v. to rats, 70% was eliminated in urine within 1 h; however, if the kidneys were ligated biliary excretion of sulfate was higher (58% in 5 h). After intraduodenal administration of the biliary conjugates of CR metabolism, all of the dose was resorbed to be resecreted in bile or excreted as sulfate in urine. Apparently, the major metabolite fate of CR in the rat is oxidation to lactam, followed by ring hydroxylation, sulfation and urinary excretion. However, a significant proportion of the dose is oxidized to the amino alc. which is conjugated for biliary secretion, intestinal resorption, and recycling.


IT 60287-09-4 88373-19-7

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolism of, dibenzoxazepine metabolism in relation to)

RN 60287-09-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 72 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1984:30555 CAPLUS

DN 100:30555

TI The fate of dibenz[b,f]-1,4-oxazepine (CR) in the rat, rhesus monkey and guinea pig. Part I. Metabolism in vivo

AU French, M. C.; Harrison, J. M.; Inch, T. D.; Leadbeater, L.; Newman, J.; Upshall, D. G.

CS Chem. Def. Establ., Salisbury/Wiltshire, SP4 0JQ, UK

SO Xenobiotica (1983), 13(6), 345-59

CODEN: XENOBH; ISSN: 0049-8254

DT Journal

LA English

AB After i.v. or intragastric administration of dibenz[b,f]-1,4-oxazepine (I) [257-07-8] to rats, guinea pigs, or monkeys most (59-93%) was excreted via urine. The principal I metabolites were 9-hydroxylactam sulfate [88373-18-6], 7-hydroxylactam sulfate [88373-20-0], and 4-hydroxylactam sulfate [88373-19-7]. The bile of rats contained only small amts. of sulfate conjugates. The predominant metabolite of the bile was identified as the conjugates of the hydroxylactams and the amino alc. [88373-14-2]. This was not identified in the urine or blood of rats. In isolated and perfused rat liver preps. I was metabolized initially into lactam [3158-85-8] and later into 4- [60287-09-4], 7- [60287-11-8], and 9-hydroxylactam [60287-13-0]. Traces of amino alc. and I were also detected. In pregnant mice injected i.v. with [14C]I a rapid distribution of 14C to liver, lung, brain, brown fats, salivary gland and kidney was observed after 1 min. Little penetrated into the fetus. However, the 14C disappeared rapidly from the tissues. The toxicity of I (to rats) was greater than that of its metabolites except for the I lactam which was 3 times more toxic than I.


IT 60287-09-4 88373-19-7

RL: BIOL (Biological study)

(as dibenzoxepine metabolite, species-related differences in)


RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 88373-19-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(sulfooxy)- (9CI) (CA INDEX NAME)



L10 ANSWER 73 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:582469 CAPLUS

DN 97:182469

TI Dibenz[b,f][1,4]oxazepine derivatives and their pharmaceutical composition

IN Ito, Kiyohiko; Koizumi, Masuo; Murakami, Yasushi; Akima, Mitchitaka; Aono, Jinichiro; Ohba, Yasuhiro; Yamazaki, Tamotsu; Sakai, Kazushige; Hata, Shun-ichi; Takanashi, Shigeru

PA Chugai Pharmaceutical Co., Ltd. , Japan

SO Eur. Pat. Appl., 18 pp.



CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------------------------|------|----------|-----------------|----------|
| PI | EP 54951 | A1 | 19820630 | EP 1981-110655 | 19811221 |
| | EP 54951 | B1 | 19841212 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, NL, SE | | | | |
| | JP 57106673 | A2 | 19820702 | JP 1980-181831 | 19801224 |
| | US 4379150 | A | 19830405 | US 1981-331897 | 19811217 |
| | CA 1169059 | A1 | 19840612 | CA 1981-392733 | 19811218 |
| | AT 10741 | E | 19841215 | AT 1981-110655 | 19811221 |
| PRAI | JP 1980-181831 | A | 19801224 | | |
| | EP 1981-110655 | A | 19811221 | | |
| OS | CASREACT 97:182469; MARPAT 97:182469 | | | | |
| GI | | | | | |



AB Title compds. I (R = H, alkyl; R1 = alkyl; R2 = H, CO2H, CONH2, carbalkoxy, alkoxy; R3, R4 = alkyl; NR3R4 = heterocyclyl; Z = alkylene) were prepared, and showed effectiveness in the treatment of angina pectoris. II (R = H) reacted with ClCH2CH2NMe3.HCl and KOH to give II (R = CH2CH2NMe2).


IT **81679-30-3**

RL: RCT (Reactant); RACT (Reactant or reagent)

(N-alkylation of, by aminoethyl chloride derivative)

RN 81679-30-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 74 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:472339 CAPLUS

DN 97:72339

TI Nonsteroidal antiinflammatory agents. 1. 10,11-Dihydro-11-oxodibenz[b,f]oxepinacetic acids and related compounds

AU Nagai, Yasutaka; Irie, Akira; Nakamura, Hideo; Hino, Katsuhiko; Uno, Hitoshi; Nishimura, Haruki

CS Res. Lab., Dainippon Pharm. Co., Ltd., Suita, Japan


SO Journal of Medicinal Chemistry (1982), 25(9), 1065-70

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI



I

AB 10,11-Dihydro-11-oxodibenz[b,f]oxepinacetic acids and related compds. were synthesized as potential inflammation-inhibitors. Among them, 2-(8-methyl-10,11-dihydro-11-oxodibenz[b,f]oxepin-2-yl)propionic acid (I, X = O) and its thiepin analog I (X = S) showed excellent antipyretic activity together with potent inflammation-inhibiting and analgesic properties in conventional biol. tests. Structure and activity relationships are discussed.


IT **82341-22-8P 82341-23-9P 82341-24-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and pharmacol. activity of)

RN 82341-22-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 82341-23-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro- α -methyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120



RN 82341-24-0 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-3-acetic acid, 10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




IT 82340-99-6P 82341-00-2P 82341-01-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)


RN 82340-99-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 82341-00-2 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-2-acetic acid, 10,11-dihydro- α -methyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 82341-01-3 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-3-acetic acid, 10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/785,120




L10 ANSWER 75 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1982:423831 CAPLUS
 DN 97:23831
 TI Dibenzoxazepine derivatives
 PA Chugai Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | JP 57002278 | A2 | 19820107 | JP 1980-74176 | 19800604 |
| PRAI | JP 1980-74176 | A | 19800604 | | |
| GI | | | | | |



I



II


AB Eighteen dibenzoxazepine derivs. I (R, R1 = H, halo, alkyl, alkoxy; R2 = H, Et) were prepared by cyclization of II (R3 = alkyl) optionally followed by hydrolysis. I had hypolipemic, antiulcer, and PGI2 production accelerating activities (no data). Thus, heating 10 g 2,4-H2N(EtO2C)C6H3OC6H4CO2Me-2 3 h at 175° gave 89% I (R = R1 = H, R2 = Et), which (5.65 g) was hydrolyzed (KOH in aqueous MeOH) to give 94% I (R = R1 = R2 = H).

IT **81679-23-4P 81679-24-5P 81679-25-6P**
81679-26-7P 81679-27-8P 81679-28-9P
81679-29-0P 81679-30-3P 81679-31-4P
81679-32-5P 81679-33-6P 81679-34-7P
81679-35-8P 81679-36-9P 81679-37-0P
81679-38-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and pharmacol. activities of)


RN 81679-23-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-24-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-25-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-26-7 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-27-8 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-28-9 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)

10/785,120




RN 81679-29-0 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 81679-30-3 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 81679-31-4 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-3-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 81679-32-5 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methyl-11-oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 81679-33-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-bromo-10,11-dihydro-11-oxo-
(9CI) (CA INDEX NAME)




RN 81679-34-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2-chloro-10,11-dihydro-11-oxo-
(9CI) (CA INDEX NAME)



RN 81679-35-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-11-
oxo- (9CI) (CA INDEX NAME)



RN 81679-36-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dichloro-10,11-dihydro-11-
oxo- (9CI) (CA INDEX NAME)

10/785,120




RN 81679-37-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 2,4-dibromo-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 81679-38-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)



L10 ANSWER 76 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1982:423828 CAPLUS

DN 97:23828

TI 5-Substituted 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones and medicaments containing them

IN Schmidt, Guenther; Bergamaschi, Mario

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 34 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------------------------------|------|----------|-----------------|----------|
| PI | EP 44989 | A1 | 19820203 | EP 1981-105421 | 19810711 |
| | EP 44989 | B1 | 19830525 | | |
| | R: AT, BE, CH, DE, FR, IT, LU, NL, SE | | | | |
| | DE 3028001 | A1 | 19820218 | DE 1980-3028001 | 19800724 |
| | AT 3548 | E | 19830615 | AT 1981-105421 | 19810711 |
| | US 4377576 | A | 19830322 | US 1981-282501 | 19810713 |
| | DD 202023 | A5 | 19830824 | DD 1981-231897 | 19810717 |
| | JP 57056470 | A2 | 19820405 | JP 1981-113421 | 19810720 |
| | DK 8103264 | A | 19820125 | DK 1981-3264 | 19810722 |
| | FI 8102321 | A | 19820125 | FI 1981-2321 | 19810723 |
| | FI 67697 | B | 19850131 | | |
| | FI 67697 | C | 19850510 | | |
| | NO 8102529 | A | 19820125 | NO 1981-2529 | 19810723 |
| | AU 8173370 | A1 | 19820128 | AU 1981-73370 | 19810723 |
| | AU 543677 | B2 | 19850426 | | |
| | GB 2081264 | A | 19820217 | GB 1981-22782 | 19810723 |
| | GB 2081264 | B2 | 19840125 | | |
| | ES 504206 | A1 | 19821116 | ES 1981-504206 | 19810723 |
| | ZA 8105043 | A | 19830330 | ZA 1981-5043 | 19810723 |
| | CA 1154763 | A1 | 19831004 | CA 1981-382372 | 19810723 |
| | HU 28455 | O | 19831228 | HU 1981-2160 | 19810723 |
| | HU 187340 | B | 19851228 | | |
| PRAI | DE 1980-3028001 | A | 19800724 | | |
| | EP 1981-105421 | A | 19810711 | | |
| OS | CASREACT 97:23828; MARPAT 97:23828 | | | | |
| GI | | | | | |



AB Dibenzodiazepinones I (R1 = H, Me, Et; R2, R3 = H, Cl; R4 = 1-pyrrolidinyl, piperidino, 2-methyl-, 2-ethyl-, 2,6-dimethylpiperidino, morpholino) and their physiol. tolerable salts, useful in inhibiting gastric secretion and gastric ulcers, were prepared Acylating 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one with Cl(CH2)2COCl in dioxane gave I (R1-R3 = H, R4 = Cl) which N-alkylated pyrrolidine in refluxing Me2CHOH in 45 min to give I (R2-R3 = H, R4 = 1-pyrrolidinyl)

(II). The ED50 for gastric secretion inhibition for II.HCl was 0.20 mg/kg (duodenum) in rats vs. 8.15 for the 5-(1-pyrrolidinylacetyl) analog.


IT **31265-85-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and N-alkylation by, of cyclic amines)

RN 31265-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(3-chloro-1-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




IT **82096-30-8P 82097-68-5P 82097-71-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 82096-30-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[3-(2-methyl-1-piperidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 82097-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

10/785,120



RN 82097-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




IT 82096-44-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acylation of, by chloropropanoyl chloride)

RN 82096-44-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)



10/785,120

L10 ANSWER 77 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1980:568316 CAPLUS
DN 93:168316
TI Procataleptogenic 5H-dibenzo[b,e]-1,4-diazepine derivative
IN Protiva, Miroslav; Sindelar, Karel; Dlabac, Antonin
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------|------|----------|-----------------|----------|
| PI | CS 179793 | B | 19770331 | CS 1976-969 | 19760213 |
| PRAI | CS 1976-969 | | 19760213 | | |
| GI | | | | | |



AB The title compound I did not have cataleptic activity but it potentiated the cataleptic activity of other neuroleptics (perphenazine) (LD and ED given). I was prepared by the following route: a mixture of HCl salt of 5-aminoanthranilic acid, 2,5-Cl₂C₆H₃NO₂, K₂CO₃, Cu, and HCONMe₂ was refluxed and gave N-(4-chloro-2-nitrophenyl)-5-methoxyanthranilic acid. Reduction with Na₂S₂O₄ in a solution of NH₄OH gave


N-(2-amino-4-chlorophenyl)-5-methoxyanthranilic acid, which was cyclized by refluxing in xylene to 8-chloro-2-methoxydibenzo[b,e]-1,4-diazepin-11[5H,10H]-one. Reaction of this compound with 1-methylpiperazine in a mixture of PhMe and PhOMe in the presence of TiCl₄ gave 8-chloro-2-methoxy-11-(4-methylpiperazino)-5H-dibenzo[b,e]-1,4-diazepine. Demethylation with BBr₃ in CH₂Cl₂ gave I.

IT **67104-22-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with methylpiperazine)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy-
(9CI) (CA INDEX NAME)



L10 ANSWER 78 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:447088 CAPLUS

DN 93:47088

TI Synthesis of aryl β -D-glucopyranosides and aryl β -D-glucopyranosiduronic acids

AU Brewster, Keith; Harrison, John M.; Inch, Thomas D.

CS Chem. Def. Establ., Porton Down, SP4 0JQ, UK

SO Tetrahedron Letters (1979), (52), 5051-4

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

AB Aryl 2,3,4,6-tetra-O-benzyl- β -D-glucopyranosides were prepared (30-68%) by stereospecific aryloxylation of 2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl bromide (I) with phenols (aqueous NaOH or KOH, CH_2Cl_2 , $\text{PhCH}_2\text{N}+\text{Et}_3 \text{ Cl}^-$ phase transfer catalyst, room temperature, 8-60 h). E.g., 68%

Ph

2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside was obtained from I and PhOH. Ph, 4-methoxyphenyl, and 2-tolyl 2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside were converted to the corresponding aryl β -D-glucopyranosiduronic acids by sequential catalytic debenzylation (H, Pd-C) catalytic oxidation (Pt, O, 85-90°, pH 8-10), benzylation, and hydrogenolysis (Pd-C, EtOH).


IT 74256-85-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and catalytic debenzylation of)

RN 74256-85-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-[[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 74256-87-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 74256-87-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(β -D-glucopyranosyloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/785,120




IT **60287-09-4**

RL: RCT (Reactant); RACT (Reactant or reagent)
(stereospecific aryloxylation by, of tetrabenzylglucopyranoside,
benzyltriethylammonium chloride-catalyzed)

RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 79 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:523990 CAPLUS

DN 89:123990

TI The metabolism of dibenz[b,f]-1,4-oxazepine (CR): In vivo hydroxylation of 10,11-dihydrodibenz[b,f]-1,4-oxazepin-11-(10H)-one and the NIH shift

AU Harrison, J. M.; Clarke, R. J.; Inch, T. D.; Upshall, D. G.

CS Chem. Def. Establ., Porton Down/Salisbury/Wiltshire, UK


SO Experientia (1978), 34(6), 698-9

CODEN: EXPEAM; ISSN: 0014-4754

DT Journal

LA English

GI




AB Studies of the in vivo metabolism by rats of 10,11-dihydrodibenz[b,f]-1,4-oxazepin-11-(10H)-one (I) [3158-85-8] specifically deuterated at C-7 implicate an arene oxide intermediate during the conversion to the 7-hydroxy derivative [60287-11-8] as evidenced by the observation of the NIH shift.

IT **60287-09-4**

RL: BIOL (Biological study)
(dihydrodibenzoxazepinone metabolite)

RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)



L10 ANSWER 80 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1978:443361 CAPLUS

DN 89:43361

TI Neurotropic and psychotropic agents. Part CXVII. Noncataleptic neuroleptics; 8-chloro-2-hydroxy-11-(4-methylpiperazino)-5H-dibenzo[b,e]-1,4-diazepine as a potential metabolite of clozapine

AU Sindelar, Karel; Dlabac, Antonin; Protiva, Miroslav


CS Res. Inst. Pharm. Biochem., Prague, Czech.

SO Collection of Czechoslovak Chemical Communications (1978), 43(1), 309-15
CODEN: CCCCAK; ISSN: 0366-547X

DT Journal

LA English

GI




AB The title compound I was prepared in 5 steps from 2,5-H₂N(MeO)C₆H₃CO₂H (II). II was condensed with 2,5-Cl₂C₆H₃NO₂ to give N-(4-chloro-2-nitrophenyl)-5-methoxyanthranilic acid which was reduced to the corresponding amino acid and cyclized to 8-chloro-2-methoxydibenzo[b,e]-1,4-diazepin-11(5H,10H)-one (III). Treatment of III with 1-methylpiperazine and TiCl₄ gave 8-chloro-2-methoxy-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e]-1,4-diazepine which was demethylated with BBr₃ in CH₂Cl₂ to give I. This potential metabolite of clozapine, per se has no cataleptic activity but it potentiates catalepsy produced by perphenazine in rats.

IT **67104-22-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and amination by methylpiperazine)

RN 67104-22-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-2-methoxy-
(9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 81 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1977:572879 CAPLUS

DN 87:172879

TI 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepin-containing solutions for oral or parenteral administration

IN Haeger, Bruce Edwin; Krueger, James Elwood; Lowery, James Alfred; Ritter, Lawrence

PA American Cyanamid Co., USA

SO Ger. Offen., 15 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | DE 2633943 | A1 | 19770217 | DE 1976-2633943 | 19760728 |
| | CA 1069823 | A1 | 19800115 | CA 1976-256154 | 19760702 |
| | IL 49996 | A1 | 19810130 | IL 1976-49996 | 19760708 |
| | GB 1546933 | A | 19790419 | GB 1976-28752 | 19760709 |
| | AU 500641 | B2 | 19790531 | AU 1976-15775 | 19760709 |
| | FI 7602171 | A | 19770207 | FI 1976-2171 | 19760729 |
| | NL 7608575 | A | 19770208 | NL 1976-8575 | 19760802 |
| | BE 844903 | A1 | 19770207 | BE 1976-169573 | 19760805 |
| | DK 7603540 | A | 19770207 | DK 1976-3540 | 19760805 |
| | DK 147727 | B | 19841126 | | |
| | DK 147727 | C | 19850617 | | |
| | SE 7608810 | A | 19770207 | SE 1976-8810 | 19760805 |
| | SE 431716 | B | 19840227 | | |
| | SE 431716 | C | 19840607 | | |
| | NO 7602713 | A | 19770208 | NO 1976-2713 | 19760805 |
| | NO 146457 | B | 19820628 | | |
| | NO 146457 | C | 19821006 | | |
| | FR 2320102 | A1 | 19770304 | FR 1976-23990 | 19760805 |
| | JP 52021313 | A2 | 19770217 | JP 1976-93257 | 19760806 |
| PRAI | US 1975-602331 | A | 19750806 | | |

GI



I

AB Stable aqueous solns. of 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (I) [1977-10-2] or 1 of its salts suitable for oral or parenteral administration are prepared by mixing I first with propylene glycol [57-55-6], adjusting the pH to 5.0-7.0 with dilute mineral acid, and then adding H₂O. For example, 63.0 g I was mixed with 2100 mL propylene glycol, and 800 mL H₂O was added to the mixture. The pH was adjusted to 6.2 by addition of 10% HCl, and the mixture was heated for 30 min at 60°, diluted with H₂O to 3000 mL, and sterilized by filtration. The final solution contained 2.0% I, and was placed in 2.0 mL ampuls. A concentrate for oral administration comprised 2.5% I in 70% aqueous propylene glycol, and was added to fruit juice in amts. of 3.5 mL/100 g juice before administration. Solns. of 10 mg I/mL in 50%, 60% and 70% aqueous propylene glycol showed good stability, containing only 120, 110, and 100 µg/mL, resp., of the I

10/785,120

hydrolysis product, 2-chloro-dibenz[b,f][1,4]oxazepin-11(10H)-one [3158-91-6], and retaining >98% of the initial I neuroleptic activity after 15 months. Encapsulated suspensions of I succinate [27833-64-3] and parenteral solns. of I as the free base showed comparable neuroleptic activity.


IT 3158-91-6

RL: BIOL (Biological study)

(piperazinyldibenzoxazepine hydrolysis product)

RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 82 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1976:592783 CAPLUS
DN 85:192783
TI Substituted dibenzo[b,f]tetrazolo[1,5-d][1,4]-oxazepines
IN Crawley, Lantz S.; Safir, Sidney R.
PA American Cyanamid Co., USA
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3966756 | A | 19760629 | US 1975-565907 | 19750407 |
| PRAI | US 1975-565907 | A | 19750407 | | |
| GI | | | | | |




AB Dibenzotetrazolooxazepines I (R = Cl, H, F) were prepared by treating the dibenzoxazepinones with PCl_5 and NaN_3 . I (R = Cl) was analgesic in mice in the phenylquinone writhing test at 100 mg/kg orally.

IT **3158-91-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination and reaction of, with azide)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **3158-90-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and chlorination and reaction of, with azide)


RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 83 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:508617 CAPLUS
 DN 85:108617
 TI Oxidation of some dibenz[b,f][1,4]oxazepines by peracetic acid
 AU Brewster, Keith; Chittenden, Rosemary A.; Harrison, John M.; Inch, Thomas D.; Brown, Charles
 CS Chem. Def. Establ., Salisbury, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1976), (12), 1291-6
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 85:108617
 GI




AB Oxidation of substituted dibenz[b,f][1,4]oxazepines with H₂O₂ in glacial AcOH gave the correspondingly substituted 2-(2-hydroxyphenyl)benzoxazole, 10-formylphenoxazine and dibenz[b,f][1,4]oxazepin-11(10H)-one. E.g., 8-chlorodibenz[b,f][1,4]oxazepine gave 49% benzoxazole I, 12% phenoxazine II, and 16% lactam III. An oxaziridine intermediate is implicated as the common precursor of the products.

IT **60344-90-3P**


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 60344-90-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



L10 ANSWER 84 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:508616 CAPLUS
 DN 85:108616
 TI Preparation of the eight monohydroxydibenz[b,f][1,4]oxazepin-11(10H)-ones
 AU Brewster, Keith; Clarke, Raymond J.; Harrison, John M.; Inch, Thomas D.;
 Utley, David
 CS Chem. Def. Establ., Salisbury, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1976), (12), 1286-90
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 85:108616
 GI




AB The 8 possible monohydroxydibenz[b,f][1,4]oxazepin-11(10H)-ones were
 prepared from substituted diphenyl ethers and their mass spectra determined
 E.g., oxidation of 1-methoxy-2-methyl-3-(2-nitrophenoxy)benzene followed by
 hydrogenation, ring closure, and demethylation gave 1-
 hydroxydibenz[b,f][1,4]oxazepin-11(10H)-one (I). With the exception of
 the 7-hydroxy derivative the fragmentation patterns of the isomers were
 similar, although the relative line intensities allowed distinctions
 between the isomers to be made. Several irritant
 monomethoxydibenz[b,f][1,4]oxazepines were also prepared
 IT **54584-61-1P 60287-33-4P 60287-34-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and demethylation of)
 RN 54584-61-1 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




RN 60287-33-4 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methoxy- (9CI) (CA INDEX NAME)

10/785,120



RN 60287-34-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methoxy- (9CI) (CA INDEX NAME)




IT 60287-08-3P 60287-09-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and mass spectrum of)


RN 60287-08-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-hydroxy- (9CI) (CA INDEX NAME)



RN 60287-09-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-hydroxy- (9CI) (CA INDEX NAME)




IT 60287-50-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, mass spectrum, and reduction of)

RN 60287-50-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-hydroxy- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 85 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:432968 CAPLUS

DN 85:32968

TI Condensed heterotricycles: novel transformation of dibenzo[b,e][1,4]diazepinones to benzimidazole derivatives under Vilsmeier-Haack reaction conditions

AU Nagarajan, K.; Shah, R. K.

CS Res. Cent., Ciba-Geigy, Bombay, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1976), 14B(1), 1-3


CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 85:32968

GI




AB Condensation of 2,5-Cl(O₂N)C₆H₃CO₂Me with o-H₂NC₆H₄NH₂ in Me₂SO in the presence of Et₂N gave 2-nitrodibenzo[b,e][1,4]diazepin-11(10H)-one (I, R = NO₂, R¹ = H) in 37% yield. Reaction of I (R = O₂N, R¹ = H) with DMF-POCl₃ gave 1-(2-dimethylcarbamoyl-4-nitrophenyl)benzimidazole (II, R₂ = Me₂N) in high yield. I (R = R¹ = H, R = H, R¹ = Cl) similarly gave analogous products II (R₂ = Me₂N). II (R = NO₂, R¹ = H, R₂ = Me₂N) was hydrolyzed to 1-(2-carboxy-4-nitrophenyl)benzimidazole, identical with a sample synthesized from benzimidazole and 2-chloro-5-nitrobenzoic acid. N-formylmorpholine and I (R = NO₂, R¹ = H) reacted in the presence of POCl₃ to give the morpholide II (R₂ = morpholino). 2-Nitro-5-acetyldibenzo[b,e][1,4]diazepin-11(10H)-one (III, R = NO₂, R¹ = H, R₂ = Me) was formed in the reaction of I (R = NO₂, R¹ = H) with dimethylacetamide-POCl₃. III (R = NO₂, R¹ = H, R₂ = Me) was reduced to the amine, which upon diazotization and treatment with hypophosphorus acid yields III (R = R¹ = H, R₂ = Me).

IT 59624-24-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deamination of)

RN 59624-24-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-2-amino-5,10-dihydro- (9CI)
(CA INDEX NAME)




IT **54255-81-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and ring contraction of)

RN 54255-81-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-amino- (9CI) (CA INDEX NAME)




IT **59624-23-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of)

RN 59624-23-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-acetyl-5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 86 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:150604 CAPLUS
 DN 84:150604
 TI Tetracyclic tetrazoles
 AU Crawley, L. S.; Safir, S. R.
 CS Lederle Lab., Div., Am. Cyanamid Co., Pearl River, NY, USA
 SO Journal of Heterocyclic Chemistry (1975), 12(5), 1075-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 84:150604
 GI



I



II


AB The tetracyclic tetrazoles I (X = O, R = H, Cl, F; X = S, R = Cl; X = MeN, R = H) were prepared by treating II with PCl₃ followed by LiN₃.

IT 3158-90-5 3158-91-6

RL: RCT (Reactant); RACT (Reactant or reagent)
 (cyclization of, with azide, tetrazolo derivative from)


RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 87 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:118772 CAPLUS

DN 82:118772

TI Structure-activity relations in the Sintamil series

AU Nagarajan, K.; David, J.; Grewal, R. S.; Govindachari, T. R.

CS CIBA Res. Cent., Bombay, India

SO Indian Journal of Experimental Biology (1974), 12(3), 217-24

CODEN: IJEBA6; ISSN: 0019-5189

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB 10-Aminoalkyl-2-nitrodibenz[b,f][1,4]oxazepines exhibited antidepressant activity. Among these, Sintamil (I) [16398-39-3] was the most active. The effects of substituting the dimethylamino group in I by acyclic and cyclic bases as well as shortening the side chain to a C2 chain were discussed. Analogs with other substituents in ring C and position isomers of I, in which the nitro group was moved to other positions, were studied. In connection with the sedative and antinociceptive activities of 2-aminodibenz[b,f][1,4]oxazepin-11(10H)-one [23474-66-0], a number of analogs in this series and in the pyridodibenzoxazepine and pyridobenzoxazine series were evaluated. Potent central nervous depressants were encountered in the class of 11-aminodibenzoxazepines and dibenzthiazepines; moderate depressant activity was exhibited by a group of 11-(aminoalkyloxy)- and 11-(aminoalkylmercapto)dibenzoxazepines and thiazepines, and a 11-(dimethylaminomethyl) derivative Imidazo, pyrimido, triazolo, and tetrazolodibenzoxazepines having common structural features were evaluated.

IT 16398-16-6 23474-55-7 23474-59-1

23474-63-7 23474-66-0 54252-66-3

54252-85-6 54252-86-7 54252-87-8

54252-88-9 54252-90-3 54252-91-4


54252-92-5 54719-75-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antidepressant activity of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



10/785,120


RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-63-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)




RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



RN 54252-66-3 CAPLUS


CN Acetamide, 2-chloro-N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 54252-85-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-amino- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-86-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methoxy-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 54252-87-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-diamino- (9CI) (CA INDEX NAME)



RN 54252-88-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methoxy-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 54252-90-3 CAPLUS


CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)

10/785,120




RN 54252-91-4 CAPLUS

CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-2-propenyl- (9CI) (CA INDEX NAME)




RN 54252-92-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 54719-75-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-diamino-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L10 ANSWER 88 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:57661 CAPLUS

DN 82:57661

TI Condensed heterotricycles. 10,11-Ring-annealed dibenz[b,f][1,4]oxazepines

AU Nagarajan, K.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 263-9

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

OS CASREACT 82:57661

GI For diagram(s), see printed CA Issue.


AB Imino chlorides I (R = H, Cl, NO₂, R₁ = H, OMe, R₂ = H, Cl) are converted into γ -hydroxypropylamines and then by treatment with POCl₃ and alkali into II. Mercaptotriazolodibenzoxazepines, triazolodibenzoxazepines, and tetrazolodibenzoxazepines were similarly prepared, but the pyrrolidone III could not be cyclized to the pyrrolodibenzoxazepine. During the formation of I (R = NO₂, R₁ = R₂ = H), benzoxazole (IV) is obtained. In the reactions of I (R = NO₂, R₁ = R₂ = H) with amines, similar benzoxazoles are obtained as byproducts.

IT **54584-61-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with dimethylaniline and phosphorus oxychloride)

RN 54584-61-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methoxy- (9CI) (CA INDEX NAME)




IT **3158-91-6 16398-16-6 16398-18-8**

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylaniline and phosphorus oxychloride)

RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 16398-16-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



RN 16398-18-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA
INDEX NAME)



L10 ANSWER 89 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:57660 CAPLUS

DN 82:57660

TI Condensed heterotricycles. Dibenz[b,f][1,4]oxazepin-11(10H)-thiones, 11-substituted dibenz[b,f][1,4]oxazepines, and dibenz[b,f][1,4]thiazepine analogs

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 258-62

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB Reaction of the imino chloride I obtained from 2-nitrodibenzoxazepinone, POCl₃, and PhNMe₂, with cyclic secondary bases, gave 11-amino derivs. and with γ-dimethyl-aminopropanol, the aminoalkoxy derivative, isomeric with Sintamil. AlCl₃-catalyzed cyclizations of o-isothiocyanatodiphenyl ethers and diphenyl sulfides gave dibenzoxazepine and thiazepinethiones which were converted to 11-amino derivs. by reaction with amines and to 11-aminoalkylmercapto derivatives by reaction with aminoalkyl chlorides. Amidoximes and azines were obtained from thiones. 11-Dimethylaminomethyldibenzoxazepine was obtained along with the ring-cleaved product by cyclization of 2,5-PhO(Cl)C₆H₃NHCOCH₂NMe₂ with polyphosphoric acid and POCl₃ or by cyclization of the chloroacetamide, followed by reaction with Me₂NH. Phenanthridinethione is readily obtained by the cyclization of 2-PhC₆H₄NCS.

IT 16398-16-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(chlorination of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 90 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:4329 CAPLUS

DN 82:4329

TI 11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepines

IN Hunziker, Fritz

PA Dr. A. Wander, A.-G.

SO Ger. Offen., 28 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | DE 2413610 | A1 | 19741010 | DE 1974-2413610 | 19740321 |
| | NL 7403657 | A | 19740925 | NL 1974-3657 | 19740319 |
| | DD 110498 | C | 19741220 | DD 1974-177349 | 19740321 |
| | BE 812742 | A1 | 19740923 | BE 1974-142382 | 19740322 |
| | JP 49126691 | A2 | 19741204 | JP 1974-31612 | 19740322 |
| | AU 7467043 | A1 | 19750925 | AU 1974-67043 | 19740322 |
| | ZA 7401884 | A | 19751126 | ZA 1974-1884 | 19740322 |
| | FR 2222102 | A1 | 19741018 | FR 1974-10147 | 19740325 |
| PRAI | CH 1973-4259 | A | 19730323 | | |
| | CH 1973-5147 | A | 19730410 | | |
| | CH 1973-6644 | A | 19730510 | | |
| GI | For diagram(s), see printed CA Issue. | | | | |
| AB | Twenty-three dibenzodiazepines I [Rn = 2,4-, 2,7-, 2,8-, 3,7-, 3,8-, or 7,8-Cl ₂ , 2,8-MeCl, -ClBr, -ClMe, -Cl(MeO), or -Cl(MeS), 8,2-Cl(Me ₂ NSO ₂), or 7,8-(MeO) ₂ , -OCH ₂ O, or -OCH ₂ CH ₂ O; R ₁ = H or Me; R ₂ = H, Me, or CH ₂ CH ₂ OH] or their salts were prepared and useful as neuroleptics and (or) antidepressants. Thus, N-methylpiperazine (II) reacted with 2,8-dichloro-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one (III) in PhOMe containing TiCl ₄ to give I (Rn = 2,8-Cl ₂ , R ₁ = H, R ₂ = Me), which was also prepared from II and the thioxo analog of III or by methylation of I (Rn = 2,8-Cl ₂ , R ₁ = R ₂ = H). | | | | |
| IT | 55051-41-7P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation and reaction with piperazines) | | | | |
| RN | 55051-41-7 CAPLUS | | | | |
| CN | 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2,8-dichloro-5,10-dihydro- (9CI) | | | | |
| | (CA INDEX NAME) | | | | |



L10 ANSWER 91 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:4223 CAPLUS

DN 82:4223

TI Condensed heterotricycles. Amino and aminoalkyldibenz[b,f][1,4]oxazepin-11(10H)-ones

AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Goud, A. Nagana; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 236-46

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

OS CASREACT 82:4223

GI For diagram(s), see printed CA Issue.


AB Treatment of 2-nitrodibenz[b,f][1,4]-oxazepin-11(10H)-one (I, R = NO₂, R₁ - R₅ = H) (II) with dimethylaminopropyl chloride in aqueous acetone-alkali gave I [R = NO₂, R₁-R₄ = H, R₅ (CH₂)₃NMe₂] characterized as the hydrochloride, Sintamil. Other analogs e.g., I (R = H, NO₂; R₁ = H, NO₂; R₂ = H, NO₂, MeO; R₃ = H, MeO, Me, Ac; R₄ = H, NO₂; R₅ = aminoalkyl), were also prepared. III undergoes ring cleavage with NaOMe to 2,5-MeO(O₂N)C₆H₃CON-[(CH₂)₃NMe₂]C₆H₄OH-2 which is converted into its Me ether. II undergoes similar ring cleavage with NaOMe, dimethylamine, and NaOH to form IV (R = MeO, NMe₂, and OH). The last reagent brings about, in addition a Smiles-type rearrangement leading to the formation of 2,4-HO₂C(O₂N)C₆H₃NHC₆H₄OH-2. Treatment of the 8-nitrodibenzoxazepinone with dimethylaminopropyl chloride in DMF and sodamide yields in addition to the expected N-(CH₂)₃NMe₂ derivative, the ring cleavage product 2-HO-C₆H₄CON[(CH₂)₃NMe₂]C₆H₃(NMe)₂NO₂-2.5. Nitration expts. on dibenzoxazepinones without a substituent on the lactam N or with a dimethylaminopropyl group are described. Many nitro derivs. are reduced to amines.

IT **54252-66-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with morpholine)

RN 54252-66-3 CAPLUS

CN Acetamide, 2-chloro-N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-(9CI) (CA INDEX NAME)




IT **23474-66-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reaction with chloroacetyl chloride)

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120




IT 16398-26-8P 23474-55-7P 23474-59-1P
23474-63-7P 54252-64-1P 54252-85-6P
54252-86-7P 54252-87-8P 54252-88-9P
54252-89-0P 54252-90-3P 54252-91-4P
54252-92-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 16398-26-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-trinitro- (8CI, 9CI) (CA
INDEX NAME)




RN 23474-55-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA
INDEX NAME)



RN 23474-59-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA
INDEX NAME)



RN 23474-63-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)

10/785,120




RN 54252-64-1 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-triamino- (9CI) (CA INDEX NAME)




RN 54252-85-6 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-amino- (9CI) (CA INDEX NAME)



RN 54252-86-7 CAPLUS

CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 54252-87-8 CAPLUS


CN Dibenzo[b,f][1,4]oxazepin-11(10H)-one, 2,8-diamino- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-88-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-7-methoxy-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 54252-89-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-diamino- (9CI) (CA INDEX NAME)



RN 54252-90-3 CAPLUS


CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



RN 54252-91-4 CAPLUS


CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-2-propenyl- (9CI) (CA INDEX NAME)

10/785,120



RN 54252-92-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(dimethylamino)- (9CI) (CA INDEX NAME)



L10 ANSWER 92 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:552201 CAPLUS

DN 81:152201

TI Condensed heterotricycles. Beckmann rearrangement of xanthone and thioxanthone oximes as a route to dibenz[b,f][1,4]-oxazepines and thiazepines

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 247-51

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB Beckmann rearrangement of xanthone and thioxanthone oximes yields dibenzoxazepinone (I, X = O) and thiazepinone (I, X = S) resp. A mixture of the two possible rearrangement products is obtained from the rearrangement of 2-nitroxanthone oxime and from 2-chlorothioxanthone oxime. The 1,5-benzoxazepine II was formed in the LiAlH₄ reduction of chromanone oxime III. LiAlH₄ reduction of xanthone oxime yields 9,9'-bis(xanthhydryl) ether. A few xanthone and thioxanthone anils were prepared

IT **16398-16-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 93 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:552199 CAPLUS

DN 81:152199

TI Condensed heterotricycles. Synthesis of dibenz[b,f][1,4]oxazepines, dibenz[b,f][1,4]thiazepines, and dibenz[b,e][1,4]diazepines by cyclization of 2-halo-2'-hydroxy(mercapto or amino)benzanilides

AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Shah, R. K.

CS Res. Cent., CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 227-35

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The action of hot aqueous alkali on 2-chloro-5-nitrobenzamides on o-aminophenols I (R, R2, R3 = H, R1 = H, Me, Cl, MeO) affords high yields of 2-nitrodibenz[b,f][1,4]oxazepin-11(10H)-ones II. Pyrolysis of the sodium salts of amides III (R, R1, R2, R3, R4, R5, R6 = H, Ac, NO2, Cl) gives the analogous tricyclic lactams IV. The synthesis has been extended to aminoalkyldibenzoxazepinones, such as the antidepressant Sintamil N-(CH2)3NMe2 derivative of IV (R-R3, R5 = H, R4 = NO2).HCl and the R4 = Cl analog. 2-Nitrodibenzoxazepine is obtained from the Schiff base and converted to a quaternary salt and the dihydro derivs. N-(2-Chloro-5-nitrobenzoyl)-o-aminothiophenol fails to undergo cyclization to a dibenzothiazepinone, since it readily passes over to a benzothiazole. However, 2-chloro and 2,5-dichlorobenzoyl derivs. of o-aminothiophenol can be converted to the expected tricycles VII. Among the o-phenylenediamine derivs. tried, the N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl) compound gives the dibenzodiazepine VIII, while pyrolysis of 2-amino-2'-carbomethoxy-4'-nitrodiphenylamine leads to IX.

IT **23474-66-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deamination of)

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



IT **3158-88-1P 3158-91-6P 16398-16-6P**

16398-17-7P 16398-18-8P 16398-19-9P

16398-20-2P 16398-21-3P 16398-22-4P

16398-23-5P 16398-24-6P 20169-49-7P


54255-57-1P 54255-81-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3158-88-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)

10/785,120




RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-17-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dinitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-18-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-19-9 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-20-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-dinitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-21-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-22-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 6,8,9-trichloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-23-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-nitro- (8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 16398-24-6 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methoxy-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 20169-49-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 54255-57-1 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methoxy-2-nitro- (9CI) (CA INDEX NAME)



RN 54255-81-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-nitro- (9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 94 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:536120 CAPLUS

DN 81:136120

TI Condensed heterotricycles. Potential metabolites of dibenz[b,f][1,4]oxazepine antidepressant, Sintamil

AU Nagarajan, K.; Maller, R. K.; Anjaneyulu, B.; Goud, A. Nagana; Venkateswarlu, A.

CS Res. Cent. , CIBA, Bombay, India

SO Indian Journal of Chemistry (1974), 12(3), 270-4

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The demethyl derivative [I, R = (CH₂)₃NHMe, R₁ = H] (II) of Sintamil [I, R = (CH₂)₃NMe₂, R₁ = H] (III) was prepared by alkylation of I (R, R₁ = H) (IV) with Cl(CH₂)₃NMeCHO followed by acid hydrolysis, by treating III with BrCN followed by hot HCl hydrolysis, or by refluxing III with ClCO₂Et in toluene to give a urethane which was treated with HBr in HOAc. IV was added to CH₂:CHCN and converted to the ester I (R = CH₂CH₂CO₂Me, R₁ = H), which was also obtained by base catalyzed addition of IV to CH₂:CHCO₂Me. Treatment of 2,5-Cl(O₂N)C₆H₃COCl with 3,4-HO(H₂N)C₆H₃OCH₂Ph gave an amide, which was cyclized in aqueous alkali to give I (R = H, R₁ = OCH₂Ph), alkylated with Cl(CH₂)₃NMe₂, and debenzylated in hot HCl to yield I [R = (CH₂)₃NMe₂, R₁ = OH].

IT **16398-16-6**

RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




IT **54026-42-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 54026-42-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro-7-(phenylmethoxy)- (9CI)
(CA INDEX NAME)



L10 ANSWER 95 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:520710 CAPLUS

DN 81:120710

TI Antiulcerous 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)-11H-dibenzo[b,e][1,4]diazepin-11-one

IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matyas; Engelhorn, Robert

PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 9 pp. Division of Ger. Offen. 2,022,790 (CA 74; 100123p).

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | DE 2065570 | A1 | 19740704 | DE 1970-2065570 | 19700509 |
| | DE 2065570 | B2 | 19760520 | | |
| | DE 2065570 | C3 | 19770127 | | |
| PRAI | DE 1970-2065570 | A | 19700509 | | |

GI For diagram(s), see printed CA Issue.


AB The dibenzodiazepinone I (R = 1-pyrrolidinyl) (II) was prepared in 50% yield by refluxing I (R = Cl) and pyrrolidine in dioxane. II had antiulcerous activity when tested orally in the rat, stomach secretion-inhibiting activity when tested intraduodenally or i.p. in the rat, and spasmolytic activity when tested in the isolated guinea pig colon.

IT **29174-20-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)


IT **29174-19-4**

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with pyrrolidine)

RN 29174-19-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 96 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:403984 CAPLUS

DN 81:3984

TI Neuroleptic and antiemetic dibenzo[b,f][1,4]oxazepine derivatives

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Fr. Demande, 20 pp. Addn. to Fr. 2,102,073 (See Ger. Offen. 2,139,016 CA 76;140923x).

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--------------|------|----------|-----------------|----------|
| PI | FR 2187338 | A2 | 19740118 | FR 1973-20407 | 19730605 |
| | FR 2187338 | B2 | 19760409 | | |
| | AU 7356683 | A1 | 19741212 | AU 1973-56683 | 19730607 |
| | ZA 7303873 | A | 19750129 | ZA 1973-3873 | 19730607 |
| PRAI | CH 1972-8441 | A | 19720607 | | |

GI For diagram(s), see printed CA Issue.


AB Dibenzoxazepine derivs. I (R = COCHMe2, COBu, COCH2CHMe2, COCHMeEt, COCMe3, COCH2CH2CHMe2) were prepared by esterifying I (R = H), prepared from 2-O2NC6H4OC6H4SMe-4 in 7 steps. I had a neuroleptic and antiemetic ED50 in the apomorphine antagonism test in rats of 2.4-3.6 mg/kg i.v.

IT **31293-95-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

RN 31293-95-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)

IT **31293-91-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 97 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:83088 CAPLUS

DN 80:83088

TI Dibenzoxazepines

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Patentschrift (Switz.), 5 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | CH 544767 | A | 19740115 | CH 1972-15415 | 19700806 |
| | US 3891647 | A | 19750624 | US 1973-326121 | 19730123 |
| PRAI | CH 1970-11922 | A | 19700806 | | |
| | CH 1971-7915 | A | 19710601 | | |
| | US 1971-166997 | A2 | 19710728 | | |
| | CH 1972-8441 | A | 19720606 | | |
| | CH 1972-15415 | A | 19721020 | | |
| | CH 1972-15416 | A | 19721020 | | |

GI For diagram(s), see printed CA Issue.


AB Dibenz[bf][1,4]oxazepines I (R1 = C3-13 alkyl; O2CR1 = oleoyloxy) (12 compds.) and their salts were prepared by N-alkylation of piperazinodibenzoxazepine II with halo esters R1-CO2CH2CH2Cl. II was prepared by chlorination of 2-nitrophenyl 4-(trifluoromethylthio)phenyl ether and then successively treated with SbF3, hydrogenated, treated with COCl2, cyclized, oxidized with H2O2, and then treated with POCl3-P2O5. The resulting imino chloride III was N-alkylated piperazine to give II.

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 98 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:83086 CAPLUS

DN 80:83086

TI Dibenzoxazepines

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO Patentschrift (Switz.), 4 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | CH 544768 | A | 19740115 | CH 1972-15416 | 19700806 |
| | US 3891647 | A | 19750624 | US 1973-326121 | 19730123 |
| PRAI | CH 1970-11922 | A | 19700806 | | |
| | CH 1971-7915 | A | 19710601 | | |
| | US 1971-166997 | A2 | 19710728 | | |
| | CH 1972-8441 | A | 19720606 | | |
| | CH 1972-15415 | A | 19721020 | | |
| | CH 1972-15416 | A | 19721020 | | |

GI For diagram(s), see printed CA Issue.


AB Dibenz[b,f][1,4]oxazepines I (R1 = C3-13 alkyl; R1CO2 = oleoyloxy) (12 compds.) and their salts were prepared by treating dibenzoxazepine II with POCl3 and the resulting imino chloride III was treated with piperazine IV. III was prepared by successive chlorination of 2-nitrophenyl 4-(methylthio)phenyl ether, SbF3 treatment, hydrogenation, and COCl2 treatment, POCl3-P2O5 cyclization, and H2O2 oxidation

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI, 9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 99 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1974:48047 CAPLUS

DN 80:48047

TI 7-Amino-2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine and its salts

IN Howell, Charles F.

PA American Cyanamid Co.

SO U.S., 4 pp. Continuation-in-part of U. S. 3,705,245 (CA 78;58481j).

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3773768 | A | 19731120 | US 1972-280033 | 19720811 |
| | US 3660406 | A | 19720502 | US 1970-84221 | 19701026 |
| | US 3705245 | A | 19721205 | US 1972-220371 | 19720124 |
| PRAI | US 1970-84221 | A2 | 19701026 | | |
| | US 1972-220371 | A2 | 19720124 | | |

GI For diagram(s), see printed CA Issue.


AB The dibenzoxazepine I (R = NO₂) was prepared by treating 2-chlorodibenz[b,f][1,4]oxazepin-11(10H)-one (II) with N-methylpiperazine, followed by nitration. Zn-HCl reduction of I (R = NO₂) gave I (R = NH₂), which was diazotized in the presence of HOAc and hydrolyzed to I (R = OH). Alternatively, the nitration and subsequent steps were carried out on II before treatment with N-methylpiperazine. I are tranquilizers with ED₅₀ for the depression of motor activity in rats of 0.24-28 mg/kg i.p.

IT **3158-91-6**

RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **37081-73-5P 37081-74-6P 37116-83-9P**

51370-03-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37081-73-5 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME)



RN 37081-74-6 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-hydroxy- (9CI) (CA INDEX NAME)




RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX NAME)



RN 51370-03-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-(acetyloxy)-2-chloro- (9CI) (CA INDEX NAME)



L10 ANSWER 100 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:97273 CAPLUS

DN 78:97273

TI Synthesis of some substituted salicylanilides of expected biological activity

AU Islam, A. M.; Hannout, I. B.; Hassan, E. A.; Ihsan, A. E.

CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt

SO Journal fuer Praktische Chemie (Leipzig) (1972), 314(5-6), 727-34

CODEN: JPCEAO; ISSN: 0021-8383

DT Journal

LA English

OS CASREACT 78:97273

GI For diagram(s), see printed CA Issue.


AB 5,2-R(HO)C₆H₃CONHC₆H₄R₁ (I; R = H, Cl; R₁ = H, Cl, Me, NO₂) were prepared in 50-94% yield by reaction of 5,2-R(HO)C₆H₃CO₂Ph (II) with R₁C₆H₄NH₂ at 180°. Reaction of II with o-HOC₆H₄NH₂ gave 52-6% dibenzoxazepinones III. Condensation of II (R = H) with X₂C₆H₃NH₂ (X = 2-Cl, 2-Br; Y = 4-, 5-O₂N) yielded 81-95% o-HOC₆H₄CONHC₆H₃XY. Coupling some I (R = H) with diazotized p-R₂C₆H₄NH₂ (R₂ = O₂N, NaO₃S) gave 55-82% p-R₂C₆H₄N:NC₆H₃(CONHC₆H₄R₁)OH-3,4 (IV). IV (R₂ = NaO₃S) were reduced with NaHSO₃ to give 61-70% 2,5-HO(H₂N)C₆H₃CONHC₆H₄R₁.

IT **3158-91-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 101 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:58481 CAPLUS

DN 78:58481

TI 7-Amino-2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepines acting on the central nervous system

IN Howell, Charles Frederick; Greenblatt, Eugene Newton

PA American Cyanamid Co.

SO U.S., 4 pp. Continuation-in-part of U.S. 3,660,406 (CA 77;62038s).

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3705245 | A | 19721205 | US 1972-220371 | 19720124 |
| | US 3773768 | A | 19731120 | US 1972-280033 | 19720811 |
| PRAI | US 1970-84221 | A2 | 19701026 | | |
| | US 1972-220371 | A2 | 19720124 | | |

GI For diagram(s), see printed CA Issue.


AB Continuation-in-part of U.S. 3,660,406 (CA 77: 62038s). Three dibenzoxazepines [I, R = NH₂ (II), NO₂, OH] useful as antidepressants and tranquilizers were prepared. Thus, 2-chlorodibenz[b,f][1,4]oxazepin-11-(10H)-one was nitrated by AcONO₂ in HOAc to give the 6-NO₂ derivative, which was treated with PCl₅ and 2-methylpiperazine to give I (R = NO₂) (III). Reduction of III in EtOH with Zn gave the title compound (II). Diazotization of II followed by hydrolysis gave the OH compound (I, R = OH).

IT **3158-91-6**

RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **37081-73-5P 37116-83-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)

RN 37081-73-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME)




RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX NAME)

10/785,120

NAME)




IT **37081-74-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37081-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-hydroxy- (9CI) (CA INDEX
NAME)



L10 ANSWER 102 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1972:462038 CAPLUS

DN 77:62038

TI 2-Chloro-7-hydroxy-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepines as tranquilizers and antidepressants

IN Howell, Charles F.; Greenblatt, Eugene N.

PA American Cyanamid Co.

SO U.S., 4 pp.

CODEN: USXXAM


DT Patent

LA English

FAN.CNT 3


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 3660406 | A | 19720502 | US 1970-84221 | 19701026 |
| | AU 7134001 | A1 | 19730405 | AU 1971-34001 | 19710929 |
| | GB 1340898 | A | 19731219 | GB 1971-45427 | 19710929 |
| | IL 37953 | A1 | 19750728 | IL 1971-37953 | 19711017 |
| | CA 971169 | A1 | 19750715 | CA 1971-125540 | 19711019 |
| | BE 774398 | A1 | 19720425 | BE 1971-109689 | 19711025 |
| | AT 311979 | B | 19731210 | AT 1971-9218 | 19711025 |
| | AT 311983 | B | 19731210 | AT 1972-10567 | 19711025 |
| | SU 437301 | D | 19740725 | SU 1971-1708711 | 19711025 |
| | PL 81422 | P | 19750830 | PL 1971-151205 | 19711025 |
| | SE 380528 | B | 19751110 | SE 1971-13522 | 19711025 |
| | DK 134066 | B | 19760906 | DK 1971-5177 | 19711025 |
| | DE 2153349 | A | 19720427 | DE 1971-2153349 | 19711026 |
| | NL 7114713 | A | 19720428 | NL 1971-14713 | 19711026 |
| | FR 2111840 | A5 | 19720609 | FR 1971-38476 | 19711026 |
| | FR 2111840 | B1 | 19750801 | | |
| | DD 97210 | C | 19730423 | DD 1971-158567 | 19711026 |
| | ES 396390 | A1 | 19750101 | ES 1971-396390 | 19711026 |
| | CH 576470 | A | 19760615 | CH 1971-15573 | 19711026 |
| | CS 172359 | P | 19761229 | CS 1971-7545 | 19711026 |
| | ES 399188 | A1 | 19750601 | ES 1972-399188 | 19720125 |
| | US 3773768 | A | 19731120 | US 1972-280033 | 19720811 |
| | CA 969937 | A2 | 19750624 | CA 1973-176267 | 19730712 |
| PRAI | US 1970-84221 | A | 19701026 | | |
| | CA 1971-125540 | A3 | 19711019 | | |
| | US 1972-220371 | A2 | 19720124 | | |
| GI | For diagram(s), see printed CA Issue. | | | | |
| AB | Chlorodibenz[b,f][1,4]oxazepin-11(10H)-one (I) was transformed by nitration, reduction, and hydrolysis into II (R = NO ₂ , NH ₂ , OH, resp.); the corresponding III, useful as tranquilizers and antidepressants, were prepared from II. Thus, I with AcONO ₂ gave II (R = NO ₂), which was treated with PCl ₅ and with N-methylpiperazine to give III (R = NO ₂). The N ₄ -oxides of III were also prepared | | | | |
| IT | 37081-73-5P 37081-74-6P 37081-78-0P 37116-83-9P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 37081-73-5 CAPLUS | | | | |
| CN | Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-amino-2-chloro- (9CI) (CA INDEX NAME) | | | | |

10/785,120




RN 37081-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-amino- (9CI) (CA INDEX NAME)




RN 37081-78-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-9-hydroxy- (9CI) (CA INDEX NAME)



RN 37116-83-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-7-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 103 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1972:140923 CAPLUS

DN 76:140923

TI Neuroleptic and antiemetic 2-(trifluoromethylsulfonyl)dibenz[b,f]-1,4-oxazepine derivatives

IN Schmutz, Jean; Hunziker, Fritz; Kuenzle, Martin F.

PA Dr. A. Wander, A.-G.

SO Ger. Offen., 26 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | DE 2139016 | A | 19720210 | DE 1971-2139016 | 19710804 |
| | CH 549593 | A | 19740531 | CH 1970-11922 | 19700806 |
| | NL 7110453 | A | 19720208 | NL 1971-10453 | 19710729 |
| | GB 1355866 | A | 19740605 | GB 1971-36235 | 19710802 |
| | FR 2102073 | A1 | 19720407 | FR 1971-28447 | 19710803 |
| | FR 2102073 | A5 | 19720407 | | |
| | BE 770956 | A1 | 19720204 | BE 1971-106758 | 19710804 |
| | DK 128355 | B | 19740416 | DK 1971-3817 | 19710804 |
| | IL 37437 | A1 | 19740516 | IL 1971-37437 | 19710804 |
| | ES 393891 | A1 | 19740701 | ES 1971-393891 | 19710804 |
| | SU 450411 | D | 19741115 | SU 1971-1850487 | 19710804 |
| | SU 451246 | D | 19741125 | SU 1971-1850485 | 19710804 |
| | SU 461501 | D | 19750225 | SU 1971-1690481 | 19710804 |
| | NO 132097 | B | 19750609 | NO 1971-2929 | 19710804 |
| | PL 82244 | P | 19751031 | PL 1971-149831 | 19710804 |
| | AU 7132060 | A1 | 19730308 | AU 1971-32060 | 19710805 |
| | CA 956942 | A1 | 19741029 | CA 1971-119861 | 19710805 |
| | AT 7106870 | A | 19750115 | AT 1971-6870 | 19710805 |
| | AT 325619 | B | 19751027 | | |
| | AT 928373 | A | 19750115 | AT 1973-9283 | 19710805 |
| | SE 379046 | B | 19750922 | SE 1971-10035 | 19710805 |
| | AT 325624 | B | 19751027 | AT 1971-325624 | 19710805 |
| | ZA 7105245 | A | 19730328 | ZA 1971-5245 | 19710806 |
| PRAI | CH 1970-11922 | A | 19700806 | | |
| | CH 1971-7905 | A | 19710601 | | |
| | CH 1971-7915 | A | 19710601 | | |

GI For diagram(s), see printed CA Issue.

AB Four title compds. [I; Q = 1,4-piperazinediyl; R = Me(CH₂)_nCO₂(CH₂)₂; n = 3, 5, 8, or 12], useful i.m. in 20-60 mg doses as 1-3% oily solns., were prepared by reaction of I (QR = H) with HQR, of I (QR = 1-piperazinyl) with Me(CH₂)_nCO₂(CH₂)₂Cl, or of I (Q = 1,4-piperazinediyl, R = CH₂CH₂OH) (II) with Me(CH₂)_nCOCl. Thus, Cl was passed into o-O₂NC₆H₄OC₆H₄SMe-p in CHCl₃ at 20° with exposure to light to give o-O₂NC₆H₄OC₆H₄SCCl₃-p (III). III (61.3 g) and 41 g SbF₃ in sulfolane was heated <30 min to 150°, the mixture kept 1.5 hr at this temperature, and HCl added to give o-O₂NC₆H₄OC₆H₄SCF₃ (IV). IV was hydrogenated over Raney Ni to give o-H₂NC₆H₄OC₆H₄SCF₃ (V). COCl₂ was passed into refluxing V in 20% COCl₂-PhMe to give o-OCNC₆H₄OC₆H₄-SCF₃ (VI). VI and P₂O₅ was refluxed 24 hr in POCl₃, the mixture evaporated, ice added to the residue, and the mixture neutralized with NaOH and kept 24 hr to give 2-(trifluoromethylthio)-10,11-dihydro-11-oxodibenz[b,f]-1,4-oxazepine (VII). H₂O₂ (30%) was added to VII in HOAc and the mixture heated 1 hr at 70° and 1.5 hr at 100-10° to give 2-(trifluoromethylsulfonyl)-10,11-dihydro-11-oxodibenz[b,f]-1,4-oxazepine (VIII). VIII and PhNMe₂ was refluxed 4.5 hr in POCl₃, 1-(β-hydroxyethyl)piperazine added, and the mixture refluxed 5 hr to give II. II and C₆H₁₃COCl in pyridine was kept overnight and the mixture alkalized to give I [Q = 1,4-piperazinediyl, R =

10/785,120


Me(CH₂)₅CO₂(CH₂)₂].

IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 31293-91-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI,
9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI,
9CI) (CA INDEX NAME)



L10 ANSWER 104 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:141907 CAPLUS

DN 74:141907

TI Amino-substituted dibenz[b,f][1,4]oxazepin-11(10H)-ones, useful as analgesics, antipyretics, and sedatives in warmblooded animals

IN Schmidt, Guenther

PA Boehringer Ingelheim G.m.b.H.

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 3546214 | A | 19701208 | US 1968-743601 | 19680710 |
| | FR 1574968 | A | 19690718 | FR 1968-1574968 | 19680711 |
| | GB 1164579 | A | 19690917 | GB 1968-1164579 | 19680711 |
| PRAI | DE 1966-1695900 | A | 19670711 | | |


GI For diagram(s), see printed CA Issue.

AB The title compds. (I, R = NH₂) and analogs are prepared by reduction of the corresponding nitro derivs. Thus, I (R = 2-NO₂) in dioxane hydrogenated 2 hr over 2 g Raney Ni at 50°/31 atm gave I (R = NH₂), m. 200-2°; HCl salt m. 320° (decomposition). I (R = NH₂) was similarly obtained by catalytic hydrogenation over PtO₂ in MeOH and Pd-C in MeOH; and by reduction with Sn/HCl in alc., by 80% N₂H₄.H₂O in boiling alc., by Na₂S₂O₆ in refluxing alc., with SnCl₂ and 5N HCl, and with Fe/HCl. Various I were similarly produced and converted to their acid addition salts.

IT **23474-55-7P 23474-56-8P 23474-59-1P****23474-60-4P 23474-63-7P 23474-65-9P****23474-66-0P**RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-56-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl


RN 23474-59-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)



RN 23474-60-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 23474-63-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)



RN 23474-65-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 105 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1971:100126 CAPLUS
 DN 74:100126
 TI Psychotropic 11-(1-piperazinyl)dibenz[b,f][1,4]oxazepines
 IN Hunziker, Fritz; Schmutz, Jean; Kuenzle, Franz M.
 PA Dr. A. Wander, A.-G.
 SO Ger. Offen., 44 pp.
 CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | DE 2037733 | A | 19710218 | DE 1970-2037733 | 19700730 |
| | CH 518304 | A | 19720131 | CH 1969-518304 | 19690806 |
| | CH 531534 | A | 19730131 | CH 1970-8679 | 19700611 |
| | GB 1318401 | A | 19730531 | GB 1970-35011 | 19700720 |
| | GB 1318402 | A | 19730531 | GB 1973-1718 | 19700720 |
| | NL 7011063 | A | 19710209 | NL 1970-11063 | 19700727 |
| | US 3717637 | A | 19730220 | US 1970-58984 | 19700728 |
| | FR 2068464 | A1 | 19710827 | FR 1970-28684 | 19700804 |
| | FR 2068464 | A5 | 19710827 | | |
| | ES 382423 | A1 | 19730416 | ES 1970-382423 | 19700804 |
| | SU 438184 | D | 19740730 | SU 1970-1732950 | 19700804 |
| | SU 439092 | D | 19740805 | SU 1970-1713244 | 19700804 |
| | JP 49040236 | B4 | 19741031 | JP 1970-67810 | 19700804 |
| | SU 451247 | D | 19741125 | SU 1970-1732949 | 19700804 |
| | SE 373851 | B | 19750217 | SE 1970-10667 | 19700804 |
| | CA 965785 | A1 | 19750408 | CA 1970-89826 | 19700804 |
| | PL 80952 | B | 19750830 | PL 1970-142517 | 19700804 |
| | SU 484690 | D | 19750915 | SU 1970-1473416 | 19700804 |
| | SU 508202 | D | 19760325 | SU 1970-1713243 | 19700804 |
| | CS 168536 | P | 19760629 | CS 1970-5438 | 19700804 |
| | ZA 7005412 | A | 19720329 | ZA 1970-5412 | 19700805 |
| | AT 314539 | B | 19740410 | AT 1970-7140 | 19700805 |
| | AT 314546 | B | 19740410 | AT 1972-5152 | 19700805 |
| | AT 314547 | B | 19740410 | AT 1972-5153 | 19700805 |
| | AT 314548 | B | 19740410 | AT 1972-5154 | 19700805 |
| | AT 314549 | B | 19740410 | AT 1972-5155 | 19700805 |
| | NO 130589 | B | 19740930 | NO 1970-3019 | 19700805 |
| | ES 393047 | A1 | 19740516 | ES 1971-393047 | 19710708 |
| | ES 393048 | A1 | 19740516 | ES 1971-393048 | 19710708 |
| | ES 393049 | A1 | 19740516 | ES 1971-393049 | 19710708 |
| | ES 393050 | A1 | 19740516 | ES 1971-393050 | 19710708 |
| | ES 393046 | A1 | 19740601 | ES 1971-393046 | 19710708 |
| PRAI | CH 1969-11925 | A | 19690806 | | |
| | CH 1969-12595 | A | 19690820 | | |
| | CH 1969-15039 | A | 19691007 | | |
| | CH 1970-8679 | A | 19700611 | | |
| | CH 1970-8699 | A | 19700611 | | |

GI For diagram(s), see printed CA Issue.

AB The psychotropic title compds. (I, X = S, SO₂) were prepared by reaction of the dibenz[b,f][1,4]oxazepines with piperazines, by cyclization of the o-aminodiphenyl ethers, by reaction of 11-aminodibenz[b,f][1,4]oxazepines with iminodiethanol esters or piperazines, or by alkylation of I (R = H). Among approx. 10 compds. prepared were I (R and X given): Me, S; Et, SO₂; HO(CH₂)₃, SO₂.


IT **31293-91-1P 31293-95-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 31293-91-1 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)thio]- (8CI,
9CI) (CA INDEX NAME)



RN 31293-95-5 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-[(trifluoromethyl)sulfonyl]- (8CI,
9CI) (CA INDEX NAME)



L10 ANSWER 106 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1971:100124 CAPLUS
 DN 74:100124
 TI 5-(Piperidinoacetyl)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-ones
 IN Schmidt, Guenther; Machleidt, Hans; Engelhorn, Robert; Leitold, Matyas
 PA Thomae, Dr. Karl, G.m.b.H.
 SO Ger. Offen., 20 pp. Addn. to Ger. Offen. 1,795,176
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | DE 1931487 | A | 19710107 | DE 1969-1931487 | 19690620 |
| | DE 1931487 | B2 | 19750417 | | |
| | DE 1931487 | C3 | 19751218 | | |
| | DE 1795176 | A | 19720203 | DE 1967-1795176 | 19680820 |
| | FI 49509 | B | 19750401 | FI 1969-2162 | 19690722 |
| | RO 56187 | P | 19750615 | RO 1969-60620 | 19690724 |
| | US 3634408 | A | 19720111 | US 1969-848356 | 19690807 |
| | ES 370395 | A1 | 19710416 | ES 1969-370395 | 19690811 |
| | SU 512704 | D | 19760430 | SU 1969-1357008 | 19690812 |
| | CH 510685 | A | 19710731 | CH 1969-510685 | 19690813 |
| | AT 292709 | B | 19710910 | AT 1969-7959 | 19690819 |
| | NO 125386 | B | 19720904 | NO 1969-3363 | 19690819 |
| | PL 69663 | P | 19730831 | PL 1969-135429 | 19690819 |
| | DK 135043 | B | 19770228 | DK 1969-4431 | 19690819 |
| | DK 135043 | C | 19770822 | | |
| | BE 737747 | A | 19700220 | BE 1969-737747 | 19690820 |
| | NL 6912653 | A | 19700224 | NL 1969-12653 | 19690820 |
| | FR 2016008 | A5 | 19700430 | FR 1969-28589 | 19690820 |
| | FR 2016008 | B1 | 19731221 | | |
| | GB 1236112 | A | 19710623 | GB 1969-1236112 | 19690820 |
| | BR 6911744 | A0 | 19730118 | BR 1969-211744 | 19690820 |
| | SE 367199 | B | 19740520 | SE 1969-11570 | 19690820 |
| | CS 163730 | P | 19751107 | CS 1969-5774 | 19690820 |
| PRAI | DE 1967-1795176 | A | 19680820 | | |
| | DE 1969-1931487 | A | 19690620 | | |

GI For diagram(s), see printed CA Issue.

AB The antiulcerous title compds. (I), which inhibit the secretion of gastric juice, were prepared Thus, refluxing 5-chloroacetyl-10,11-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one and 2-methylpiperidine in C₆H₆ 18 hr gave 45% I (R = Me, R₁ = R₂ = R₃ = R₄ = R₅ = R₆ = H). Similarly prepared were I (R-R₆ given): H, Me, H, H, H, H, H; H, H, Me, H, H, H, H; Et, H, H, H, H, H; Et, H, H, H, H, Me, H; H, H, MeO, H, H, H, H; Me, H, H, H, Cl, H, H; Et, H, H, H, Cl, H, H; Me, H, H, H, Cl, Et, H; Et, H, H, H, H, Et, H; H, H, Pr, H, H, H, H; Me, H, H, H, H, Et, H; Me, H, H, H, H, H, Cl; Me, H, H, Me, H, H, H.


IT 29174-44-5P 29174-45-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 29174-44-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)

10/785,120



RN 29174-45-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 107 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:100123 CAPLUS

DN 74:100123

TI Ulcer- and secretion-inhibiting 5-(aminoacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones

IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matays; Engelhorn, Robert

PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 10 pp. Addn. to Ger. Offen. 1,795,176


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | DE 2022790 | A | 19710211 | DE 1970-2022790 | 19700509 |
| | DE 2022790 | B2 | 19760708 | | |
| | DE 2022790 | C3 | 19770707 | | |
| | FI 49509 | B | 19750401 | FI 1969-2162 | 19690722 |
| | FR 2016008 | A5 | 19700430 | FR 1969-28589 | 19690820 |
| | FR 2016008 | B1 | 19731221 | | |
| PRAI | FI 1969-2162 | A | 19690722 | | |
| | DE 1967-1795176 | A | 19680820 | | |
| | DE 1969-1931487 | A | 19690620 | | |
| GI | For diagram(s), see printed CA Issue. | | | | |
| AB | The title compds. (I) and their physiol. compatible salts, the activities of which were tested in rats and guinea-pigs, were prepared by refluxing the 5-chloroacetyl derivative and the cyclic amine in a solvent. Prepared were I bis(hydrogenfumarate) (R = Me, X = H, n = 1) and I (R = H, X = Cl, n = 0) of LD50 3400 and >1500 mg/kg, resp., in mice on oral administration. Formulations containing I are reported. | | | | |
| IT | 29174-19-4P 29174-20-7P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 29174-19-4 CAPLUS | | | | |
| CN | 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME) | | | | |



RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)

10/785,120



10/785,120

L10 ANSWER 108 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1971:100121 CAPLUS
DN 74:100121
TI Antiulcerous N-(diallylaminoalkanoyl)-1,4-benzodiazepinones
IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas
PA Thomae, Dr. Karl, G.m.b.H.
SO Ger. Offen., 28 pp. Addn. to Ger. Offen. 1,795,183
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | DE 1936670 | A | 19710204 | DE 1969-1936670 | 19690718 |
| | DE 1936670 | B2 | 19760318 | | |
| | DE 1936670 | C3 | 19761104 | | |
| | FI 50242 | B | 19750930 | FI 1970-1744 | 19700622 |
| | SE 380800 | B | 19751117 | SE 1970-8854 | 19700625 |
| | CS 164864 | P | 19751128 | CS 1970-4848 | 19700709 |
| | US 3691159 | A | 19720912 | US 1970-54624 | 19700713 |
| | ZA 7004861 | A | 19720329 | ZA 1970-4861 | 19700715 |
| | CH 530988 | A | 19730115 | CH 1970-530988 | 19700715 |
| | RO 55559 | P | 19731120 | RO 1970-63923 | 19700715 |
| | ES 381898 | A1 | 19730401 | ES 1970-381898 | 19700716 |
| | BE 753664 | A | 19710118 | BE 1970-753664 | 19700717 |
| | NL 7010618 | A | 19710120 | NL 1970-10618 | 19700717 |
| | NL 165933 | B | 19810115 | | |
| | NL 165933 | C | 19810615 | | |
| | FR 2059530 | A5 | 19710604 | FR 1970-26501 | 19700717 |
| | FR 2059530 | B1 | 19740830 | | |
| | GB 1265467 | A | 19720301 | GB 1970-1265467 | 19700717 |
| | AT 298495 | B | 19720510 | AT 1970-6542 | 19700717 |
| | NO 127447 | B | 19730625 | NO 1970-2815 | 19700717 |
| | IL 34947 | A1 | 19731128 | IL 1970-34947 | 19700717 |
| | DK 135285 | B | 19770328 | DK 1970-3725 | 19700717 |
| | PL 79758 | P | 19750630 | PL 1970-142155 | 19700718 |
| | US 3749785 | A | 19730731 | US 1972-277096 | 19720801 |
| | NL 8100572 | A | 19810601 | NL 1981-572 | 19810206 |
| | NL 170856 | B | 19820802 | | |
| | NL 170856 | C | 19830103 | | |
| PRAI | DE 1969-1936670 | A | 19690718 | | |
| | US 1970-54624 | A3 | 19700713 | | |
| | NL 1970-10618 | | 19700717 | | |

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) were prepared from II and (CH₂:CHCH₂)₂NH (III). I of LD₅₀ >1500 mg/kg (orally in mice) had antiulcerous effects in rats and inhibited gastric secretion. Thus, refluxing II (Q = N, R = R₁ = H, n = 1) and III 18 hr in C₆H₆ gave the corresponding I. Among about 15 I prepared were (Q, R, R₁, and n given): N, Et, H, 1; N, H, H, 2; CH, Me, H, 1; CH, Me, Cl, 2; CH, H, Cl, 2.

IT 31262-24-5P 31265-74-4P 31265-76-6P

31265-79-9P 31265-85-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 31262-24-5 CAPLUS


CN 11H-Dibenzo[b,e]-[1,4]diazepin-11-one, 2-chloro-5-(N,N-diallyl-glycyl)-5,10-dihydro-, fumarate (2:1) (8CI) (CA INDEX NAME)

CM 1

CRN 31265-74-4

10/785,120

CMF C21 H20 Cl N3 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 31265-74-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallylglycyl)-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 31265-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallyl- β -alanyl)-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl


RN 31265-79-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(N,N-diallylalanyl)-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 31265-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(3-chloro-1-oxopropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)



L10 ANSWER 109 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1971:74869 CAPLUS

DN 74:74869

TI Effects of a group of dibenzodiazepines on fatal systemic anaphylaxis in mice, rats, and guinea pigs

AU Greig, Margaret E.; Gibbons, Anna J.; Young, Gerald Alan

CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA

SO Journal of Medicinal Chemistry (1971), 14(2), 153-6

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

GI For diagram(s), see printed CA Issue.


AB The varying degrees of protection against fatal systemic anaphylaxis in 3 species of animals by 34 dibenzodiazepines (I) were correlated with their inhibition of chymotrypsin activity. The most active compds. being I[R1 = (CH₂)₃NMe₂, R = R₂ = H] and I[R1 = (CH₂)₃NMe₂, RR = O, R₂ = H] were superior to tripeleennamine in protecting mice against the fatal anaphylaxis. I was comparable to cyproheptadine in mice and rats, but was superior in guinea pigs.

IT **32038-67-8**

RL: BIOL (Biological study)
(anaphylaxis prevention by)

RN 32038-67-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[3-(dimethylamino)propyl]-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

10/785,120

L10 ANSWER 110 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:520695 CAPLUS

DN 73:120695

TI 5,10-Dihydro-11H-dibenzo[b,e] [1,4]diazepine-11-ones substituted in 5-position, and their ulcer-inhibiting activity

IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas; Machleidt, Hans

PA Thomae, Dr. Karl, G.m.b.H.

SO S. African, 49 pp.


CODEN: SFXAB

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|-------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | ZA 6905930 | | 19700312 | | |
| | DE 1795176 | | | DE | |
| | FR 2016008 | | | FR | |
| | GB 1236112 | | | GB | |
| | US 3634408 | | 19720000 | US | |
| PRAI | DE | | 19680820 | | |
| | DE | | 19690620 | | |
| AB | I (R = H, 2-Cl, 8-Cl; R1 = H, Me; X = pyrrolidino, piperidino, morpholino, 4-substituted 1-piperazinyl, etc.) ulcer- and secretion-inhibiting compds., are prepared from II. Thus, 10 g 5-(chloroacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-one and 10 ml N-methylpiperazine gave I (R = R1 = H; X = 4-methyl-1-piperazinyl). Forty-seven prepns. are given. | | | | |
| IT | 29174-19-4P 29174-20-7P 29174-23-0P 29174-26-3P 29174-44-5P 29174-45-6P 29183-81-1P 29183-82-2P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 29174-19-4 CAPLUS | | | | |
| CN | 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-(chloroacetyl)-5,10-dihydro- (8CI, 9CI) (CA INDEX NAME) | | | | |



RN 29174-20-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)

10/785,120



RN 29174-23-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(piperidinoacetyl)- (8CI) (CA INDEX NAME)



RN 29174-26-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(morpholinoacetyl)- (8CI) (CA INDEX NAME)

10/785,120



RN 29174-44-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)

10/785,120



RN 29183-81-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

RN 29183-82-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 111 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:111530 CAPLUS

DN 72:111530

TI Antidepressant 10-(aminoalkyl)-11-oxo-10,11-dihydrodibenz[b,f][1,4]oxazepines

IN Nagarajan, Kuppuswamy

PA CIBA Ltd.

SO Patentschrift (Switz.), 9 pp.

CODEN: SWXXAS

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | CH 481936 | A | 19691130 | CH 1966-481936 | 19661205 |
| PRAI | CH 1966-17305 | A | 19661205 | | |

GI For diagram(s), see printed CA Issue.

AB A solution of 6.6 g 2,5-Cl(O2N)C6H3COCl in 50 ml dry Et2O was added over 1 hr to a stirred mixture of 5.2 g Na-HCO3 in 50 ml H2O and 3.3 g o-HOC6H4NH2 in 50 ml Et2O at 0° to give 2,5-Cl(O2N)C6H3CO NHC6H4OH-o, m. 189-92° (aqueous MeOH), which (4.5 g) was heated with 0.8 g NaOH in 150 ml H2O on a steam bath 16 hr to give 2-nitro-11-oxo-10,11-dihydrodibenz[b,f][1,4]oxazepine (I), m. 258-60° (Me2CO-MeOH). I (3 g), 4.7 g Me2N(CH2)3Cl.HCl (II), 18 ml H2O, 1.8 g NaOH, and 30 ml Me2CO was refluxed 5 hr, Me2CO distilled, and the residue diluted with H2O to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2) (IV), oil; HCl salt m. 223-6° (absolute EtOH); oxalate m. 212-14° (decomposition) (aqueous MeOH); maleate m. 166-8° (MeOH-Et2O). Fuming HNO3 (2 ml) was added to 1 g IV in 5 ml concentrated H2SO4 at 0° and ice and NH4OH added after 1.5 hr to give III (n = 3, R = Me2N, R1 = R2 = R4 = R6 = H, R3 = R5 = NO2) (V); HCl salt hemihydrate m. 205° (decomposition) (EtOH); picrate m. 158-60° (decomposition) (Me2COMeOH). 11-Oxo-10, 11-dihydrodibenz[b,f][1,4]oxazepine was treated with NaH in HCONMe2, followed by II to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R5 = R6 = H) (VI); maleate m. 124-6°. VI treated with H2SO4-HNO3 as above gave V. IV.HCl (11.3 g) in 250 ml MeOH was hydrogenated 1.5 hr at 29° and 4.3 atm in the presence of 0.3 g Pt oxide to give III.HCl (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NH2), m. 222-4° (EtOH), which was converted into the base and treated with Ac2O and Et3N 2 days at room temperature to give III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = R6 = H, R5 = NHAc) (VII), oil. VII and concentrated HNO3 kept 1 hr at 0° gave III (n = 3, R = Me2N, R1 = R2 = R3 = R4 = H, R5 = NHAc, R6 = NO2); HI salt m. 156-9° (MeOH-EtOH-Et2O). By similar methods were prepared VIII, HCl salt m. 239-41°, and 15 other III. CNBr (2.6 g) in 15 ml dry Et2O was added over 15 min to 5.6 g IV in 25 ml dry Et2O and the mixture stirred 4 hr at room temperature to give III [n = 3, R = Me(CN)N, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2], m. 135-6° (CHCl3-hexane). This refluxed 4 hr with 4N HCl or heated 3 hr at 140-60° with polyphosphoric acid gave III (R1 = R2 = R3 = R4 = R6 = H, R = Me2NH, R5 = NO2). (IX) ClCO2Et (4.3 g) in 5 ml dry xylene was added over 10 min to 3.4 g IV in 20 ml dry xylene and the mixture refluxed 6 hr to give III [n = 3, R = EtO2CNMe, R1 = R2 = R3 = R4 = R6 = H, R5 = NO2], which (1.4 g) in 12 ml 48% HBr in AcOH was kept 3 days to give IX. The title compds. are local anesthetics and antidepressants, also showing antiinflammatory, antihistaminic, antiserotonin and anti-acetylcholine activity.


IT 16398-16-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 112 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:491552 CAPLUS

DN 71:91552

TI 11-(1-Piperazinyl)dibenz[b,f][1,4]oxazepines and -thiazepines

IN McEvoy, Francis J.; Allen, George R., Jr.

PA American Cyanamid Co.

SO Ger. Offen., 28 pp. Addn. to Ger., Offen. 1670032

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------|------|----------|-----------------|------|
| PI | DE 1802728 | | 19690626 | DE | |
| | FR 326 | | | FR | |
| | US 3560622 | | 19710000 | US | |
| PRAI | US | | 19671013 | | |

OS MARPAT 71:91552

GI For diagram(s), see printed CA Issue.

AB The title compds. (Ia and Ib) were prepared for use as tranquilizers and antidepressants. Thus, 29.8 g. (p-F3COC6H4NH2)2.H2SO4 in 300 ml. H2O and 33 ml. 98% H2SO4 treated dropwise within 15 min. at 0° with 7.6 g. NaNO2 in 75 ml. H2O, the solution stirred 40 min. gave F3COC6H4OH (I), an oil. I (11.6 g.) in 200 ml. Et2O treated 15 min. with 1 equivalent NaH in mineral oil, on ceasation of gas evolution the mixture refluxed 10 min., evaporated, and the residue dissolved in HCONMe2, added to 10.3 g. o-ClC6H4NO2 in 100 ml. HCONMe2, the solution refluxed 90 min. and worked up gave 2-RC6H4OC6H4OCF3-4 (II, R = NO2) (IIa), an oil. IIa in 200 ml. EtOH treated with H in the presence of 16 g. Raney Ni gave II (R = NH2) (III). III in 150 ml. C5H5N treated dropwise with 8.0 ml. ClCO2Ph, the mixture kept 18 hrs. at room temperature and worked up, the product in 150 ml. C6H6 treated 70 min. with 23 ml. 1-methylpiperazine gave 4-methyl-2'-(p-trifluoromethoxy)-1-piperazinecarboxanilide (IV), m. 98-100°, HCl salt m. 214-16°, IV.HCl (2.5 g.) refluxed 24 hrs. with 2.5 g. P2O5 in 5 ml. POCl3 treated with 6N HCl gave Ia (R = Me), m. 200-10°. Also prepared was 4-methyl-2'-(p-trifluoromethoxyphenylthio)-1-piperazinecarboxanilide-HCl, which on treatment with P2O5 in POCl3 gave Ib (R = Me). 2-(p-Trifluoromethoxyphenoxy)phenyl isocyanate, prepared by treatment of 2-(p-trifluoromethoxyphenoxy)aniline with COCl2 in o-Cl2C6H4, treated with AlCl3 gave 2-trifluormethoxy-10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepine (V), m. 172-5°. V treated with POCl3 gave 11-chloro-2-trifluoromethoxydibenz-[b,f][1,4]oxazepine, which on treatment with 1-methylpiperazine gave 11-(4-methyl-1-piperazinyl)-2-trifluoromethoxydibenz-[b,f][1,4]oxazepine, diHCl.2H2O m. 201-10°. Similarly were prepared Ib (R = H), Ia (R = HOCH2CH2), Ia (R = H). 2-p-Trifluoromethoxyphenoxy)carbanilate treated with 1-(2-hydroxyethyl)piperazine gave 4-(2-hydroxyethyl)-2'-(p-trifluoromethoxy)-1-piperazinecarboxanilide (VI), m. 76-8°, HCl salt m. 212-14°. VI.HCl treated with P2O5 in POCl3 gave Ia (R = HOCH2CH2), m. 245° (decomposition). Pharmaceutical formulations were given.


IT 23891-39-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23891-39-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(trifluoromethoxy)- (8CI) (CA INDEX NAME)

10/785,120



L10 ANSWER 113 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:481451 CAPLUS

DN 71:81451

TI 11-[Piperazinyl]dibenz[b,f][1,4]oxazepines and analogous thiazepine tranquilizers

IN Howell, Charles F.; Hardy, Robert A., Jr.; Quinones, Nicanor Q.

PA American Cyanamid Co.

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3458516 | A | 19690729 | US 1968-705900 | 19680216 |
| PRAI | US 1968-705900 | A | 19680216 | | |

GI For diagram(s), see printed CA Issue.

AB I, which are physiol. active on the central nervous system, were prepared for use as tranquilizers and hypnotics. Thus, 27.8 g. p-RC6H4OR1 (II, R = COMe, R1 = H), 31.5 g. o-ClC6H4NO2, 27.6 g. K2CO3 and 0.2 g. Zn precipitated Cu were refluxed in 200 ml. C6H6 4 hrs. to give II (R = COMe, R1 = o-C6H4NO2), m. 95-6°, which was reduced in EtOH in the presence of H and Pd to give II (R = COMe, R1 = o-C6H4NH2) (III)m. 70-1°. III (10 g.) in 100 ml. CHCl3 was mixed with 15 ml. ClCO2Et in 150 ml. Et2O at 0-15° and 15 ml. pyridine was added. The mixture was refluxed 2 hrs. to give II (R = COMe, R1 = o-C6H4NHCOEt), m. 56-8°, 26 g. of which was heated at 100° 3 days with 30 ml. N-methylpiperazine and a trace of NaOMe, refluxed 4 hrs. and concentrated to give

2'-(p-acetylphenoxy)-4-

chromatog. to

2'-methyl-1-piperazinylcarboxanilide, m. 131-4°. The hydrochloride of this product (10 g.) was refluxed 20 hrs. with 40 ml. POCl3 and 10 g. P2O5 and concentrated to give a 6 g. mixture of bases, separated by partition

give I (R = Ac, R1 = Me, X = O), m. 116-18°. p-HOC6H4SO2Na.2H2O (56 g.) was refluxed 4 hrs. with 110 ml. Ac2O to give a solid which was treated with 200 ml. PhMe and 60 g. PCl5 and refluxed 1 hr. The mixture obtained was treated with 200 ml. CHCl3 and saturated at 0-10° with Me2NH for 4 hrs. Concentration of the filtered solution gave II (R = SO2NMe2,

R1 =

H) as an oil which was stirred with 40 g. K2CO3 in 200 ml. HCONMe2 at 10° for 2 hrs. and refluxed for 4 hrs. with 40 g. o-ClC6H4NO2 in the presence of Zn precipitated Cu to give II (R = SO2NMe2, R1 = o-C6H4NO2) (IIa), m. 111-12°. IIa (20 g.) was treated with 60 g. SnCl2 in 600 ml. Et2O and 20 ml. concentrated HCl was added at reflux to give II (R = SO2NMe2, R1 = o-C6H4NH2) (IIb), m. 152-5°. IIb was treated in the same way as III to give II (R = SO2NMe2, R1 = o-C6H4NHCOEt), m. 134-5°, 2'-(p-dimethylsulfamoylphenoxy)-4-methyl-1-piperazino-carboxanilide-HCl, m. 241-3°, and I (R = SO2NMe2, R1 = Me, X = O) with a maleate salt m. 142-5°. The following I were also prepared (R, R1, X, and m.p., given): ClC2H2, Me, O, 64-8°; SO2NMe2, H, S, 176-8°; SO2NMe2, H, O, 187-9°; SO2NMe2, Me, S, 162-5°; CO2Et, Me, O, 109-11°; NO2, Me, O, 189-91°; NH2, Me, O, 112-13°. Other intermediates prepared were (compound and m.p., given). 4-(N,N-dimethylsulfamoyl)diphenyl disulfide, 132-6°; 4-mercapto-N,N-dimethylbenzenesulfon-amide, 100-2°; o-(p-dimethylsulfamoylphenylthio)aniline, 120-2°; p-(o-aminophenylthio)acetophenone, 78-80°; 2'-(p-dimethylsulfamoylphenylthio)-4-methyl-1-piperazinocarboxanilide, 151-2°.


IT 16398-16-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

10/785,120

RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



10/785,120

L10 ANSWER 114 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:450016 CAPLUS

DN 71:50016

TI Aminodibenz[b,f][1,4]oxazepin-11(10H)-ones

IN Schmidt, Guenther

PA Thomae, Dr. Karl, G.m.b.H.

SO S. African, 28 pp.

CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------|------|----------|-----------------|------|
| PI | ZA 6804436 | | 19681122 | | |
| | FR 1574968 | | | FR | |
| | FR 7681 | | | FR | |
| | GB 1164579 | | | GB | |
| PRAI | DE | | 19670711 | | |

OS MARPAT 71:50016

GI For diagram(s), see printed CA Issue.


AB The title compds. (I, R = NH₂) useful as analgesics and sedatives, are prepared by reduction of the corresponding nitro compds. by a variety of methods. Thus, 2.8 g. 2-nitrodibenz[b,f][1,4]oxazepin-11(10H)-one (II) was suspended in 200 cc. of dioxane, mixed with 2 g. Raney Ni and hydrogenated at 50° and 31 atmospheric 2 hrs. to give I (R₁ = R₂ = H, R = 2-NH₂), m. 200-2° (EtOH or 50% aqueous HCONMe₂); HCl salt m. 320° (decomposition) (dilute HCl). Na₂S₂O₆, Fe/HCl, N₂H₄.H₂O/Raney Ni, Sn/HCl, PtO₂ and Pd/C were also used as catalysts. Hydrogenations of the nitro compds. were carried out to give the following I (R, R₁, R₂, and m.p. given): 3-NH₂, H, H, 287-9°; H, H, 7-NH₂, 268-71°; 2-NH₂, Me, H, 133-6°; 2-NH₂, Et, H, 165-6°; 2-NH₂, H, 8-Me, 169-70° (HCl salt m. >300°); 2-NH₂, Et, Me, 114-15° [HCl salt m. 248-50° (decomposition)]; 2-NH₂, H, 8-Cl, 266-7°; 2-NH₂, Et, 8-Cl, 166-7°; [HCl salt m. 255° (decomposition)]; 3-NH₂, Me, H, 187-9°; H, Me, 7-NH₂, 194-6°.

IT 23474-55-7P 23474-56-8P 23474-59-1P
23474-60-4P 23474-63-7P 23474-65-9P
23474-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23474-55-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro- (8CI, 9CI) (CA INDEX NAME)



RN 23474-56-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-chloro-, monohydrochloride (8CI) (CA INDEX NAME)

10/785,120




● HCl

RN 23474-59-1 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl- (8CI, 9CI) (CA INDEX NAME)




RN 23474-60-4 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-8-methyl-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 23474-63-7 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-amino- (8CI, 9CI) (CA INDEX NAME)



RN 23474-65-9 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino-, monohydrochloride (8CI) (CA INDEX NAME)


10/785,120



● HCl

RN 23474-66-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-amino- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 115 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:106484 CAPLUS

DN 70:106484

TI Seven-membered heterocycles. XII. Dibenzo[b,f]-1,4-oxazepin-11(10H)-ones and dibenzo[b,e]-1,4-oxazepin-11(5H)-ones

AU Kuenzle, F.; Schmutz, J.

CS Forschungsinst., Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1969), 52(3), 622-8

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 70:106484

AB 2-(R-Substituted)-dibenz[b,f]-1,4-oxazepin-11-(10H)-ones (I) (where R = NO₂, CN, SO₂R₁, or SO₂NR₂₁; and R₁ = Me or Et, or NR₂₁ = pyrrolidinyl) were prepared by cyclization of 3,6-RXC₆H₃CONHC₆H₄OH-o (II) (where X = Cl or Br). Cyclization of II (R = SO₂NMe₂) in N-methylpyrrolidinone also gave Smiles rearrangement to 2-(dimethylaminosulfonyl)dibenz-[b,e]-1,4-oxazepin-11(5H)-one, also obtained from 2,4-HO₂C-RC₆H₃NHC₆H₄OH-o (III) (where R = SO₂NMe₂). Hydrolysis of II (where R = SO₂Me) gave III (R = SO₂Me₂). Treatment of I (R = NO₂) with dilute NaOH gave III (R = NO₂).

IT 16398-16-6P 22361-74-6P 22361-75-7P


22361-76-8P 22361-77-9P 22361-78-0P

22361-79-1P 22362-39-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 22361-74-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-carbonitrile, 10,11-dihydro-11-oxo- (8CI) (CA INDEX NAME)




RN 22361-75-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylsulfonyl)- (8CI) (CA INDEX NAME)




RN 22361-76-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(ethylsulfonyl)- (8CI) (CA INDEX NAME)




RN 22361-77-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, 10,11-dihydro-N,N-dimethyl-11-oxo- (8CI, 9CI) (CA INDEX NAME)




RN 22361-78-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepine-2-sulfonamide, N,N-diethyl-10,11-dihydro-11-oxo- (8CI) (CA INDEX NAME)



RN 22361-79-1 CAPLUS


CN Pyrrolidine, 1-[(10,11-dihydro-11-oxo-dibenz[b,f][1,4]oxazepin-2-yl)sulfonyl]- (8CI) (CA INDEX NAME)




10/785,120

RN 22362-39-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-(methylthio)- (8CI) (CA INDEX NAME)



L10 ANSWER 116 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1969:87772 CAPLUS
DN 70:87772
TI Cyclization reactions of methyl 2-chloro-3,5-dinitrobenzoate
AU Gupta, Chhitar M.; Bhaduri, Amiya P.; Khanna, Nandoo M.
CS Cent. Drug Res. Inst., Lucknow, India
SO Indian Journal of Chemistry (1968), 6(12), 758-9
CODEN: IJOCAP; ISSN: 0019-5103
DT Journal
LA English
AB Reaction of Me 2-chloro-3,5-dinitrobenzoate with guanidine,
2-aminopyridine, o-phenylenediamine and phenylhydrazine gives
2-amino-6,8-dinitro-4(H)-quinazolinone, 1,3-dinitro-6a-pyrido[1,2-
a]quinazolin-5-one, 2,4-dinitro-11-oxo-5H,10H-dibenzo[be]-1,4-diazepine
and 5,7-dinitro-2-phenylindazolone, resp.
IT **22177-14-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22177-14-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2,4-dinitro- (8CI, 9CI)
(CA INDEX NAME)



L10 ANSWER 117 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1969:57923 CAPLUS

DN 70:57923

TI 11-Tertiary-aminodibenz[b,f][1,4]oxazepines and thiazepines

IN Howell, Charles F.; Hardy, Robert A., Jr.; Quinones, Nicanor Q.

PA American Cyanamid Co.

SO Fr., 20 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|------|
| PI | FR 1508536 | | 19680105 | FR | |
| | DE 1645954 | | | DE | |
| | FR 6274 | | | FR | |
| | GB 1177956 | | | GB | |
| | GB 1177957 | | | GB | |

PRAI US 19660117

OS MARPAT 70:57923

GI For diagram(s), see printed CA Issue.

AB Title products (I) (optional 10 → 11 unsatn.) with central nervous system activity are prepared. Thus, a solution of 7.9 g. carbonyldiimidazole in 80 cc. tetrahydrofuran is added to a mixture of 9 g. 2-chloro-5-(trifluoromethyl)benzoic acid and 10 cc. tetrahydrofuran, and the mixture is refluxed 30 min., treated with 4.36 g. o-aminophenol, refluxed 15 min., and evaporated to dryness to give 2-chloro-2'-hydroxy-5-(trifluoromethyl)benzanilide (II), m. 112-13°. A mixt of 6.4 g. PC15, 20 cc. benzene, and 6.5 g. II is refluxed 5 min., then a solution of 4 g. N-methylpiperazine in 40 cc. toluene is added, and the mixture is refluxed 1 hr. and treated to give 1-[1-(6-chloro- α,α,α -trifluoro-m-tolyl)-N-(o-hydroxyphenyl)-formimidoyl]-4-methylpiperazine, which (3.3 g.) is mixed with 1.1 g. K₂CO₃, 0.3 g. powdered Cu, and 8 cc. AcNMe₂, and heated at 180° for 1 hr., cooled, mixed with 80 cc. water and 20 cc. ether, and filtered. The organic layer is evaporated to give 2-(trifluoromethyl)-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 215-16°. A mixture of 2-chloro-2'-hydroxy-5-nitrobenzanilide, PC15, and anhydrous benzene is refluxed until a clear solution

is obtained, then N-methylpiperazine is added and the mixture refluxed to give 1-[1-(2-chloro-5-nitrophenyl)-N-(o-hydroxyphenyl)formimidoyl]-4-methylpiperazine, which is heated with anhydrous K₂CO₃ and powdered Cu in AcNMe₂ to give 2-nitro-11-(4-methyl-1-piperazinyl)dibenzo[b, f][1, 4]oxazepine (III), m. 189-91°. A solution of 0.35 g. III in 10 cc. 0.3N HCl is hydrogenated over 3 mg. PtO₂ to give 2-amino-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, which in turn is diazotized with 52 mg. NaNO₂ and treated with 90 mg. Cu₂Cl₂ to give 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 108-11°. Similarly the following were prepared: 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 97-8°; 2-fluoro-11-(4-methyl-1-piperazinyl)-dibenz[b, f][1, 4]oxazepine (fumarate m. 204-5°); 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b, f][1, 4]thiazepine, m. 93°; 11-[N-methyl-2-(methylamino)ethylamino]dibenz[b, f][1, 4]oxazepine-2 HCl, m. 220-5°; 2-chlorodibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 245-6°; 2-(trifluoromethyl)dibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 213-14°; 2-nitrodibenz[b, f][1, 4]oxazepin-11(10H)-one, m. 260-2°; 11-aminodibenz[b, f][1, 4]oxazepine, m. 198-200° (HCl salt m. 239-41°); 11-(dimethylamino)dibenz[b, f][1, 4]oxazepine, m. 111-13°; 2-chloro-11-(dimethylamino)dibenz[b, f][1, 4]oxazepine, m. 234-6° (decomposition); 2-chloro-11-(1-

10/785,120


piperazinyl)dibenzo[b, f][1, 4]thiazepine, m. 127-33° (HCl salt m. 218°); 11-(1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 116-17°; 2-chloro-11-(1-piperazinyl)dibenz[b, f][1, 4]oxazepine, m. 175-6°; 2-chloro-11 - [4 - (2 - hydroxyethyl) - 1 - piperazinyl]dibenz[b, f]-[1, 4]oxazepine(fumarate m. 201-4°).

IT **3158-91-6P 16398-16-6P 21636-22-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 3158-91-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 16398-16-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 21636-22-6 CAPLUS

CN Dibenz[b, f][1, 4]oxazepin-11(10H)-one, 2-(trifluoromethyl)- (8CI) (CA INDEX NAME)



L10 ANSWER 118 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:506685 CAPLUS

DN 69:106685

TI New synthesis of dibenz[b,f][1,4]oxazepine, dibenzo[b,f][1,4]thiazepine, and dibenzo[b,e][1,4]diazepine derivatives

AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.

CS CIBA Res. Centre, Goregaon, India

SO Indian Journal of Chemistry (1968), 6(4), 225-6

CODEN: IJOCAP; ISSN: 0019-5103

DT Journal

LA English


AB Beckmann rearrangement of xanthone oxime (Graebe and Roder, 1899) in ether using PCl_5 catalyst afforded 50% 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepine (I), m. $210-12^\circ$, identical with a sample obtained by thermal lactamization of 2-amino-2'-carbethoxydiphenyl ether (CA 61:8326d). Similarly, thioxanthone oxime, m. $192-3^\circ$, gave on rearrangement 52% 10,11-dihydro-11-oxodibenzo[b,f][1,4]thiazepine, m. $261-2^\circ$, identical with a sample prepared by the alternative procedure. I was also prepared by refluxing N-(2-chlorobenzoyl)-2-hydroxyaniline (II), m. $188-90^\circ$, as its dry Na salt in HCONMe_2 72 hrs. Ano. of analogs with other substituents in the nuclei were similarly synthesized. As expected, activation of the Cl atom by electron-withdrawing groups suitably situated in the aryl part of II facilitated ring closure. An extension to N-(γ -dimethylaminopropyl)-N-(2,5-dichlorobenzoyl)-2-hydroxyaniline, m. $176-9^\circ$, offered an efficient alternative synthesis of 80% 2-chloro-10,11-dihydro-10-(γ -dimethylaminopropyl)-11-oxodibenz[b,f][1,4]oxazepine (III) of psychotropic interest (CA 62: 16283a). III was characterized as the HCl salt, m. $191-3^\circ$, identical with an authentic sample (CA 62: 16283a). N-(2-Chlorobenzoyl)-o-phenylenediamine as its N-p-tolylsulfonyl derivative could not be cyclized. However, N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl)-o-phenylenediamine, m. $161-3^\circ$, could be similarly treated to afford 60% 10,11-dihydro-2-nitro-11-oxo-5-(p-tolylsulfonyl)dibenzo[b,e][1,4]diazepine, m. $252-5^\circ$.

IT 20169-49-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20169-49-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 119 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:427464 CAPLUS

DN 69:27464

TI Preparation of dibenzo[b,f][1,4]thiazepines and dibenz[b,f][1,4]oxazepines

IN Schmutz, Jean; Hunziker, Fritz; Schindler, Othmar; Kuenzle, Franz M.

PA Dr. A. Wander, A.-G.

SO U.S., 4 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 3367930 | A | 19680206 | US 1964-399096 | 19640924 |
| PRAI | US 1964-399096 | A | 19640924 | | |

GI For diagram(s), see printed CA Issue.

AB I, in which X is O, S, CH₂, or C₂H₄, were prepared by cyclization of the corresponding isocyanate. Thus, 98 g. AlCl₃ in 900 ml. o-Cl₂C₆H₄ at 90-100° was mixed with 183.2 g. 2-isocyanato-4'-chlorodiphenyl sulfide, prepared by the reaction of 2-amino-4'-chlorodiphenyl sulfide with COCl₂, in 600 ml. o-Cl₂C₆H₄ added dropwise and the mixture was heated to 150° in 1 hr., poured over ice, and steamed-distilled. The residue after filtration was boiled with 700 ml. Me₂CO to give I (R = 4-Cl, R₁ = R₂ = H, X = S), m. 260-2°. Other I were prepared similarly (R, R₁, R₂, X, and m.p. given): H, H, H, O, 215-17°; 1-Cl, H, H, O, 251-5°; H, H, H, S, 259-60°; 2-F, H, H, S, 257-8°; 2-Br, H, H, S, 270-1°; 2-Me, H, H, S, 239-40°; 2-tert-Bu, H, H, S, 239-42°; 4-Me, H, H, S, 253-4°; H, H, 8-Cl, S, 302-3°; 1-Me, H, H, O, 229-31°; 3-Me, H, H, O, 218-19°; 2-Cl, H, H, O, 244-5°; 2-Me, H, H, O, 193-6°; 4-Cl, H, H, O, 256-9°; 4-Me, H, H, O, 192-4°; H, H, 7-Cl, O, 295°; H, H, 8-Cl, O, 258-61°; H, 2-Cl, 8-Cl, O, 293-4°; H, H, 6-Cl, O, 284-5°; 2-F, H, H, O, 245-6°; 2-Br, H, H, O, 240-1°; 1-Me, 4-Me, H, O, 251-3°; 3-Me, 4-Me, H, O, 213-14°; H, H, H, CH₂, 201-3°; H, H, H, CHMe, 203-6°; 2-OMe, H, H, S, 128-9°; 4-Cl, H, H, S, 271-3°; H, H, 8-OMe, S, 221-3°; H, H, 8-OH, S, 298-300°; 4-Cl, H, 8-Cl, S, 287-8°; 1-Cl, 4-Me, H, S, 319-21°; H, 4-Me, 7-Cl, S, 318-21°; H, 4-Me, 8-Cl, S, 298-300°; 3-Cl, H, H, O, 266-7°; 4-Et, H, H, O, 153-4°; 1-Cl, 4-Cl, H, O, 221-2°; 2-Cl, 4-Cl, H, O, 260-4°; H, 4-Cl, 8-Cl, O, 296-7°; 1-Cl, 4-Me, H, O, 258-9°; H, 4-Me, 7-Cl, O, 310-11°; H, 4-Me, 8-Cl, O, 259°; 2-Cl, H, H, CH₂, 261-2°; H, H, 8-Cl, CH₂, 239-40°. Also prepared similarly were 3-chloro-5,6-dihydro-6-oxo-11H-dibenz[b,e]azepine, m. 273-5°, and 5,6,11,12-tetrahydro-6-oxodibenz[b,f]azocine, m. 240-3°.

IT 3158-86-9P 3158-88-1P 3158-90-5P

3158-91-6P 3158-92-7P 3158-93-8P

3158-94-9P 3158-95-0P 3158-96-1P

3950-69-4P 3950-70-7P 3950-71-8P

3950-72-9P 3950-73-0P 3950-74-1P

3950-75-2P 3950-76-3P 3950-77-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 3158-86-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-92-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)



RN 3158-93-8 CAPLUS


10/785,120

RN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX
CN NAME)




RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX
NAME)




RN 3158-95-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX
NAME)



RN 3158-96-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-69-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX
NAME)


10/785,120




RN 3950-70-7 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-71-8 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-72-9 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-73-0 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-74-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-77-4 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7CI, 8CI) (CA
INDEX NAME)



L10 ANSWER 120 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:95871 CAPLUS

DN 68:95871

TI 10-(ω -Diethylaminoalkyl)-2,4-dichlorodibenz[b,f][1,4]oxazepin-11(10H)-ones

PA Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France

SO Fr. M., 6 pp.


CODEN: FMXXAJ

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | FR M4500 | | 19661114 | FR | 19650715 |
| OS | MARPAT 68:95871 | | | | |
| GI | For diagram(s), see printed CA Issue. | | | | |
| AB | <p>Compds. of the general formula I are prepared and tests on rats and mice show that they have anticonvulsive properties. Thus, a mixture of 23 g. Na in 400 ml. alc., 177 g. 2,4,6-MeCl₂C₆H₂OH, 500 ml. HCONMe₂, and 158 g. o-ClC₆H₄NO₂ is refluxed 12-13 hrs. to give 78% 2-(o-nitrophenoxy)-3,5-dichlorotoluene (II), m. 100°. A solution is prepared from 52 g. II, 160 ml. HOAc, and 17 ml. water, treated with a mixture of 68 g. CrO₃, 136 ml. water, 290 ml. HOAc, and 107 g. 93% H₂SO₄, and refluxed 5.5 hrs. to give 2-(o-nitrophenoxy)-3,5-dichlorobenzoic acid (III), m. 175-6°. A mixture of 94 g. III, 290 ml. water, 30 ml. 30% MeOH, and 156 g. Na₂S₂O₄ is refluxed 2 hrs. to give 2-(o-aminophenoxy)-3,5-dichlorobenzoic acid (IV), m. 190-1°. A mixture of 31 g. IV and 460 ml. xylene is refluxed 7 hrs. to give 93% 2,4-dichlorodibenz[b,f][1,4]oxazepin-11(10H)-one (V), m. 261-2°. V (39 g.) is added to a solution of 3.5 g. Na in 70 ml. alc., the mixture refluxed 10 min., the alc. distilled, the mixture collected, the precipitate dissolved in 350 ml. PhMe, and the solution cooled, treated with 22 g. Et₂NCH₂CH₂Cl, refluxed 8 hrs., cooled, and treated with concentrated HCl to give 94% 10-(3-diethylaminoethyl)-2,4-dichlorodibenzo[b,f][1,4]oxazepin-11(10H)-one-HCl, m. 146-7°. Similarly prepared is I (n = 3).HCl, m. 170°.</p> | | | | |
| IT | 3950-70-7P RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 3950-70-7 CAPLUS | | | | |
| CN | Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME) | | | | |



10/785,120

L10 ANSWER 121 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:502756 CAPLUS

DN 67:102756

TI Aminoalkyldibenzodiazepines

IN Hanze, Arthur R.

PA Upjohn Co.

SO Fr. M., 3 pp.

CODEN: FMXXAJ

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------|------|----------|-----------------|------|
| PI | FR M3747 | | 19660117 | FR | |
| PRAI | US | | 19620828 | | |

OS MARPAT 67:102756

GI For diagram(s), see printed CA Issue.


AB Oral and parenteral combinations with the usual vehicles are described containing title compds. (I) where R1 and R2 are H or lower alkyl or together with -N = form a saturated heterocyclic amino group containing 5-7 atoms in the ring, e.g. pyrrolidino, morpholino or thiomorpholino. Y is H or Cl or F or lower alkyl or alkoxy or CF3. Examples of I are 5-(2-diethylaminoethyl)-[5H]-dibenzo[b,e][1,4]diazepin-11(10H)-one, m. 132.5-3.5°; and its analogs: 3-dimethylaminopropyl, m. 147.5-49°, 3-diethylaminopropyl, m. 115.5-17°, 3-methylaminopropyl, m. 146.5-47.5°, 3-dimethylaminopropyl-3-chloro, m. 145.5-6.5°. These and their acid addition salts are useful as tranquilizing, hypotensive, and antihistaminic agents and inhibitors of pseudocholinesterase.

IT 18277-21-9

RL: BIOL (Biological study)
(pharmaceutical preps. containing)

RN 18277-21-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[3-(dimethylamino)propyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



L10 ANSWER 122 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1967:490856 CAPLUS
 DN 67:90856
 TI 10-Aminoalkyl 10,11-dihydrodibenzo[b,f][1,4]oxazepines
 PA CIBA Ltd.
 SO Neth. Appl., 43 pp.
 CODEN: NAXXAN
 DT Patent
 LA Dutch
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------|------|----------|-----------------|-------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | NL 6608671 | | 19661227 | NL | |
| PRAI | CH | | 19650623 | | |
| | CH | | 19660404 | | |

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), wherein at least one of the benzo-moieties is substituted by a NO₂ group, especially I (R₁ = 2-NO₂, R₂ = H, A = (CH₂)₃, Am = NMe₂, X = O) (Ia), are prepared and have antidepressive properties. They reverse the reserpine-induced hyperthermia and ptosis and (or) potentiate the activity of 3,4-dihydroxyphenylalanine in mice, which are treated with a monoamine oxidase inhibitor. II are prepared via III. Thus, a solution of 6.6 g. 2-chloro-5-nitrobenzoyl chloride in 50 ml. Et₂O is added over 1 hr. at 0° to a stirred mixture of 5.2 g. o-aminophenol in 50 ml. Et₂O. After stirring the mixture a few hrs. a 1st crop of III (R₁ = 3-NO₂, R₂ = H) (IIIa), m. 189-91° (H₂O-MeOH) is obtained. Work up of the ethereal layer of the filtrate by washing with dilute HCl and H₂O, followed by evaporation, yields a 2nd crop IIIa. Similarly, the following III are prepared (R₁, R₂, and m.p. given) 5-NO₂, 5-Cl, 221-2°; 5-NO₂, 5-Me, 200°; 5-NO₂, 5-NO₂, 239-44° (IIIb); 5-NO₂, 4-NO₂, 201-4°; 5-NO₂, 5-Ac, 230-1°; 5-NO₂, 3,5,6-Cl₃, 199-202°; 4-NO₂, H, 199°; 5-NO₂, 4-MeO, 195-7°. A solution of 4.5 g. IIIa and 0.8 g. NaOH in 150 ml. H₂O is heated 16 hrs. at 100° to yield II (X = O, R₁ = 2-NO₂, R₂ = H) (IIa), m. 258-60° (Me₂CO-MeOH). In an alternative method, a solution of 20 g. IIIb in 60 ml. N aqueous NaOH is evaporated to dryness by azeotropic distillation with

C₆H₆. The residue is dissolved in 150 ml. HCONMe₂ (DMF), refluxed 2 hrs., and diluted with H₂O to give II (X = O, R₁ = 2-NO₂, R₂ = 8-NO₂), m. > 330° (H₂O-EtOH). The following II (X = O) are prepared by similar methods (R₁, R₂, m.p., and reaction medium given): 2-NO₂, 8-Cl, >320°, H₂O; 2-NO₂, 8-Me, 326-7°, H₂O; 2-NO₂, 7-NO₂, 285-90°, DMF; 2-NO₂, 8-Ac >330°, DMF; 2-NO₂, 3,5,6-Cl₃, 320-2°, DMF; 3-NO₂, H, 295-7°, DMF; 2-NO₂, 7-MeO, 292-4°, DMF. The preparation of IIa by 2 other methods is also given. Thus, a mixture of 8.5 g. 2-nitroxanthone and 13.8 g. NH₂OH.HCl in 150 ml. C₅H₅N is refluxed 75 hrs. The solvent is distilled and the residue is washed repeatedly with cold H₂O, dilute HCl, H₂O and a small amount of CHCl₃ to yield 9-hydroximino-2-nitroxanthone, m. 210-11° (CHCl₃), 1 g. of which with 5 g. PCl₅ in 150 ml. anhydrous Et₂O is stirred several days. After adding H₂O, the organic layer is evaporated and the residue is washed with dilute

NaOH and with H₂O to yield IIa, m. 245-50° (Me₂CO-MeOH). Further, a solution of 1.25 g. 2-isocyanato-4'-nitrodiphenyl ether in 5 ml. o-dichlorobenzene (DCB) is added over 10 min. at 100° to a suspension of 0.7 g. anhydrous AlCl₃ in 10 ml. DCB. The mixture is heated slowly to 150° and kept at this temperature for 1 hr. After cooling the mixture is decomposed by addition of ice-cold dilute HCl and extracted with CHCl₃ to

yield IIa, m. 260-1.5° (Me₂CO-MeOH). On treating 5 g. IIa with an ice-cold solution of 50 ml. concentrated HNO₃ in 50 ml. H₂SO₄ and heating the mixture

at 60-70°, a dark yellow clear solution is obtained which is poured into excess H₂O to yield II [X = O, R₁ = R₂ = (presumably) 2,7,9-(NO₂)₃], m. 232-5° (Me₂CO-MeOH). Portionwise addition of 1 g. II (X = O, R₁ = R₂ = H) over 10 min. at 60° to 10 ml. concentrated HNO₃ gives a clear solution which after 5 min. becomes cloudy. After stirring the mixture 1 hr. at 60° and 30 min. at room temperature, it is diluted with 25 ml. ice-water to yield II (X = O, R₁ = H, R₂ = H, R₂ = 7-NO₂), m. 315-18° (DMF-EtOH). A mixture of 9.3 g. 2-chloro-5-nitrobenzaldehyde, 5.2 g. o-aminophenol, and 75 ml. anhydrous EtOH is refluxed 6 hrs. and worked up to yield N-(2-chloro-5-nitrobenzylidene)-2-hydroxyaniline, m. 161-3° (EtOH). To a suspension of this product in 5 ml. 2-3N aqueous NaOH is added 10 ml. EtOH and the mixture is heated until a clear solution is obtained. After evaporating the mixture to dryness, the residue in 100 ml. DMF is refluxed 5 min. and extracted with 150 ml. Et₂O. The extract is washed successively with H₂O, 15 ml. 10% aqueous NaOH, and H₂O, to yield 2-nitrodibenzo[b,f][1,4]oxazepine (IIb), m. 155° (Et₂O-hexane). IIb (2.2 g.) in 10 ml. dioxane and 15 ml. MeOH is reduced by portionwise addition of 0.5 g. NaBH₄ to yield II (X = H₂, R₁ = 2-NO₂, R₂ = H) m. 140-1° (Et₂O-hexane). A mixture of 3 g. IIa, 4.7 g. Cl(CH₂)₃NMe₂.HCl and 1.8 g. NaOH in 18 ml. H₂O and 30 ml. Me₂CO is refluxed 5 hrs. After distilling the organic solvent in vacuo, the residue is diluted with H₂O to yield the free base of Ia, which is extracted with Et₂O. [TABLE OMITTED] The extract is washed with H₂O and treated with concentrated HCl, to yield the hydrochloride of Ia, m. 223-6° (anhydrous EtOH). Other I (X = O) prepared by similar methods are given in the table (* = piperidinoethyl). In another method, 14 g. 3-bromopropanol, 10.3 g. IIa, and 21 g. anhydrous K₂CO₃ in 350 ml. hot Me₂CO is refluxed 4 hrs., the inorg. salts are filtered off, and the filtrate is evaporated. The residue is taken up in 50 ml. cold Et₂O and filtered. The solvent and unreacted 3-bromopropanol is distilled at 50-60°/3 mm. to yield crude IV (Z = OH) as an oily residue. This is dissolved in 100 ml. C₆H₆, 20 ml. SOCl₂ is added while cooling, and the solution is refluxed 3 hrs. to yield IV (Z = Cl) (IVa), m. 105-7°. Reaction of IVa with HNMe₂ in a closed vessel, followed by the usual work up yields the HCl salt of Ia, m. 215-17°. A solution of 2.6 g. BrCN in 15 ml. anhydrous Et₂O is added dropwise over 15 min. to a solution of 5.6 g. Ia in 25 ml. Et₂O. After stirring the mixture 4 hrs. at room temperature, 25 ml. H₂O is added to yield IV (Z = NMeCN) (IVb), m. 135-6° (CHCl₃-hexane). Work up of the organic layer of the filtrate gives a 2nd crop of IVb. A suspension of 3 g. IVb in 75 ml. 4N HCl is refluxed 4 hrs. After cooling, the mixture is extracted with Et₂O, and the aqueous layer is alkalized by addition of liquid NH₃ (sic) and extracted with CH₂Cl₂. The extract is concentrated and saturated with gaseous HCl to give the HCl salt of I (X = O, R₁ = 2-NO₂, R₂ = H, A = (CH₂)₃, Am = NHMe) (Ib), m. 215-17° (EtOH/Et₂O). Ib is obtained by heating a mixture of 2 g. IVb and 25 g. polyphosphoric acid, first for 30 min. at 140° and then 3 hrs. at 160° and working up the mixture by usual methods. A solution of 4.3 g. ClCO₂Et in 4 ml. anhydrous xylene is added over 10 min. to a solution of 3.4 g. Ia in 20 ml. anhydrous xylene and the mixture is refluxed 6 hrs. After cooling the mixture is divided between 50 ml. Et₂O and 50 ml. dilute HCl and the organic solution is worked up to yield crude IV (Z = NMeCO₂Et) (IVc). A mixture of 1.4 g. IVc and 12 ml. 48% HBr in AcOH is kept 3 days at room temperature, 100 ml. Et₂O is added. After cooling, the supernatant is decanted and the residue is treated with 100 ml. H₂O and


filtered. Work up of the filtrate yields Ib. Finally a hot solution of 5.1 g. IIa in 125 ml. anhydrous dioxane is added to a suspension of 1 g. NaNH₂ in the same solvent, after 30 min. followed by 3.4 g. N-formyl-N-methylaminopropyl chloride. The mixture is refluxed 6 hrs. to yield crude IV (Z = NMeCHO), a dark oil, which on hydrolysis with 30 ml. 6N HCl in 70 ml. EtOH yields Ib.

IT **16398-16-6P 16398-17-7P 16398-18-8P**
16398-19-9P 16398-20-2P 16398-21-3P
16398-22-4P 16398-23-5P 16398-24-6P
16398-26-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 16398-16-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-17-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dinitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-18-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-19-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-methyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)


10/785,120




RN 16398-20-2 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7-dinitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-21-3 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-acetyl-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-22-4 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 6,8,9-trichloro-2-nitro- (8CI, 9CI) (CA INDEX NAME)




RN 16398-23-5 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-nitro- (8CI, 9CI) (CA INDEX NAME)



10/785,120


RN 16398-24-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-methoxy-2-nitro- (8CI, 9CI) (CA INDEX NAME)



RN 16398-26-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,7,9-trinitro- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 123 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:402582 CAPLUS

DN 67:2582

TI Oximes of 2- and 4-phenylxanthenes and their Beckmann rearrangement

AU Troshchenko, A. T.; Lobanova, T. P.

CS Novosibirsk. Inst. Org. Khim., Novosibirsk, USSR

SO Zhurnal Organicheskoi Khimii (1967), 3(3), 501-3

CODEN: ZORKAE; ISSN: 0514-7492

DT Journal

LA Russian


GI For diagram(s), see printed CA Issue.

AB A mixture of 5 g. 4-phenylxanthone (I), 18 g. $\text{NH}_2\text{OH}\cdot\text{HCl}$, and 50 ml. anhydrous pyridine was boiled 25 hrs. Pyridine was partially evaporated and the product crystallized from MeOH and C_6H_6 to yield 85% 4-phenylxanthone oxime (II), m. $159-60^\circ$, which heated with dilute HCl gave I, m. $143-5^\circ$. In the same way 2-phenylxanthone oxime (III), m. $131-2^\circ$ (benzene), was prepared in 86% yield. Heating 0.1 g. II in 5 g. polyphosphoric acid 1 hr. at $150-60^\circ$, followed by precipitation with water and recrystn. gave 60% yield of 2-(2-aminophenoxy)biphenyl-3-carboxylic acid lactam, m. $174-6^\circ$ (alc.), which on ammonolysis with alc. NH_4OH solution in a sealed tube at $210-30^\circ$ 14 hrs. gave 80% yield of o-aminophenol, m. $173-4^\circ$, and 81% yield of 2-amino-3-phenylbenzoic acid (IV), m. $209-12^\circ$ (alc.). Last reaction proved anti-configuration of II. Diazotization of IV followed by heating with 60% H_2SO_4 gave 2-hydroxy-3-phenylbenzoic acid, m. $178-9^\circ$. Heating II in polyphosphoric acid gave only II and no Beckmann rearrangement product.

IT **16190-72-0P**RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16190-72-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-phenyl- (8CI) (CA INDEX NAME)



L10 ANSWER 124 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:94957 CAPLUS

DN 66:94957

TI Heterocycles with 7-membered rings. IX. 11- Amino substituted dibenzo[b,f]-1,4-thiazepines and -oxazepines

AU Schmutz, Jean; Kuenzle, G.; Hunziker, Fritz; Gauch, R.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1967), 50(1), 245-54

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 66:94957

GI For diagram(s), see printed CA Issue.

AB cf. CA 65, 13654g; 64, 8182g. (o-NH₂C₆H₄)₂S (40 g.) in 150 ml. PhMe was added to 170 ml. 20% COCl₂ in PhMe and heated to give clear solution. The excess COCl₂ was removed by passing N and PhMe was evaporated to give 42.2 g. (o-OCNC₆H₄)₂S, b_{0.07} 125-30°. 2-Isocyanato-4'-methoxydiphenyl sulfide, b_{0.07} 155-60°, and 2-isocyanato-4'-methoxydiphenyl ether, m. 43-5°, were similarly prepared. o-OCNC₆H₄SC₆H₄OMe-p (28 g.) in 100 ml. benzene was added to 28 g. N-methylpiperazine in 100 ml. benzene dropwise and refluxed for 2 hrs. to give 4-methyl-1-piperazinocarboxy[2-(4-methoxyphenylthio)anilide], m. 83-4°. 1-Piperidinocarboxy(2-phenylthioanilide) (I), m. 84-5°, 1-piperidinocarboxy(2-phenoxyanilide), m. 49-50°, 4-methyl-1-piperazinocarboxy(2-phenoxyanilide), m. 65-8°, and 4-methyl-1-piperazinocarboxy[2-(4-methoxyphenoxy)anilide], m. 78-9°, were similarly prepared. I (7 g.) and 40 ml. POCl₃ were refluxed for 14 hrs., treated with ice-water and concentrated NH₄OH after removal of excess POCl₃ and extracted with ether. The ether phase was extracted with dilute HCl and basified with concentrated NH₄OH. The

base was taken up with ether to give 11-(1-piperidinyl)dibenzo[b,f]-1,4-thiazepine (II), m. 133-4°. 11-(1-Piperidinyl)dibenzo[b,f]-1,4-oxazepine, m. 90-2°, was similarly prepared. Similarly prepared were dibenzo[b,f]-1,4-thiazepines (III, X = S); 11-amino, m. 176-7°; 11-(β-dimethylaminoethyl)amino, m. 96-7°; 11-(β-dimethylaminoethyl)methylamino, m. 89-90°; 11-(γ-dimethylaminopropyl)amino, m. 124-6°; 11-(γ-dimethylaminopropyl)methylamino, m. 69-70°; 11-(N-methylpiperazino), m. 102-3°; 11-(N-methylpiperazino), 2-fluoro, m. 80-4°; 11-piperazino, 2-chloro, m. 132-4°; 11-(N-methylpiperazino), 2-chloro, m. 121-3°; 11-[N-(β-hydroxyethyl)piperazino], 2-chloro, m. 194-200° (decomposition) (2HCl); 11-[N-(β-methoxyethyl)piperazino], 2-chloro, m. 215-25° (decomposition) (2HCl); 11-(N-methylpiperazino), 2-bromo, m. 137-8°; 11-(N-methylpiperazino), 2-methyl, m. 99-107°; 11-(N-methylpiperazino), 2-methoxy, m. 213-49° (decomposition) (2HCl); 11-(N-methylpiperazino), 3-chloro, m. 205° (decomposition) (HCl); 11-(N-methylpiperazino), 4-chloro, m. 130-1°; 11-(N-methylpiperazino), 6-chloro, m. 83-8°; 11-(N-methylpiperazino), 7-chloro, m. 137-9°; 11-(N-methylpiperazino), 8-chloro, m. 166-7°. Similarly prepared were dibenzo[b,f]-1,4-oxazepines (III, X = O): 11-(β-dimethylaminoethyl)amino, m. 88-9°; 11-(γ-dimethylaminoethyl)amino, m. 108-9°; 11-piperazino, 2-chloro, m. 178-80°, 11-[N-(β-hydroxyethyl)piperazino], 2-chloro, m. 197-237° (decomposition) (2HCl); 11-(N-methylpiperazino), m. 96-8°; 11-(N-methylpiperazino), 2-fluoro, m. 81-6°; 11-(N-methylpiperazino), 2-chloro, m. 108-10°; 11-(N-methylpiperazino), 2-bromo, m. 95-9°; 11-(N-methylpiperazino), 2-methyl, m. 130-1°; 11-(N-methylpiperazino), 2-methoxy, m. 107-8°; 11-(N-methylpiperazino), 3-chloro, m. 122-4°; 11-(N-methylpiperazino), 4-chloro, m. 173-4°; 11-(N-


methylnpiperazino), 6-chloro, m. 84-7°; 11-(N-methylnpiperazino), 7-chloro, m. 147-8°; 11-(N-methylnpiperazino), 8-chloro, m. 105-6°. 2-Chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-thiazepine (22 g.) in 400 ml. AcOH at 80° was treated with 33.6 ml. 30% H₂O₂ for 2 hrs., and refluxed for 1.5 hrs. to give 2-chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-thiazepine 5,5-dioxide (IV), m. 270-1°. 10,11-Dihydro-11-oxodibenzo[b,f]-1,4-thiazepine (50 g.) with 400 ml. POCl₃ and 15 ml. PhNMe₂ was refluxed for 5 hrs., and ether extraction gave 49 g. 11-chlorodibenzo[b,f]-1,4-thiazepine (V), m. 110-11°. Similarly prepared were V derivs.: 2-fluoro, m. 71-2°, 2-chloro, m. 132-4°; 2-bromo, m. 141-2°; 2-methyl, m. 124-6°; 4-chloro, m. 117-21°; 6-chloro, m. 144-7°; 8-chloro, m. 118-19°. Similarly prepared were 11-chlorodibenzo[b,f]-1,4-oxazepines: 2-fluoro, m. 94-6°; 2-chloro, m. 131-4°; 2-bromo, m. 143-6°; 2-methyl, m. 57-9°; 3-chloro, m. 111-13°; 4-chloro, m. 95-6°; 6-chloro, m. 115-16°; 7-chloro, m. 147-9°. V (4.9 g.) in 50 ml. xylene was refluxed with 3.4 g. piperidine for 5 hrs. and extracted with dilute HCl after removal of piperidine-HCl. Basification with NH₄OH and ether extraction gave 4.8 g. II. IV (11.3 g.) with 39 ml. PhNMe₂ and 90 ml. POCl₃ was refluxed for 4 hrs., evaporated in vacuo, dissolved in xylene and treated with ice-water. Organic phase was concentrated to 200 ml. solution in vacuo and refluxed with 15 ml. N-methylnpiperazine for 5 hrs., washed with NaOH, water and dilute HCl, and basified with NH₄OH to give 7.5 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5,5-dioxide (VI), m. 155-6°. Similarly prepared was 2-chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5,5-dioxide, m. 189-91° (decomposition). Hydrolysis of 2 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-oxazepine by heating with 100 ml. 2N HCl for 16 hrs. gave 1.4 g. 2-chloro-10,11-dihydro-11-oxodibenzo[b,f]-1,4-oxazepine, m. 242-4°. Oxidation of 8.6 g. VI in 50 ml. AcOH with 7.6 ml. 30% H₂O₂ at 20° for 8 days gave 2.25 g. IV, 2.05 g. starting material, and 2.2 g. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5-oxide (VII), m. 134-7°. 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f]-1,4-thiazepine (6.9 g.) in 10 ml. AcOH and 60 ml. water at 0° was treated with 4.5 g. NaIO₄, and the precipitate formed was dissolved at 20° by prolonged stirring, kept overnight, diluted with water, basified with NH₄OH and extracted with HCl. CHCl₃ washing, NH₄OH basification and ether extraction gave 5.8 g. VII. 2-Chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-thiazepine 5-oxide, m. 197-200° was similarly prepared. Thin-layer chromatog. data for the sulfoxides are given.

IT 3158-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 125 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:43922 CAPLUS

Correction of: 1965:472112

DN 64:43922

Correction of: 63:72112

OREF 64:8223b-h

TI Dibenzazepine, dibenzothiazepine, and morphanthridine derivatives

PA Dr. A. Wander A.-G.

SO 11 pp.

DT Patent

LA Unavailable

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|------|
| PI | NL 6411504 | | 19650412 | NL | |
| PRAI | CH | | 19631009 | | |
| GI | For diagram(s), see printed CA Issue. | | | | |
| AB | <p>A series of compds. (I and II) was prepared o-H₂NC₆H₄SC₆H₄Cl-p (83 g.) in 650 cc. dry MePh treated dropwise at -5 to 0° with stirring with 330 cc. 20% COCl₂-MePh, refluxed 15 min. while being treated with gaseous COCl₂, and purged with N yielded 91.5 g. p-ClC₆H₄-SC₆H₄NCO-o (III), b_{0.07} 140-5°, m. 37-40°. III (183.2 g.) in 600 cc. o-C₆H₄Cl₂ added dropwise at 90-100° to 98 g. AlCl₃ in 900 cc. o-C₆H₄Cl₂, heated 1 hr. at 150° poured onto ice, and steam distilled, and the residue boiled with 700 cc. Me₂CO yielded 181 g. I (R = 2-Cl, R₁ = H, X = S), m. 260-2°. o-OCN-C₆H₄OPh (166.9 g.), 111 g. AlCl₃, and 1000 cc. o-C₆H₄Cl₂ yielded similarly 163.5 g. I (R = R₁ = H, X = O), m. 215-17°. o-OCN-C₆H₄OC₆H₄Cl-m (143.2 g.), b_{0.07} 125-30°, cyclized with 81.5 g. AlCl₃ in 1000 cc. o-C₆H₄Cl₂ yielded 110.5 g. I (R = 3-Cl, R₁ = H, X = O), m. 266-7° (C₅H₅N), and 18 g. I (R = 1-Cl, R₁ = H, X = O), m. 251-5° (C₅H₅N). 2,5-BzClC₆H₃NH₂ reduced with N₂H₄.H₂O in basic medium, and the resulting 5,2-Cl-(PhCH₂)-C₆H₃NH₂ treated with 20% COCl₂-MePh gave 4,2-Cl(OCN)-C₆H₃CH₂C₆H₅ (IV), b_{0.1} 118-21°. IV (20.2 g.) cyclized at 120° with 13 g. AlCl₃ in 110 cc. o-C₆H₄Cl₂ yielded 19.5 g. II (R₁ = 7-Cl, R = H, R₂ = H), m. 273-5° (AcOH). o-H₂N-C₆H₄CH₂CH₂Ph (9 g.) in 10 cc. dry MePh treated dropwise with COCl₂-MePh and then refluxed during 0.5 hr. with gaseous COCl₂, purged with N, and evaporated, and the residue (11 g.) cyclized at 130° with 5.5 g. AlCl₃ in 60 cc. o-C₆H₄Cl₂ yielded 4 g. 5,6,11,12-tetrahydrobenz[b,f]azocine, m. 240-3° (CHCl₃-Et₂O). Similarly were prepared the I listed in the table. Similarly were prepared the following II (R, R₁, R₂, m.p., and yield given): H, H, H, 201-3°, 96; H, H, Me, 203-6° 87; 2-Cl, H, H, 261-2° 93; H, 8-Cl, H, 239-40°, 89°.</p> | | | | |
| IT | <p>3158-86-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- 3158-88-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- 3158-90-5, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- 3158-91-6, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- 3158-92-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- 3158-93-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- 3158-94-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- 3158-95-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- 3158-96-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- 3950-69-4, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- 3950-70-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- 3950-71-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- 3950-72-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- 3950-73-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- 3950-74-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- 3950-75-2, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- 3950-76-3, Dibenz[b,f][1,4]oxazepin-11(10H)-</p> | | | | |

10/785,120

one, 7-chloro-4-methyl- **3950-77-4**, Dibenz[b,f][1,4]oxazepin-
11(10H)-one, 8-chloro-4-methyl-
(preparation of)


RN 3158-86-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX
NAME)




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX
NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX
NAME)



RN 3158-91-6 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX
NAME)




RN 3158-92-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)


10/785,120




RN 3158-93-8 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3158-94-9 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-95-0 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3158-96-1 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-69-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-70-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-71-8 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-72-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)


10/785,120




RN 3950-73-0 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-74-1 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS
CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA


10/785,120

INDEX NAME)



RN 3950-77-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7Cl, 8Cl) (CA
INDEX NAME)



L10 ANSWER 126 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:82580 CAPLUS

DN 62:82580

OREF 62:14681g-h,14682a-h,14683a-c

TI Seven-membered heterocycles. IV. New synthesis of dibenzo[b,f]-1,4-thiazepine, -oxazepine, and dibenzo[b,e]azepine lactams

AU Schmutz, J.; Kuenzle, F.; Hunziker, F.; Buerki, A.

CS A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1965), 48(2), 336-47

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 62:82580

GI For diagram(s), see printed CA Issue.

AB cf. CA 61, 8313c. I, II, and III were prepared in good yields by the intramol. application of the Leuckart amide synthesis by using isocyanatodiphenyl sulfides, oxides, and methanes. The appropriate o-chloronitrobenzene (1.1 moles) and 1 mole suitable thiophenol treated with 1.1 moles NaOH in EtOH, or the chloronitrobenzene and excess phenol treated with KOH, or the Na phenolate treated in Me₂SO with excess chloronitrobenzene gave the corresponding IV (R = NO₂, X = S, O). o-ClC₆H₄NO₂ (115.8 g.) and p-MeOC₆H₄SH in 450 cc. boiling EtOH treated dropwise with 30.7 g. NaOH in 70 cc. H₂O and refluxed 1 hr. yielded 164.5 g. p-MeOC₆H₄SC₆H₄NO₂-o, m. 97-8° (Me₂CO-Et₂O).. 2,3-Me₂C₆H₃OH (30 g.) in 150 cc. dry Et₂O added dropwise with stirring to 8.7 g. NaNH₂ in 100 cc. dry Et₂O and refluxed 15 min., the Et₂O replaced by 150 cc. Me₂SO, and the mixture treated at 140° with 35.2 g. o-ClC₆H₄NO₂ in 60 cc. Me₂SO and heated 1 hr. at 140° yielded 51.1 g. 2,3-Me₂C₆H₃OC₆H₄N₂-o, m. 76-8°, b0.07 130-5°. The various IV (R = NO₂, X = S, O) were reduced with Raney Ni in EtOH or in AcOEt to the corresponding IV (R = NH₂). By these methods were prepared the IV listed in the 1st table. The appropriate o-amino-benzophenone reduced with Na in EtOH or in the presence of a Cl-substituent with N₂H₄ in (HOCH₂CH₂)₂O or treated with MeMgI (or EtMgI), dehydrated with dilute H₂SO₄, and hydrogenated in AcOEt over Pd-C yielded the corresponding o-aminodiphenylmethanes. o-MeC₆H₄COC₆H₄NH₂-o (30 g.) in 180 cc. absolute EtOH added rapidly with stirring to 18 g. Na and refluxed 0.5 hr. yielded 26 g. o-MeC₆H₄CH₂C₆H₄NH₂-o, m. 67-9° (Et₂O-petr. ether). 5,2-Cl(H₂N)C₆H₃Bz (50 g.) in 600 cc. dry Et₂O added dropwise with stirring to MeMgI from 27.5 g. Mg and 150 g. MeI in 600 cc. dry Et₂O and refluxed 3 hrs. yielded 43.8 g. 5,2-Cl(H₂N)C₆H₃CMePhOH (V), m. 93-4° (Et₂O-petr. ether). V (46.5 g.) and 320 cc. 35% H₂SO₄ refluxed 1 hr. gave 41.7 g. 5,2-Cl(H₂N)C₆H₃CPh:CH₂ (VI), b0.1 142-5°. VI treated 15 min. at 70° and 12 hrs. at 20° with Ac₂O-C₅H₅N gave the N-Ac derivative, m. 134-5° (Me₂CO-Et₂O). VI (22.9 g.) in 150 cc. AcOEt hydrogenated at 20° over 2.5 g. 5% Pd-C yielded 22 g. 5,2-Cl(H₂N)C₆H₃CHPhMe, b0.07 127-30° N-Ac derivative m. 98-9° (Et₂O-petr. ether). Similarly were prepared the IV listed in the 2nd table. o-H₂NC₆H₄SC₆H₄Cl-p (83 g.) in 650 cc. dry MePh added dropwise at -5 to 0° with stirring to 330 cc. 20% COCl₂ in MePh, and the mixture refluxed 15 min. while being treated with gaseous COCl₂ and then purged with N gave 91.5 g. o-OCNC₆H₄SC₆H₄Cl-p (VII), b0.07 140-5°, m. 37-40°. VII (183.2 g.) in 600 cc. o-C₆H₄Cl₂ added dropwise during 15 min. with stirring to 98 g. AlCl₃ in 900 cc. o-C₆H₄Cl₂ at 90-100° and heated 1 hr. at 150° yielded 181 g. I (R = 2-Cl, R' = H), m. 260-2° (CHCl₃). 2,4-OCN(MeO)C₆H₃SPh (38.7 g.) and 20.9 g. AlCl₃ in 350 cc. o-C₆H₄Cl₂ gave similarly 8.5 g. I (R = H, R' = 8-MeO) (VIII), m. 221-3°, and 8.8 g. I (R = H, R' = 8-OH) (IX), m. 298-300° (dioxane-Et₂O). Similarly were prepared the following I (R, R', and m.p. given): H, H, 259-60°; 2-F, H, 257-8° (AcOH); 2-Br, H, 270-1°; 2-Me, H, 239-40° (CHCl₃); 2-tert-Bu, H,


239-42° (AcOH); 2-MeO, H, 128-9° (Me₂CO-Et₂O); 4-Cl, H, 271-3° (dioxane); 4-Me, H, 253-4°; H, 8-Cl, 302-3°; 4-Cl, 8-Cl, 287-8° (AcOH); 1-Cl, 4-Me, 319-21° (HCONMe₂); 4-Me, 7-Cl, 318-21° (AcOH); 4-Me, 8-Cl, 298-300° (AcOH). IX (150 mg.) in 40 cc. MeOH treated 10 hrs. at 20° with CH₂N₂-Et₂O gave 130 mg. VIII, m. 221-3° (Me₂CO-petr. ether). o-ONCC₆H₄O₂Ph (166.9 g.) with 111 g. AlCl₃ in 1 l. o-C₆H₄Cl₂ yielded similarly 163.5 g. II (R = R' = H), m. 215-17° (AcOH). o-OCNC₆H₄OC₆H₄Me-m (87.9 g.), b0.07 100-3°, cyclized with 54.8 g. AlCl₃ in 800 cc. o-C₆H₄Cl₂ yielded 49 g. II (R = 3-Me, R' = H), m. 218-19° (AcOH), and 4.5 g. II (R = 1-Me, R' = H), prisms, m. 229-31° changing at about 200° to plates. o-OCNC₆H₄OC₆H₄Cl-m (143.2 g.), b0.07 125-30°, 81.5 g. AlCl₃, and 1 l. o-C₆H₄Cl₂ yielded 145 g. mixture, m. 215-50°, which fractionally recrystd. from 2.5 l. C₅H₅N gave II (R = 3-Cl, R' = H), m. 266-7°, and 18 g. II (R = 1-Cl, R' = H), m. 251-5° (AcOH). Similarly were prepared the following II (R, R' and m.p. given): 1-Cl, H, 251-5° (AcOH); 2-F, 245-6° (Me₂CO); 2-Cl, H, 244-5° (AcOH); 2-Br, H, 240-1° (AcOH); 2-Me, H, 193-6° (Me₂CO); 3-Cl, H, 266-7° (C₅H₅N); 4-Cl, H, 256-9° (AcOH); 4-Me, H, 192-4° (Me₂CO); 4-Et, H, 147-9° and 153-4° (Me₂CO); H, 6-Cl, 284-5° (AcOH); H, 7-Cl, .apprx.295° (AcOH); H, 8-Cl, 258-61° (Me₂CO); 1-Cl, 4-Cl, 221-2° (AcOH); 2-Cl, 4-Cl, 260-4° (AcOH); 2-Cl, 8-Cl, 293-4° (AcOH); 4-Cl, 8-Cl, 296-7° (AcOH); 1-Me, 4-Me, 251-3° (dioxane); 3-Me, 4-Me, 213-14° (CHCl₃-Et₂O); 1-Cl, 4-Me, 258-9° (AcOH); 4-Me, 7-Cl, 310-11° (dioxane); 4-Me, 8-Cl, 259° (dioxane). Similarly were prepared the following III (R, R', R'', and m.p. given): H, H, H, 201-3° (Me₂CO-H₂O); H, H, Me, 203-6° (Me₂CO); H, H, Et, 198-200° (CHCl₃Me₂CO); 2-Cl, H, H, 261-2° (Me₂CO); 2-Cl, H, Me, 235-6° (AcOH); 3-Cl, H, H, 273-5° (sublimed); 3-Cl, H, Me, 196-8° (Me₂CO-Et₂O); H, 8-Cl, H, 239-40° (CHCl₃-petr. ether); H, 8-Cl, Me, 258-60° (CHCl₃-petr. ether); H, 8-Me, H, 207-9° (Me₂CO); H, 8-Me, Me, 236-40° (Me₂CO); H, 10-Me, H, 231-2° (CHCl₃-Et₂O).

IT 3158-86-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl-
 3158-88-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro-
 3158-90-5, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro-
 3158-91-6, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro-
 3158-92-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo-
 3158-93-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl-
 3158-94-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro-
 3158-95-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl-
 3158-96-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl-
 3950-69-4, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro-
 3950-70-7, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro-
 3950-71-8, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro-
 3950-72-9, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro-
 3950-73-0, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl-
 3950-74-1, Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl-
 3950-75-2, Dibenz[b,f][1,4]oxazepin-11(10H)-one,
 1-chloro-4-methyl- 3950-76-3, Dibenz[b,f][1,4]oxazepin-11(10H)-
 one, 7-chloro-4-methyl- 3950-77-4, Dibenz[b,f][1,4]oxazepin-
 11(10H)-one, 8-chloro-4-methyl-
 (preparation of)

RN 3158-86-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-methyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3158-88-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-90-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-fluoro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-91-6 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3158-92-7 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-bromo- (7CI, 8CI) (CA INDEX NAME)



RN 3158-93-8 CAPLUS


10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-methyl- (7CI, 8CI) (CA INDEX NAME)




RN 3158-94-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-chloro- (7CI, 8CI, 9CI) (CA INDEX NAME)




RN 3158-95-0 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3158-96-1 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-ethyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-69-4 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dichloro- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-70-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-dichloro- (7CI, 8CI) (CA INDEX NAME)




RN 3950-71-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,8-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-72-9 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4,8-dichloro- (7CI, 8CI) (CA INDEX NAME)



RN 3950-73-0 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)

10/785,120




RN 3950-74-1 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3,4-dimethyl- (7CI, 8CI) (CA INDEX NAME)




RN 3950-75-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-76-3 CAPLUS


CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-chloro-4-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 3950-77-4 CAPLUS

10/785,120

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 8-chloro-4-methyl- (7CI, 8CI) (CA
INDEX NAME)



L10 ANSWER 127 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1964:425478 CAPLUS

DN 61:25478

OREF 61:4380e-h

TI 5-(Basic substituted)-10,11-dihydro-11-oxo-5H-dibenzo-[b,e][1,4]-diazepine derivatives (I)

PA Dr. A. Wander A.-G.

SO 6 pp.

DT Patent

LA Unavailable

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------|------|----------|-----------------|------|
| PI | GB 959995 | | 19640603 | GB | |
| | CH 380144 | | | CH | |
| | US 3150125 | | 1964 | US | |
| PRAI | CH | | 19590922 | | |

AB The title compds. are prepared by cyclization of the appropriate o-amino-o'-carboxydiphenylamines. Hence, 23.3 g. N- [β-(dimethylamino)ethyl]-2-nitrodiphenylamine-2'-ethyl carboxylate was catalytically hydrogenated and the resulting 2-amino compound dissolved in 500 cc. xylene. After 4 hrs. the xylene was distilled and the residue dried, boiled with 200 cc. N AcOH, and made alkaline with NH₃ to give 9.7 g. 5-[β-(dimethylamino)ethyl]-10,11-dihydro-11-oxo-5H-dibenzo [b,e][1,4]diazepine (I), m. 195-6°. Similarly prepared are the following derivs. of I (% yield and m.p. given): 7-chloro, 54, 197-8°; 8-chloro, 44, 180-4°; 8-methyl, 40, 165-7°; 8-methoxy, 56, 157-9°; 3-chloro, 38, 194°; 8-chloro-10-methyl, 57, - (b0.01 179°); 8-methoxy-10-methyl, 62, 115-18°; 8,10-dimethyl, 56, 71-4°; 7-methoxy, 68, 203-5°; 7-methylthio, 63, 185-7°; 7-chloro-10-methyl, 59, - (hydrochloride m. 216-19°). Further derivs. of I were prepared (substituents): 5-[γ-(dimethylamino)propyl], 59, 141-4°; 5-[γ-(dimethylamino)propyl]-7-chloro, 56, - [hydrochloride m. 244-5° (decomposition)]; 5-[γ-(dimethylamino)propyl]-8-chloro, 42, 184-7°; 5-[γ-(dimethylamino)propyl]-10-benzyl, 47, b0.03 230°; 5-(β-piperidinoethyl), 75, 184-6°; 5-(γ-piperidinopropyl), 58, 141-3°; 5-(β-morpholinoethyl), 66, 218-19°; 5-[β-(N'-methylpiperazino)ethyl], 60, 159-61°; 5-(pyrrolidinoethyl)-7-chloro-10-methyl, 67, - (hydrochloride m. 221-6°). These compds. are useful as parasympatholytics, antihistaminics, spasmolytics, tranquilizers, and psychic energizers.

IT **93407-98-8**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (preparation of)

RN 93407-98-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (7CI) (CA INDEX NAME)



L10 ANSWER 128 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1964:30958 CAPLUS

DN 60:30958

OREF 60:5505a-h,5506a-c

TI Seven-membered heterocycles. II. 5H-Dibenzo[b,e]-1,4-diazepines with basic substituents at position 5

AU Hunziker, F.; Kuenzle, F.; Schmutz, J.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1963), 46(6), 2337-46

CODEN: HCACAV; ISSN: 0018-019X

DT Journal

LA German

OS CASREACT 60:30958

GI For diagram(s), see printed CA Issue.

AB cf. CA 59, 8753f. Pepn. of compds. of types I, II, and III is described.

The various I were prepared in 4 steps from the appropriate o-PhNHC₆H₄NO₂.Thus, e.g., 12.2 g. 2,5-O₂N(MeO)C₆H₃NHPh was refluxed 1 hr. with 23.5 g.NaNH₂ in absolute dioxane, 8.7 g. Me₂N(CH₂)₃Cl in 40 ml. C₆H₆ added, and the mixture refluxed 20 hrs. and worked up to give 76% N-(γ-dimethylaminopropyl)-2-nitro-5-methoxydiphenylamine, m. 85-7°(Et₂O-petr. ether). The NO₂ group in N-(β-dimethylaminoethyl)-2-nitro-5-chlorodiphenylamine was reduced with Raney Ni and H at 20°and 1 atmospheric in AcOEt to give 96% N-(β-dimethylaminoethyl)-2-amino-5-chlorodiphenylamine, m. 101-2° (Et₂O-petr. ether). Reduction of

similar nitro compds, without Cl or MeS substituents was performed in

alc., while Na₂S₂O₄ in aqueous-alc. KOH was used to reduce the nitro precursor of N-(β-dimethylaminoethyl)-2-amino-2'-methylthiodiphenylamine. Amixture of 35 ml. anhydrous HCO₂H and 4.1 g. Ac₂O was refluxed 2 hrs., 7 g.o-H₂NC₆H₄NPh-(CH₂)₂NMe₂ added, the mixture refluxed 1.5 hrs., evaporated to

dryness in vacuo, and the residue worked up to give 88%

N-(β-dimethylaminoethyl)-2-formamidodiphenylamine (IV, R = R₁ = H, n= 2), m. 85-6° (Et₂O-petr. ether). The following R₁ substitutedderivs. of IV were similarly prepared (R, R₁, n, and b.p. or m.p. given):

Me, H, 2, 72°; iso-Pr, H, 2, b0.01 170°; Me, 4'-OMe, 2,

-(HCl salt m. 192-4°); Me, 3'-OMe, 2 (IVa), 79-80°; Me,

2'-OMe, 2, 94-5°; Me, 2'-SMe, 2, 130-2°; H, 5-Cl, 2,

123-5°; Me, 5-Cl, 2 (IVb), b0.04 175-80°; Me, 5-OMe, 2,

b0.05 200°; Me, 4-Me, 2, 89-92°; H, H, 3, 60-1°; Me,

H, 3, b0.01 154-5°; Me, 4'-OMe, 3, b0.07 182-6°; Me, 3'-OMe,

3, b0.07 190-5°; Me, 2'-OMe, 3, b0.07 185-90°; H, 5-Cl, 3,

99-101°; Me, 5Cl, 3, b0.03 182°; and Me, 5-OMe, 3, b0.05

200°. I were prepared by treatment of IV with polyphosphoric acid

(PPA) (R, R₁, n, and b.p. or m.p. given): Me, Cl, 2, m. 97-8°; H,

H, 2, m. 98°; Me, H, 2 (Ia), m. 113-15°; iso-Pr, H, 2, m.

72-4°; Me, 1-OMe, 2 (Ib), m. 104-5°; Me, 2-OMe, 2, m.

103-4°; Me, 3-OMe, 2 (Ic), m. 100-1°; Me, 4-OMe, 2, m.

94-7°; Me, 4-SMe, 2, m. 78-81°; H, 7-Cl, 2, m. 91-3°;

Me, 7-OMe, 2, m. 101-3°; Me, 8-Me, 2, -(maleate m. 151-4°);

H, H, 3, b0.01 162°; Me, H, 3, b0.01 164°; Me, 2-OMe, 3,

-(maleate m. 138-9°); Me, 3-OMe, 3, -(maleate m. 160-4°);

Me, 4-OMe, 3, m. 90-1°; H, 7-Cl, 3, -(maleate m. 155-6°);

Me, 7-Cl, 3, -(maleate m. 182-6°); Me, 7-OMe, 3, -(maleate m.

152-5°). Ib and Ic were separated from a single reaction mixture In a

typical preparation of II, 2-(o-O₂NC₆H₄NH)C₆H₄CO₂Et was alkylated with NaNH₂and Me₂N(CH₂)₃Cl to give Et N-(γ-dimethylaminopropyl)-2-

nitrodiphenylamine-2'-carboxylate, which was hydrogenated over 5% Pd-C at

20°/1 atmospheric, and the product worked up to give II (R = R₁ = H, n =3), m. 151-2° (Et₂O-petr. ether). The following II were similarlyprepared (R, R₁, n, and m.p. given): H, H, 2, 194-6°; H, 3-Cl, 2,

194-7°; H, 7-Cl, 2, 202-4°; H, 7-OMe, 2, 203-5°; H,

7-SMe, 2, 185-7°; H, 8-Me, 2, 165-7°; Me, 8-Me, 2,

71-5°; H, 8-Cl, 2 (IIa), 186-7°; H, 8-CF₃, 2, 122-38°; H, 8-OMe, 2, 157-9°; Me, 8-OMe, 2, 115-18°; H, 7-Cl, 3, -(HCl salt m. 244-5°); H, 8-Cl, 3, 183-5°. III derivs, were prepared by 2 routes. The appropriate I or preferably II was reduced with a large excess of LiAlH₄ in tetrahydrofuran. The second method involved catalytic reduction. Thus, a mixture of 20 g. Ia, 3 g. Raney

Ni,

I g. 5% Pd-C, and 120 ml. EtOH was hydrogenated at 20° and I atmospheric, filtered, evaporated to dryness, and the residue in Et₂O passed through Al₂O₃ and evaporated to give 89% III (R = R₂ = H, R₁ = Me, n = 2), m. 75-6° (Et₂O-petr. ether). The following III were prepared similarly (R, R₁, R₂, n, and m.p. given): H, H, H, 2 (IIIa) - (b0.03 162-4°); Ac, H, H, 2, 114°; Ac, Me, H, 2, 126-8°; Bz, Me, H, 2, 97-8°; H, Me, 2-OMe, 2, 73-6°; H, Me, 4-OMe, 2, 101-3°; H, H, 7-Cl, 2, 114-16°; H, Me, 7-Cl, 2 (IIIb), 107-9°; H, H, 8-Me, 2, 75-8°; H, H, 8-Cl, 2, 107-9°; H, H, H, 3, 102-4° H, Me, H, 3, 86-8°; Ac, Me, H, 3, 81-2°; H, H, 7-Cl, 3, 114-16°; H, Me, 7-Cl, 3, 74-8°. Conversion of III to I was also achieved. Thus, a mixture of 1.32 g. IIIa 3.5 g. Hg(OAc)₂, 25 ml. AcOH, and 75 ml. H₂O was heated 2.5 hrs. at 110°, cooled, filtered, and worked up to give 0.30 g. Ia. Alkylation of V (R = H) (VI) was also examined. Thus, a mixture of 12.0 g. VI, 70 ml. absolute dioxane, tert-BuOK


(from

2.1 g. K), and 40 ml. tert-BuOH was refluxed 1 hr., treated with 20 g. MeI, refluxed 4 hrs., and evaporated to dryness in vacuo. The residue was distributed between aqueous KHCO₃-CHCl₃ and the organic layer worked up to give 72% V (R = Me), m. 165-6° (CHCl₃-petr. ether). The 8-Me derivative of V (R = Me), m. 166-8° (Me₂CO-petr. ether), was similarly prepared. The compds. were tested pharmacol. by comparing their antibenzoquinolizine effect against tetrabenazine (Nitomane). Several III were effective; IIIb was comparable to Imipramine. The same effect was generally much weaker in I. II (especially those with a substituent at C-8) showed antihistamine and antianaphylactic effects. IIa showed less acute per os toxicity and was 2 and 4 times, resp., as effective against histamine-induced asthma and anaphylactic shock in the guinea pig as (±)-Chlorpheniramine. A discussion of infrared and ultraviolet spectra (maximum are recorded) is presented for some of the compds. prepared

IT **93407-98-8**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro-
(preparation of)

RN 93407-98-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5-[2-(dimethylamino)ethyl]-5,10-dihydro- (7CI) (CA INDEX NAME)



L10 ANSWER 129 OF 129 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1963:448394 CAPLUS

DN 59:48394

OREF 59:8753f-h,8754a-h,8755a-c

TI Chemistry and pharmacology of dibenzo[b,e][1,4]diazepine derivatives with basic substituents in position 10

AU Hunziker, F.; Lauener, H.; Schmutz, J.

CS Forschungsinst. Dr. A. Wander A.-G., Bern, Switz.

SO Arzneimittel-Forschung (1963), 13, 324-8

CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.

AB A series of I derivs. was prepared according to Clemono, et al. (CA 19, 293) and Burton and Gibson (CA 19, 987) by an Ullmann-synthesis from o-bromonitrobenzenes and free anthranilic acid derivs. in presence of K₂CO₃ and catalytic amts. of Cu in a higher alcohol as solvent. The N-methylated anthranilic acids gave lower yields (50-60%) than the corresponding primary amines. The esters of I were best obtained via the acid chlorides. Thus, the following I derivs. were prepared (R₁, R₂, R₃, and m.p. given): H, 4-Me, H, 213-15°; H, 4-Me, Et, 99-100°; Me, 4-Me, H, 140-1°; H, 4-Cl, H, 245-8°; H, 4-Cl, Et, 134-6°; Me, 4-Cl, H, 139-42°; H, 4-CF₃, H, 225-6°; H, 4-CF₃, Me, 147-8°; Me, 4-CF₃, H, 154-6°; H, 4-OMe, H, 228-30°; H, OMe, Et, 104°; Me, 4-OMe, H, 164-6°; H, 5-Cl, Me, 157-8°; H, 5-Cl, Et, 127-8°; Me, 5-Cl, H, 160°; Me, 5-Cl, Me, 92-3°; H, 5-OMe, Me, 149°; H, 5-SMe, Et, 187-8°; Me, 5-SMe, Me, 102-3°; H, 6-Cl, Me, 119-20°; H, 5'-Cl, Et, 106-7°; H, 5'-OMe, H, 235-7°; H, 4'-Cl, H, 232-5°; H, 4'-Cl, Me, 138°; H, 4'-OMe, H, 240°; Me, 4'-OMe, H, 168-72°. To a cooled solution of 5.9 g. K in 110 ml. tert-BuOH was added under stirring 12 g. MeSH. At 20°, a solution of 40.3 g. I (R₁ = R₃ = Me, R₂ = 5-Cl) in 300 ml. HCONMe₂ was added. After 2 hrs. stirring at 80°, evaporation to dryness in vacuo, distribution between benzene and NaHCO₃ solution, evaporation of the benzene, and crystallization from Et₂O/petr. ether gave 40 g. I (R₁ = R₃ = Me, R₂ = 5-SMe), m. 102-3°. To 135.6 g. I (R₁ = R₃ = H, R₂ = 5-Cl) 10.3, suspended in 1.8 l. 2N aqueous NH₃ was added within 3 hrs. 266 g. Na₂S₂O₄. The mixture was heated to 80° till solution was complete. Charcoal treatment, acidification to pH 4.5 with AcOH, addition of NaCl, and work-up gave 121.3 g. II (R₁ = R₃ = H, R₂ = 5-Cl), m. 208-5° (decomposition) (MeOH-H₂O). Similarly prepared were the II derivs. (R₁, R₂, R₃, m.p. given): H, 4-Me, H, 213-15°; Me, 4-Me, H, 144-6°; H, 4-Cl, H, 200-5°; Me, 4-Cl, H, 155°; H, 4-CF₃, H, 214-15°; Me, 4-CF₃, H, 160°; H, 4-OMe, H, 200°; Me, 4-OMe, H, 132-4°; H, 5-Cl, Me, 117-18°; Me, 5-Cl, H, 155°; H, 5-OMe, H, 178-9°; H, 5-SMe, H, 170-2°; H, 6-Cl, Me, 135-9°; H, 5'-Cl, H, 175-7°; H, 5'-OMe, H, 182-4°; H, 4'-Cl, H, 197-8°. II (R₁ = R₃ = H, R₂ = 5-Cl) (121.3 g.) was refluxed in 3 l. xylene 40 hrs. under continuous removal of H₂O. After distillation of the solvent and vapor distillation for removal of impurities, the residue was made alkaline with dilute NH₃, filtered, treated with charcoal, and crystallized from Me₂CO-H₂O to give 71.3 g. III (R₁ = H, R₂ = 7-Cl), m. 253-4°. The same compound was also obtained by refluxing of 2.5 g. II (R₁ = H, R₂ = 5-Cl, R₃ = Me) with 0.39 g. NaNH₂ in 20 ml. dioxane, dilution with H₂O, and filtration in 83% yield. Similarly prepared were the following III derivs. (R₁, R₂, m.p. given): H, 2-Cl, 259-60°; H, 2-OMe, 220-1°; Me, 2-OMe, 200-12°; H, 3-Cl, 271°; H, 3-OMe, 232-3°;

H, 3-Me, 267-9°; H, 6-Cl, 244-6°; Me, 7-Cl, 226-7°;
H, 7-OMe, 239-40°; H, 7-SMe, 211-12°; Me, 7-SMe,
225-6°; H, 8-Cl, 231-2°; Me, 8-Cl, 214-15°; H, 8-Me,
194-5°; Me, 8-Me, 228-9°; H, 8-CF₃, 176-7°; Me,
8-CF₃, 239-40°; H, 8-OMe, 174-6°; Me, 8-OMe, 221-3°.

III (R₁ = H, R₂ = 7-Cl) (52.5 g.) was refluxed 1 hr. with 9.2 g. NaNH₂ in 350 ml. dioxane, then 29 g. ClCH₂CH₂NMe₂ in 50 ml. benzene was added and the mixture refluxed 16 hrs. Concentration in vacuo, distribution between benzene/H₂O, extraction of the benzene with diluted HCl, alkalization of the extract with NH₃, extraction with CHCl₃, evaporation of the solvent, and crystallization from

Me₂CO/Et₂O gave 50.8 g. IV (R₁ = H, R₂ = 7-Cl), m. 165-6°,
ε_D²⁰ 32,740 (EtOH); hydrochloride m. 225-33° (EtOH-Et₂O).

The same compound was obtained by refluxing 11.4 g. II (R₁ = H, R₂ = 5-Cl, R₃ = Me) 90 min. with 1.8 g. NaNH₂ in 90 ml. dioxane, then adding 6 g. ClCH₂CH₂NMe₂ in 20 ml. benzene, and refluxing 15 hrs. (and usual work-up) in 56% yield. Similarly prepared were the following IV derivs. (R₁ R₂, m.p. free base, m.p. hydrochloride, L.D. 59 mg./kg. mouse per os given): H, H, 112-14°, -, 705; Me, H, 116-17°, 234-40°, 215; H, 2-Cl, 172-3°, -, 175; Me, 2-OMe, -, 205-10°, 900; H, 3-Cl, 159-60°, -, 305; H, 3-OMe, 141-3°, -, 150; H, 6-Cl, 122-3°, -, 260; H, 7-Cl, 165-6°, 225-33°, 330; Me, 7-Cl, -, 247-53°, 500; H, 7-OMe, 152-3°, -, 220; H, 7-SMe, 126-9°, -, 345; Me, 7-SMe, -, 205-7°, 520; H, 8-Cl, 140-5°, -, -; Me, 8-Cl, -, 240-5°, 500; H, 8-OMe, 126-7°, -, 220; H, 8-CF₃, 115-18°, -, 150; Me, 8-CF₃, -, 222-6°, 240; H, 8-Me, 137-8°, -, 127; Me, 8-Me, -, 214-17°, 100. Also prepared were the V derivs. (X, m.p., D.L. 50 mg./kg. mouse per os given): 2-pyrrolidinoethyl, 159-60°, 700; 2-piperidinoethyl, 187-9°, 700; 2-morpholinoethyl, 220-2°, >2500; CH₂CHMeNMe₂, 197-9°, 320; (CH₂)₃NMe₂, 137-9°, 1000.

Reduction of the corresponding oxo derivs. with LiAlH₄ in tetrahydrofuran gave the VI derivs. (R₁, R₂, m.p., L.D. 50 mg./kg. mouse per os given): H, H, (maleate m. 100°), 600; Me, H, - (maleate m. 149-51°), 760;


H, Cl, 87-9°, 275. IV (R₁ = H, R₂ = 2-Cl) (20 g.) was refluxed 24 hrs. in 200 ml. 5N HCl. Concentration in vacuo, addition of NaOH, and

isolation of


the resulting base gave 14.8 g. VII, b.p. 130-8°. Acetylation with Ac₂O in pyridine gave VIII, m. 109-11°. To prove the structure, VIII was also synthesized independently. Thus, IX was acetylated to give X, m. 89-90° (Et₂O-petr. ether). X (31 g.) was alkylated with 4 g. NaNH₂ and 9.5 g. ClCH₂CH₂NMe₂ in 150 ml. dioxane to give after usual work-up 31.5 g. VIII. To test the influence of the N bridge on the pharmacol. properties, XI was prepared by refluxing 11.7 g. phenanthridone with 2.95 g. NaNH₂ in 120 ml. dioxane for 2 hrs. Addition of 7 g. ClCH₂CH₂NMe₂ in 50 ml. dioxane during 4 hrs., refluxing for 10 hrs, and normal work-up gave XI; hydrochloride m. 268-70° (MeOH-Et₂O). The XII derivs. were also prepared (X, m.p., L.D. 50 mg./kg. mouse per os given): S, 268-71° (hydrochloride) 870; SO₂, 113-23°, 620; O, 230-3° (hydrochloride), 500. The influence of the chemical constitution on the pharmacological activity was studied. A heterocyclic bridge in position 5 is indispensable for activity; derivs. of benzanilide and phenanthridone having basic substituents are inactive. An unsubstituted NH-group in position 5 has a more favorable effect than the Me-substituted N and is superior in activity to other hetero-bridges such as SO₂, S, and O. Compds. with substituents in position 7 show greater activity than the unsubstituted compound. A carbonyl group in position 11 is essential for activity, the corresponding VI derivs., although closely related to known antihistamines of the benzyraniline group are practically inactive in vivo. In agreement with other classes of antihistamines, the (CH₂)₂NMe₂ and (CH₂)₃NMe₂ groups are the most effective basic

substituents. IV (R1 = H, R2 = 7-Cl) and the corresponding 7-SMe derivative belong to the most potent antihistaminics of today.


IT **82096-44-4**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,
2-chloro-5,10-dihydro- **90353-73-4**, 11H-Dibenzo[b,e][1,4]diazepin-
11-one, 3-chloro-5,10-dihydro- **92148-65-7**, 11H-
Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methyl-
93533-09-6, 11H-Dibenzo[b,e][1,4]diazepin-11-one,
5,10-dihydro-3-methoxy- **94860-63-6**, 11H-
Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy-5-methyl-
167997-02-6, 11H-Dibenzo[b,e][1,4]diazepin-11-one,
5,10-dihydro-2-methoxy-
(preparation of)
RN **82096-44-4** CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)



RN **90353-73-4** CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro- (7CI, 9CI)
(CA INDEX NAME)




RN **92148-65-7** CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methyl- (7CI) (CA
INDEX NAME)




RN **93533-09-6** CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-methoxy- (7CI) (CA
INDEX NAME)

10/785,120




RN 94860-63-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy-5-methyl-
(7CI) (CA INDEX NAME)



RN 167997-02-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-2-methoxy- (9CI) (CA
INDEX NAME)



10/785,120

=> d his

(FILE 'HOME' ENTERED AT 15:02:16 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:02:41 ON 01 MAR 2006
ACT A10785120/A

L1 STR
L2 3101 SEA FILE=REGISTRY SSS FUL L1

FILE 'STNGUIDE' ENTERED AT 15:03:13 ON 01 MAR 2006

FILE 'REGISTRY' ENTERED AT 15:05:08 ON 01 MAR 2006
L3 STRUCTURE UPLOADED
L4 QUE L3
L5 46 S L4 SAM SUB=L2
L6 1087 S L4 FUL SUB=L2

FILE 'CAPLUS' ENTERED AT 15:06:47 ON 01 MAR 2006
L7 128 S L6


FILE 'REGISTRY' ENTERED AT 15:06:58 ON 01 MAR 2006
L8 45 S L6
L9 1151 S L6 FUL

FILE 'CAPLUS' ENTERED AT 15:08:55 ON 01 MAR 2006
L10 129 S L9

=> d l1; d l4; d his; log y

L1 HAS NO ANSWERS

L1 STR



G1 C,N

G2 O,N

Structure attributes must be viewed using STN Express query preparation.

L4 HAS NO ANSWERS

L3 STR